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Abstract 
The primary aim of the work described in this thesis was to investigate the 
physiological role of glucose sensing neurones within the arcuate nucleus of the 
hypothalamus (ARC). To this end, recombinant adeno-associated virus encoding 
glucokinase (rAAV-GKS) was delivered to the ARC of adult male Wistar rats. 
Glucokinase (GK) catalyses the first reaction in glycolysis and has been hypothesised to 
act as a regulator of hypothalamic glucose sensing. Furthermore, manipulation of GK 
has been shown to alter the sensitivity of glucose sensing neurones in vitro. I 
hypothesised that increasing GK expression in the ARC using rAAV-GKS would 
influence the sensitivity of glucose sensing neurones in vivo and provide insight into 
their physiological role.   
Bilateral administration of rAAV-GKS to the ARC resulted in a 14-fold increase in 
hypothalamic GK mRNA expression compared to controls. Food intake and body 
weight gain were significantly increased in rAAV-GKS treated rats compared to 
controls on standard chow. The increased body weight of the rAAV-GKS group was 
attributed to a significant increase in adipose tissue with no difference in lean mass. 
Food intake and body weight gain were also significantly increased in rAAV-GKS 
treated animals maintained on a high calorie “western-style” diet.  
Despite their increased adiposity, rAAV-GKS treated rats displayed significantly 
improved glucose tolerance compared to controls. The increased glucose tolerance of 
the rAAV-GKS group was associated with increased glucose-stimulated insulin 
secretion.  
rAAV-GKS treated rats consumed a significantly greater volume of a 10% glucose 
solution compared to controls over a 16 hour period. In addition, rAAV-GKS animals 
showed a clear preference for glucose over standard chow compared to controls over 24 
hours and during a 31 day longitudinal study.   
The results of this work suggest that glucose sensing neurones in the ARC may be 
involved in the regulation of energy balance and glucose homeostasis. These results are 
of broader significance considering the proposed use of GK activating drugs in the 
treatment of type II diabetes mellitus.   
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Glucose is the major product of photosynthesis in plants and most photosynthetic 
bacteria, and is the conduit by which solar energy is stored and utilized by most life on 
Earth. Within biology glycolysis is virtually universal, occurring in organisms as 
evolutionarily distant as haloarchaea (Falb & Muller, 2008) and man.  In multicellular 
organisms glucose is utilized by all cells; in aerobic and fermentative tissues alike, and 
is vital for the function of a number of organs including the brain. Intracellular glucose 
levels must be tightly controlled, as both high and low levels of glucose can be 
cytotoxic (Bronk, 1999). Classically, glucose homeostasis is believed to be largely 
regulated by the autonomously functioning endocrine pancreas. However, it is 
becoming increasingly clear that glucose-sensing neurones in the other organs play an 
important role in glucose homeostasis (Bronk, 1999;Levin et al, 1999). Since glucose 
homeostasis represents a small, but integral, part of total energy balance it is 
unsurprising that glucose-sensing neurones are also sensitive to other nutrients and have 
been postulated to have additional roles in energy balance; including the regulation of 
food intake (Loftus et al, 2000). In the present work the physiological role of 
hypothalamic glucose-sensing neurones is investigated utilizing adeno-associated viral 
gene transfer of glucokinase; an enzyme vital to the glucose-sensing mechanism of 
some cell types.   
 
1.1 The importance of maintaining normoglycaemia  
 
In healthy humans, plasma glucose is usually maintained between 4-6mmol/l, regardless 
of changes in glucose uptake by peripheral tissues or dietary contribution. This is 
important, as hypo- and hyperglycaemia can result in ill health. Severe hypoglycaemia 
most frequently occurs as a result of intensive insulin therapy in the treatment of type I 
diabetes mellitus. In humans, hypoglycaemia presents with symptoms including 
perspiration, shaking and dizziness, confusion and hunger (McAulay et al, 2001).  In 
healthy individuals hypoglycaemia is usually avoided by an increased urge to feed and 
by the counter regulatory response (CRR). The CRR is a hormonally and neurally 
mediated cascade, primarily involving a decrease in plasma insulin and an increase in 
plasma glucagon, which reduces peripheral glucose utilization whilst simultaneously 
24 
 
increasing endogenous glucose production and release by the liver (Evans et al, 2004). 
In type I diabetes intensive insulin therapy blunts the CRR, and masks the physical 
manifestations of hypoglycaemia resulting in potentially fatal hypoglycaemic events 
(Mokan et al, 1994). It has been estimated that 2-10% of all type I diabetes deaths are as 
a result of iatrogenic hypoglycaemia (Cryer, 1997;Skrivarhaug et al, 2006). 
Hyperglycaemia is usually associated with type II diabetes mellitus but also occurs in 
conditions of acute stress such as myocardial infarction, stroke, burns and infection.  
The early stage of type II diabetes is characterised by peripheral insulin resistance 
which results in persistent and moderate hyperglycemia. Type II diabetes is by far the 
most prevalent form of diabetes accounting for 90-95% of all cases of diabetes 
worldwide (American Diabetes Association, 2011). The pathogenesis of type II diabetes 
is closely related to obesity; in particular central adiposity. In fact, almost 80% of type 
II  diabetes sufferers are obese (Bloomgarden, 2000).  
Insulin resistance describes the state in which tissues (primarily the skeletal muscle, 
liver and adipose tissue) are resistant to the plasma glucose lowering effects of insulin. 
In addition to insulin resistance, type II diabetes is characterised by progressive β-cell 
dysfunction which, combine with the increased demand created by insulin resistance, 
can lead to β-cell burnout and the requirement for insulin therapy.  
Hyperglycaemia may also occur in type I diabetes mellitus as part of diabetic 
ketoacidosis (DKA) or hyperosmolar hyperglycaemia syndrome (HHS).  Both 
conditions are caused by relative lack of insulin action and both are potentially lethal 
(Rosenbloom & Hanas, 1996;Magee & Bhatt, 2001). Aside from DKA and HHS, 
hyperglycaemia is rarely acutely lethal. Rather, chronic hyperglycemia over a period of 
decades causes micro- and macrovascular injury. Microvascular complications include 
diabetic retinopathy, neuropathy and nephropathy. While macrovascular injury can 
result in cardiovascular-, cerebrovascular- and peripheral vascular disease (American 
Diabetes Association, 2011). Sufferers of type II diabetes are at a two- to fourfold 
increased risk of coronary heart disease (Haffner & Miettinen, 1997).  
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1.2 Glucose homeostasis and glucose sensing 
 
In order to maintain glucose homeostasis, it is necessary that at some level the body is 
„aware‟ of the concentration of glucose in bodily tissues and also „aware‟ of the quantity 
of glucose entering the system. In mammals this is achieved via the combined effort of 
numerous cell types with glucose-sensing ability that are located both within the 
circulatory system and outside it.  
Glucose-sensing cells convert changes in local glucose concentrations into signals 
(usually endocrine or neural) that inform and influence the function of other cells within 
the body. In the following sections, glucose-sensing cells will be described and 
considered in terms of their roles in glucose homeostasis and regulation of energy 
balance.   
 
1.2.1 The endocrine pancreas and insulin action 
 
In the classical textbook description of glucose homeostasis the pancreas is described as 
an autonomously functioning master regulator that controls plasma glucose levels 
through altered hormonal secretion. In this model, glucose homeostasis is maintained by 
pancreatic hormones modulating peripheral glucose utilization and hepatic glucose 
production. Although this is a vast over-simplification, it is still the case that the 
endocrine pancreas plays a central role in glucose homeostasis and that many extra-
pancreatic glucose sensors mediate their effects via modulation of pancreatic endocrine 
signalling.   
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The Islets of Langerhans constitute the endocrine portion of the pancreas and make up 
approximately 1-2% of pancreatic mass. Pancreatic islets are composed of 4 endocrine 
cells types;  
1)     α-cells; containing glucagon granules  
2)     β-cells; containing insulin granules  
3)     δ cells; containing somatostatin granules  
4)     PP cells; containing pancreatic polypeptide granules  
(Elayat, 1995) 
Of the four cell types α and β cells are most important in glucose homeostasis.  In 
humans and in rats β pancreatic cells are located in central regions of the islets while α-
cells are located peripherally (Sacchi & Bani, 1985). Insulin, a 5800Da endocrine 
hormone consisting of an α and β chain linked by two disulphide bridges, is the primary 
secretory product of β-cells.  It is produced from a single chain precursor, proinsulin, by 
proteolytic cleavage and is subsequently stored in cytoplasmic secretory vesicles. The 
secretion of mature insulin is regulated by numerous hormonal and non-hormonal 
extracellular signals. In the postprandial state, secretion of insulin occurs primarily in 
response to increases in plasma glucose although, nervous innervation plays an 
important role (Henquin, 2000).  
 
1.2.2 Insulin secretion  
 
The stimulation of insulin release by glucose is primarily mediated via an increased rate 
of glycolysis in β-cells in response to hyperglycaemia. This increases intracellular 
adenosine triphosphate (ATP) levels which inhibits ATP-sensitive K
+
 channels, 
resulting in membrane depolarisation. Depolarisation of the membrane opens voltage 
gated Ca
2+
channels causing a rapid influx of Ca
2+
down its electrochemical gradient. 
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Increasing cytoplasmic Ca
2+
levels facilitates the binding of secretory vesicles with the 
plasma membrane and subsequently the exocytosis of insulin (Henquin, 2000).  
Insulin secretion by the β-cell is dependent on its ability to sense local glucose 
concentrations, for this to happen the rate of glycolysis within the cell must be tightly 
coupled to changes in local plasma glucose levels. This is only possible because the β-
cell expresses both glucokinase (GK) and the glucose transporter type II (GLUT 2) 
(Matschinsky, 1990;Matschinsky et al, 1993). 
The GLUT family facilitate the transport of sugars including glucose and fructose 
across the plasma membrane of most mammalian cells. Members of the GLUT family 
create aqueous pores in the plasma membrane through which sugars are transported in 
an energy-independent manner. Since transport via the GLUT family is passive, sugars 
will only move down their concentration gradient.  
GLUT 2 has a high Km for glucose meaning that it does not become saturated in the 
normal physiological range. This ensures that glucose transport across the cell 
membrane increases in line with changes in plasma glucose (Thorens, 1992). However, 
this is only possible because the β-cell also express GK.  
GK belongs to the hexokinase family of enzymes which is comprised of four members. 
Hexokinases catalyse the first reaction in glycolysis; glucose + ATP to glucose-6-
phosphate (G-6-P) + ADP. The conversion of glucose to G-6-P creates the 
concentration gradient required for the passive transport of glucose across the cell 
membrane. The rate of transport is, therefore, at least partially dependent on the rate at 
which specific hexokinases convert glucose to G-6-P. Phosphorylation also prevents 
glucose from escaping the cell because mammalian cells do not possess a G-6-P 
transporter (Iynedjian, 2009).   
Hexokinase I is the most widely expressed hexokinase in the mammalian biology. It is 
typical of the group in that it has a low Km for glucose (and is therefore saturated at 
physiological glucose concentrations) and is inhibited by its product G-6-P. Hexokinase 
I acts as a regulatory step in both glycolysis and glycogen synthesis.  
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GK is an atypical member of the hexokinase family. It is approximately half the 
molecular weight of the other hexokinases and shares only 54.4% homology with 
hexokinase I (Zhang et al, 2006). It also possess significant functional and kinetic 
differences; GK has a high Km for glucose (~8 mmol/l) and is not inhibited by its 
product G-6-P (Iynedjian, 1993).  
Two isoforms of GK are expressed in mammals under the control of tissue specific 
promoters. The first promoter produces the neuroendocrine isoform of GK which is 
expressed in the pancreas, central nervous system (CNS) and intestine. The second 
promoter produces the hepatic isoform of GK which is expressed exclusively in the 
liver. The two isoforms are functionally and kinetically identical and differ only by 13-
15 amino acids at their N-termini. The major difference between the isoforms occurs at 
the level of their expression (Iynedjian, 2009). Expression of the liver isoform but not 
the neuroendocrine is dependent on insulin. Hepatic GK expression is reduced by 90% 
in  streptozotocin-induced diabetic rats (Iynedjian et al, 1988).  
In the pancreas, the high Km of GK and lack of end product inhibition maintains the 
concentration gradient between intracellular and extracellular glucose as plasma glucose 
levels increase post prandially. This, combined with rapid glucose transport by GLUT 2, 
couples the post-prandial rise in plasma glucose with glycolysis and ultimately insulin 
secretion.  
 
1.2.3 Insulin’s actions  
 
Insulin signals at target tissues via receptor-ligand interaction with the ubiquitously 
expressed plasma membrane insulin receptor (IR). The IR is a member of the receptor 
tyrosine kinase family of transmembrane receptors and is composed of two α- and two 
β-subunits. Binding of insulin to insulin-binding sites located on the extracellular α-
subunits causes localized conformational change, which ultimately results in the 
autophosphorylation of specific tyrosine residues on the intracellular β-subunits. 
Autophosphorylation of the β-subunits induces further conformational changes and 
increases receptor kinase activity (Baron et al, 1992). Activation of IR kinase activity 
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regulates a variety of intracellular phosphorylation cascades involved in metabolic 
regulation and gene expression. 
In skeletal muscle and adipose tissue, binding of insulin to the IR increases glucose 
uptake by initiating translocation of the GLUT 4 from cytoplasmic storage vesicles to 
the plasma membrane. GLUT 4 is the only member of the GLUT family that is insulin 
responsive. Translocation of GLUT 4 to the plasma membrane of myocytes and 
adipocytes is the most important mechanism involved in insulin-induced post prandial 
glucose clearance. Indeed, approximately two-thirds of all postprandial insulin-mediated 
glucose disposal occurs in skeletal muscle alone (Klip and Paquet 1990).  
The other major site involved in insulin-induced post prandial glucose clearance is the 
liver. Hepatocytes express both the GLUT 2 and GK. GLUT 2 is not insulin-induced 
however its high Km and affinity for glucose allows glucose to be rapidly taken up by 
the liver when plasma glucose is high as it does in the pancreas. As previously 
discussed, hepatic GK expression is insulin dependent. At basal plasma insulin levels 
hepatic GK expression and glucose uptake is low. Insulin-induced increases in hepatic 
GK assists in postprandial glucose clearance by increasing the rate at which glucose is 
phosphorylated to G-6-P; thus creating the concentration gradient required for passive 
glucose transporter by GLUT2.  Hepatic knockout of GK does not markedly influence 
plasma glucose levels in the basal state. However, glucose tolerance, hepatic glucose 
uptake and hepatic glycogen synthesis are impaired in hepatic GK knockout mice 
demonstrating the importance of hepatic GK in the post prandial state (Postic et al, 
2001).       
Insulin is also able to cross the blood brain barrier and the IR is expressed within the 
central nervous system, with particularly high expression in the hypothalamus and the 
olfactory bulb (Havrankova et al, 1978). Neurones do not express the insulin-dependent  
hepatic isoform of GK and insulin is not believed to play a major regulatory role in their 
glucose uptake or metabolism (Seaquist et al, 2001). Rather, insulin signalling in the 
CNS regulates peripheral glucose metabolism and energy balance. Infusion of insulin 
into the CNS inhibits feeding and stimulates the vagus nerve which increases pancreatic 
insulin secretion and inhibits hepatic glucose production (Obici et al, 2002;Szabo et al, 
1983). This not only highlights the importance of insulin signalling in the CNS but also 
the importance of CNS-peripheral interactions in the regulation of glucose homeostasis.  
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Furthermore, the pancreas-insulin-CNS pathway provides an example of how glucose-
sensing (in this case in the pancreas) indirectly influences feeding behaviour. 
 
1.2.4 Glucagon and its actions 
 
In the transition between the absorptive and post-absorptive states plasma glucose 
slowly falls as peripheral glucose uptake exceeds glucose appearance. This is 
accompanied by reduced insulin release by β-cells, increased secretion of glucagon by 
α-pancreatic cells, and increased plasma adrenaline (Evans et al, 2004).  Glucagon is a 
3500 Da peptide with essentially opposing metabolic actions to insulin. The pathways 
regulating glucagon secretion are complex and ill understood.  What is known is that 
secretion of glucagon is inhibited by glucose, somatostatin and activation of β-cells, and 
is stimulated by pyruvate (Ishihara et al, 2003). Increased plasma glucagon-to-insulin 
ratio in the early post absorptive state promotes glycogenolysis and subsequent glucose 
release from the liver. Furthermore, glucagon promotes lipolysis and proteolysis in 
adipose tissue and skeletal muscle respectively, and thereby provides precursors for 
hepatic gluconeogenesis (Bronk, 1999).   
Interestingly, in addition to its effects on glucose metabolism, glucagon has been shown 
to influence feeding behaviour. As is the case with insulin, there is a small increase in 
plasma glucagon within minutes of feeding (De Jong et al, 1977). Plasma glucagon also 
increases following sham feeding which suggests that this phenomenon may be 
regulated by cephalic stimulation (Nilsson & Uvnas Wallensten, 1977). Administration 
of glucagon to humans reduces meal size and it has been shown that glucagon elicits its 
effects on feeding via a pathway involving the liver, the vagus nerve and the CNS 
(Geary, 1990;Geary & Smith, 1983;Weatherford & Ritter, 1988).  
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1.3 Extra pancreatic glucose sensing  
 
In addition to the pancreas, glucose sensing cells are located in the CNS, the mouth, the 
gut and the hepatic portal vein. Glucose sensing in each of these regions is required for 
proper regulation of glucose homeostasis.    
Glucose-sensing begins within seconds of glucose entering the body, as evidenced by 
the preabsorptive or cephalic insulin response. In the mouth glucose interacts with the 
sweet taste receptor which is a member of the T1R family of taste receptors that include 
the receptors for bitter and umami taste modalities. The sweet taste receptor is a 
heteromeric g-protein coupled receptor formed of T1R2 and T1R3 proteins (Nelson et 
al, 2001). α-gustducin is a taste-specific g-protein that plays an important role in the 
transduction of both sweet and bitter taste. In mice, knock-out of α-gustducin results in 
reduced responsiveness to bitter and sweet taste modalities(Wong et al, 1996).  
Activation of the sweet taste receptor results in insulin release via parasympathetic 
stimulation of the pancreas by vagal efferents (Berthoud et al, 1980). 
The ability to sense glucose in food as early in the digestive process as in the mouth is 
likely to offer a number of evolutionarily important advantages. Firstly, it allows the 
body to prepare for an imminent increase in plasma glucose and thus dampens the post-
prandial hyperglycaemia associated with ingestion of carbohydrate rich foods. In 
addition, the ability to recognise sources of simple sugars or high calorie food stuffs 
would be advantageous to any mammal for which future food supply is uncertain (such 
as early man). Aversive feeding behaviour to bitter tasting compounds is believed to 
protect against the ingestions of toxins and it possible that activation of the sweet taste 
receptor would increase the drive to feed high calorie simple sugars that could be stored 
in adipose tissue and skeletal muscle and called upon in times of need.   
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1.3.1 Intestinal glucose-sensing 
 
Following its ingestion, glucose is sensed in the intestine by K and L cells. K and L 
cells secrete the incretin hormones glucose-dependent insulinotropic peptide (GIP) and 
glucagon-like peptide 1 (GLP-1) respectively. As is the case with the taste receptors of 
the tongue, the primary function of GIP and GLP-1 is to prepare the body for the 
forthcoming post prandial increase in plasma glucose. The term „incretin‟ describes the 
ability of these hormones to increase or augment insulin release.   
GIP is released from K-cells in response to post prandial increases in both fats and 
carbohydrates. The exact mechanism of glucose sensing in K cells is poorly understood. 
However, glucose sensing in this cell type is dependent on the expression of the 
sodium-dependent glucose transporter 1 (SGLT-1) and ATP-sensitive K+ channels, 
suggesting that glycolysis may be involved as it is in the β-cell (Parker et al, 2009). GIP 
signals via the glucose-dependant insulinotropic peptide receptor (GIPr) and is believed 
to primarily exert its metabolic effects at the level of the adipose tissue and pancreas. In 
adipose tissue GIP has been shown to increase both uptake of glucose and conversion of 
glucose to fatty acids and thus aides post-prandial glucose clearance (Hauner et al, 
1988). At the level of the pancreas GIP increases glucose-stimulated insulin release via 
interaction with its g-protein coupled receptor and subsequent increase of cytosolic 
cAMP and calcium (Siegel & Creutzfeldt, 1985;Lu et al, 1993). 
GLP-1 secretion from L-cells is also believed to be dependent on the expression of 
SGLT-1 and ATP-sensitive K+ channels (Reimann et al, 2008).The glucagon-like 
peptide 1  receptor (GLP-1r) is expressed in numerous sites throughout the body 
including the pancreas, hepatic portal vein, vagus nerve and the central nervous system 
(including the hypothalamus) (Drucker, 2007). In the pancreas, the GLP-1r is expressed 
on both α and β-cells. GLP-1 increases glucose-stimulated insulin release while 
decreasing glucagon secretion.  
In addition to its effects on glucose metabolism, GLP-1 has also been shown to 
influence feeding behaviour. In humans, intravenous GLP-1 infusion results in a dose 
dependent  decrease in food intake (Gutzwiller et al, 1999).  In rodents, 
intracerebroventricular (ICV) infusion of GLP-1 results in reduced intake of both food 
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and water (Tang-Christensen et al, 1996). Thus, as is the case in the pancreas, glucose 
sensing in the intestine influences both glucose homeostasis and feeding behaviour.  
 
1.3.2  Portal glucose sensing  
 
Following absorption, glucose enters the circulation at the hepatic portal vein, which 
transports blood from the gastrointestinal tract to the hepatic capillary beds. As well as 
being the conduit between the gastrointestinal tract and the liver, the hepatic portal vein 
is an important glucose sensor. Glucose is sensed in the hepatic portal vein by glucose-
sensing neurones projecting from the nodose ganglia which express both the ATP 
sensitive K+ channel and GLUT 2 (Grabauskas et al, 2010;Burcelin et al, 2000b). 
Knockout of GLUT2 appears to abolish glucose sensing which suggests that glucose-
sensing in the hepatic portal vein is dependent  on glucose transport and metabolism 
(Burcelin et al, 2000b). This further suggests that the glucose-sensing mechanism in 
hepatic neurones is similar to that of the pancreatic β-cell. 
Infusion of glucose into the hepatic portal vein activates a number of glucose-lowering 
mechanisms including increasing hepatic and peripheral glucose uptake, and decreasing 
food intake (Stempel & Jungermann, 1997;Burcelin et al, 2000a;Berthoud et al, 
1980;Russek, 1970). The hepatic portal vein is also sensitive to GLP-1. Infusion of 
GLP-1 into the hepatic portal vein reduces plasma glucose by increasing hepatic glucose 
uptake and pancreatic insulin secretion (Nishizawa et al, 2003). Administration of 
chlorisondamine (a ganglionic blocker) prevents the augmentation of insulin release by 
hepatic portal GLP-1 administration, suggesting that its effects are mediated via a neural 
mechanism (Balkan & Li, 2000).      
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1.4 CNS regulation of glucose homeostasis and feeding  
 
Within the central nervous system, glucose-sensing neurones are found in numerous 
regions including the hypothalamus, hindbrain, motor cortex, amygdala and septum 
(McCrimmon, 2008). Glucose-sensing neurones may be broadly divided in to two 
groups based on their electrophysiological response to glucose.  Glucose-excited (GE) 
neurones increase their firing rate as ambient glucose levels increase while glucose-
inhibited (GI) neurones decrease their firing rate in response to the same stimulus 
(Oomura et al, 1964). With regard to glucose homeostasis and feeding behaviour, it is 
those neurones located in the hypothalamus which have received the greatest attention.   
 
1.4.1 A brief history 
 
The earliest indication of the brains involvement in glucose homeostasis was provided 
by Claude Bernard in 1849. Bernard showed that punching holes in the floor of the 
fourth cerebral ventricle resulted in glycosuria in the dog (Pyke, 1979). In the early 
1950‟s Jean Mayer proposed the „Glucostatic Hypothesis‟, in which he suggested that 
food intake was regulated by alterations in plasma glucose. Mayer hypothesized that the 
hypothalamus contained glucose-sensitive neurones which acted as “glucoreceptors”. 
He proposed that these glucoreceptors altered their electrical activity in response to 
changes in their rate of glucose utilisation; to produce feelings of hunger when glucose 
was limiting and satiety when plasma glucose was adequate (Mayer, 1952). Although 
this hypothesis has never been proven, and is almost certainly an over simplification, it 
correctly predicted the existence of glucose-sensitive neurons in the hypothalamus. In 
1964 two groups, Omura et al and Anand et al, separately documented the presence of 
glucose-sensitive neurones in the hypothalamus using electrophysiological 
methods  (Oomura et al, 1964;Anand et al, 1964). 
With regard to the physiological function of glucose-sensing neurones, most evidence to 
date has been derived from manipulation of glucose supply or glucose metabolism. In 
1989, Biggers et al, demonstrated the importance of CNS glucose-sensing by inducing 
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peripheral hypoglycaemia while maintaining euglycemia in the brain by infusing 
glucose bilaterally into the carotid and vertebral arteries. It was found that this treatment 
dramatically reduced release of the counter regulatory hormones glucagon and 
adrenaline and peripheral hypoglycaemia remained uncorrected (Biggers et al, 1989). 
The CRR to hypoglycaemia is also abolished if glucose is infused directly into the 
ventromedial hypothalamus (VMH) (Borg et al, 1997). Conversely, infusion of 2-
deoxy-glucose (2DG) (a glucose anti-metabolite) into the VMH results in initiation of 
the CRR, even in the presence of peripheral euglycemia (Borg et al, 1995). Thus, 
central glucose-sensing appears to be the major mechanism regulating the CRR to 
hypoglycaemia.  
In line with the Mayer “Glucostatic” hypothesis, both acute (Kurata et al, 1986) and 
chronic (Davis et al, 1981) central glucose infusion has been shown to reduce feeding in 
rodents. Again, the VMH appears to be involved, as chronic infusion of glucose into the 
VMH results in 27% reduction in feeding (Panksepp & Rossi III, 1981). Conversely 
administration of 2DG into the third cerebral ventricle results in a dose dependent  
increase in food intake, suggesting that inhibition of glucose metabolism therein is 
sufficient to induce feeding (Tsujii & Bray, 1990).  
 
1.4.2 Hypothalamic distribution  
 
Within the hypothalamus glucose-sensing neurones are found in the paraventricular 
nucleus (PVN), lateral hypothalamic area (LHA) and in the ventromedial hypothalamus 
(VMH); which includes the arcuate nucleus (ARC) and ventromedial nucleus (VMN) 
(Lynch et al, 2000).  While the absolute role, and indeed neurotransmitter identity, of 
glucose-sensing neurones in each of these regions is currently unknown, suggestive 
experimental evidence is gathering, particularly with regard to neuronal populations in 
the VMH and LHA.  
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1.4.2.1 The arcuate nucleus (ARC) 
 
The ARC is superior to the median eminence and extends from the optic chiasm to the 
mammillary bodies; encapsulating the third cerebral ventricle. The ARC has a semi 
permeable blood brain barrier, resulting from a highly fenestrated local capillary 
network, and thus is exposed to peripheral signals involved in energy homeostasis such 
as glucose, fatty acids, leptin and ghrelin.  With regard to feeding, the ARC contains 
two neuronal populations which have been well characterised; one population 
which  co-expresses the orexigenic peptides  neuropeptide Y (NPY) and agouti related 
peptide (AgRP), and another which expresses the anorexic peptides pro-
opiomelanocortin (POMC) and cocaine-and-amphetamine-related transcript 
(CART).  NPY/AgRP neurones project to the LHA and the PVN and are activated by 
ghrelin and inhibited by leptin. POMC/CART neurones project to numerous 
hypothalamic and extra-hypothalamic regions and are activated by leptin and insulin, 
and in some cases glucose, resulting in reduced feeding (Cone et al, 2001).  
The ARC also contains a large number of glucose-sensing neurones and evidence 
suggests that these populations partially overlap with both NPY/AgRP and 
POMC/CART neurones. Muroya et al (1999) found that 94% of GI neurones isolated 
from the rat ARC were immunoreactive for NPY (Muroya et al, 1999). While Ibrahim 
et al (2003) identified 80% of POMC neurones as glucose excited by taking electrical 
readings of transgenic POMC-eGFP neurones from mouse brain slices (Ibrahim et al, 
2003). These results are consistent with glucose being a satiety signal. However, the GE 
nature of POMC neurones is controversial. Some investigators have reported no effect 
of glucose on POMC firing rate while others have reported a reduced firing rate with 
increasing glucose concentration (Fioramonti et al, 2007).The situation is further 
confused by a study showing no POMC immunoreactivity in 8/8 GE neurones from the 
mouse ARC (Wang et al, 2004). Further investigation is required to resolve these 
discrepancies. 
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1.4.2.2 Ventromedial hypothalamic nucleus  
 
The VMN lies superior to the ARC and, was classically defined as the hypothalamic 
“satiety” centre after lesioning of the area was shown to induce hyperphagia (reviewed 
in (Schwartz et al, 2000). The VMN receives input from hypothalamic nuclei including 
the PVN, dorsomedial hypothalamic nucleus (DMN) and LHA and returns projections 
to the LHA and DMN.  Unlike the ARC and LHA, the neuropeptide expression of the 
VMN, especially with regard to glucose sensitive neurones, is less well understood 
(Burdakov et al, 2005b). With regard to glucose-sensing the VMH remains the most 
well studied region of the hypothalamus and has been shown to be of importance in the 
regulation of glucose homeostasis and feeding. However, it should be remembered that 
the VMH, as opposed to the VMN, also contains the ARC. So it is difficult to 
extrapolate a specific function of VMN glucose-sensing neurones.  
 
1.4.2.3 The lateral hypothalamic area (LHA)  
 
The Lateral hypothalamic area (LHA) is a large, poorly defined region of the 
hypothalamus lying lateral to the VMN. The LHA was classically described as the 
“feeding centre” of the hypothalamus after lesioning of the area was shown to induce 
hypophagia (Anand & Brobeck, 1951).  Two of the major neuronal population in the 
LHA are those expressing orexin (De Lecea et al, 1998) and melanin concentrating 
hormone (MCH) (Broberger et al, ). 
Activation of NPYergic neurones, which project from the ARC to the LHA, causes the 
release of orexin A and B from orexin neurones (Horvath et al, 1999).  Orexins are 
orexigenic neuropeptides that increase arousal and food searching behaviour. The 
greater majority, ~95%, of orexin neurones in the mouse LHA are inhibited by glucose 
at physiologically relevant concentrations (0.2-5mmol/l) and have been classified as 
being GI (Burdakov et al, 2005a).  
Evidence from mice with targeted deletion of either MCH or the MCH receptor, and 
intracerebroventricular injection of MCH suggest that MCH may play an opposing role 
to that of the orexins (i.e. promoting sleep and suppression of activity). Interestingly, it 
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has recently been shown that the majority of MCH neurones in the LHA, some 80%, are 
excited by glucose in a dose  manner (Burdakov et al, 2005a).   
The neuropeptide co-localisation of glucose-sensing neurones in the ARC and LHA 
suggests that their activation/inhibition may result in entirely different physiological 
outcomes. This is also likely to be the case for other hypothalamic and extra-
hypothalamic regions.  
 
1.4.3 Mechanism of glucose-sensing  
 
1.4.3.1 Glucose uptake  
 
For a cell to be capable of sensing glucose via metabolism, it must be able to take up 
glucose at a rate that allows intracellular glucose levels to closely reflect extracellular 
levels. In the β-cell this is facilitated by expression of the high capacity GLUT-2 
transporter and GK; and glucose-sensing in the β-cell is dependent on their expression.  
Although GLUT-2 is expressed in the hypothalamus, there is some controversy as to 
which glucose transporter is most important in hypothalamic glucose sensing. GLUT-2 
does appear to be involved in the glucose-sensing of some hypothalamic neurones 
(Stolarczyk et al, 2010). However, in the hypothalamus GLUT-2 is primarily expressed 
on astrocytes rather than neurones (Leloup et al, 1994).  
Some neurones in glucose-sensing regions co-express the insulin receptor and the 
insulin-sensitive GLUT-4 transporter (Vannucci et al, 1998). The Km for glucose of 
GLUT-4 is 4.6mmol/l (Nishimura et al, 1993), this is above the normal range of glucose 
within the brain so it is possible that GLUT-4 is involved in neuronal glucose-sensing. 
However, the majority of glucose-sensing neurones express GLUT-3.  
Of the class I glucose transporters (1,2,3,4), GLUT-3 has the lowest Km. Despite this, 
the transport capacity of GLUT-3 is higher than that of GLUT-1 and GLUT-4 owing to 
its high affinity for glucose. The high affinity of GLUT-3 makes it well suited for rapid 
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uptake of glucose in the physiological range of the brain (usually ~1-2mmol/l) (Simpson 
et al, 2008). 
Glucose levels in the VMH are higher than most other brain regions and have been 
shown to range from 0.73 to 4.23mmol/l (Mayer et al, 2006;de Vries et al, 2005). Since 
no single transporter is maximally active across this range it makes teleological sense 
that neurones in the VMH express a variety of transporters with varying kinetics.  
 
1.4.3.2 GE neurones  
 
After it is transported across the cell membrane, glucose is sensed in GE neurones in 
much the same way as in the β-cells of the pancreas. As intracellular glucose levels 
increase, glucose is rapidly converted to G-6-P and enters glycolysis leading to an 
increase in the ATP/ADP ratio. In some neurones this is facilitated by GK, which is 
expressed in 64% of GE neurones (Kang et al, 2004). High ATP/ADP ratio causes the 
closure of ATP sensitive K
+
 channels resulting in membrane depolarisation, action 
potential and neurotransmitter release (Levin et al, 2004).  
Glucose-sensing in GE neurones has been shown to be dependent on the expression and 
closure of ATP sensitive K
+
. ATP levels within neurones are well buffered so changes 
in glucose utilization are unlikely to alter absolute cellular levels sufficiently to affect 
ATP sensitive K
+
 channels. This suggests that the increase in ATP may be 
compartmentalised at the cell membrane and proximal to the ATP sensitive K
+
 channel.  
However, to date this has not been demonstrated experimentally (Levin et al, 2004). 
(figure 1.1) 
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Figure 1.1 Glucose excited neurone: The potential mechanism of glucose-sensing in the 
GE neurones. Rate of glycolysis is translated to increased ATP/ADP ratio resulting in 
closure of ATP sensitive K+ channel and subsequent membrane depolarisation.  
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1.4.3.3 GI neurones  
Compared to GE neurones, the glucose-sensing mechanisms of GI neurones are less 
well understood.  Approximately 45% of GI neurones express GK (Kang et al, 2004) so 
it is possible that the sensing mechanism is directly related to glucose metabolism, as it 
is in the GE neurone. In the case of GI neurones it has been postulated that membrane 
depolarisation may occur at low glucose levels as a result of activation of Adenosine 
Monophosphate Activated Protein Kinase (AMPK) in response to low ATP/ADP 
ratio.  It has been suggested that activation of AMPK may phosphorylate, and 
deactivate, membrane Cl
-
channels, leading to depolarisation (Mountjoy & Rutter, 
2007). (figure 1.2) 
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Figure 1.2 Glucose inhibited neurone: The potential mechanism of glucose sensing in 
the GI neurones. Reduced rate of glycolysis results in a decrease in cellular ATP and 
activation of AMPK which inhibits membrane Cl- channels causing membrane 
depolarisation.    
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1.4.4 Is GK the primary regulator of hypothalamic glucose sensing?  
 
It has been stated, primarily by Levin et al, that GK acts as the primary regulator of 
neuronal glucose sensing, as it does in the β-cells of the pancreas (Levin et al, 
2004;Kang et al, 2004). However, GK is not expressed in all GE and GI neurones. This 
observation has led some investigators to question the importance of GK in glucose-
sensing in the hypothalamus.  
In the hypothalamus, the neuroendocrine form of GK is expressed. Hypothalamic GK is 
expressed only in regions where glucose-sensing neurones are found, suggesting a 
specific role. In ex vivo VMH neurones, pharmacological activation of GK increases 
activity of GE neurones and inhibits the stimulatory effect of low glucose on GI 
neurones.  Furthermore, a 90% reduction in GK mRNA in cultured VMH neurones 
results in total loss of glucose sensitivity in GI and GE neurones, suggesting that 
glucose-sensing is dependent on GK in both cell types (Kang et al, 2006).  
A sticking point in the “GK as a glucose-sensor” hypothesis is that the Km of GK 
(~8mmol/l for glucose) is far higher than glucose levels observed in the brain (Kang et 
al, 2006; Roncero et al, 2000). It is therefore questionable as to whether it is GK which 
gives glucose-sensing neurones their sensitivity to changes in glucose concentration; 
especially as GE neurones have been shown to be most sensitive to changes in glucose 
concentration at <2mmol/l (Wang et al, 2004).  
Considering the fact that GK is not expressed in all glucose-sensing neurones it is 
impossible to confidently state that it is the primary hypothalamic glucose sensor, and it 
is certain that other glucose sensors exist, including AMPK.  
Interestingly, it also appears that at least some glucose-sensing neurones sense glucose 
via non-metabolic mechanisms. That is to say that glucose is sensed without being taken 
up by the neurone and without being metabolised. For example, in addition to its role as 
a glucose transporter, GLUT-2 also possesses receptor activity via an intracytoplasmic 
loop domain. Transgenic mice have been produced in which the receptor activity of the 
GLUT-2 loop domain is blocked but the transport function is maintained. Such mice 
display decreased c-Fos activation in the ARC following glucose infusion and increased 
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food intake as a result of increased meal size; demonstrating the importance of glucose-
sensing via the cytoplasmic loop (Stolarczyk et al, 2010).  
It has also been shown that T1R2/T1R3 sweet taste receptor and α-gustducin are 
expressed in the ARC and the PVN (Ren et al, 2009). This suggests that some glucose-
sensing neurones may sense glucose using the same machinery as taste receptors of the 
tongue. Thus, non-metabolic glucose sensing in the hypothalamus appears to be 
important in the regulation of energy balance. Non-metabolic glucose-sensing might 
also explain how some neurones that do not express GK are able to sense changes in 
extracellular glucose.   
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1.4.5 Glucose sensors or metabolic sensors? 
 
Finally, it is important to address the term “glucose-sensing” neurone, which may be 
something of a misnomer.  While it is true that these cells respond to glucose, they also 
respond to a variety of other nutrients and nutrient-related hormones. For example, 
some neurones in the ARC are responsive to oleic acid. Wang et al found that 13% of 
ARC neurones are excited by oleic acid and 6% are inhibited when they are incubated 
with 2.5mmol/l glucose.  When incubated in 0.1mmol/l glucose, oleic acid inhibits 30% 
of neurones and excites none (Wang et al, 2006). Therefore it is possible that there are 
interactions between fatty acid and glucose metabolism within glucose-sensing neurons 
which regulate their activity.   
One hypothesis suggests that this occurs as a result of accumulation of long chain fatty 
acyl-CoAs (LCFA-CoA) in the cytoplasm. Briefly, the end product of glycolysis, 
acetyl-CoA, is converted to malonyl-CoA by acetyl-CoA carboxylase (ACC) when 
cellular ATP is high. Malonyl-CoA is a potent inhibitor of mitochondrial membrane 
transporter Carnitine palmitoyltransferase 1 (CPT-1). CPT-1 mediates transport of fatty 
acyl-CoAs across the outer mitochondrial membrane and in so doing regulates β-
oxidation. Inhibition of CPT-1 results in the accumulation of lipid in the cytosol, which 
in turn activates Protein kinase C causing membrane depolarisation. When glucose is 
limiting, malonyl-CoA is low and CPT1 is active, thus lipids do not accumulate in the 
cytoplasm and the membrane remains polarised (figure 1.3). 
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Figure 1.3 Hypothalamic Lipid Sensing: In the presence of glucose mitochondrial lipid 
transport is inhibited by malonyl-CoA, leading to accumulation of lipid in the 
cytoplasm. The causes membrane depolarisation and may signal the fed state. Adapted 
from Lam et al, 2005.    
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AMPK may also play an important role in this pathway. AMPK is the primary regulator 
of ACC, the enzyme responsible for the conversion of acetyl-CoA to malonly- CoA. 
Activation of AMPK, when the ratio of ATP-ADP is low, results in the inhibition of 
ACC and reduced malonyl-CoA, thus reducing CPT-1 inhibition and accumulation of 
LCFA-CoAs in the cytoplasm. In healthy individuals, high plasma glucose plus high 
plasma lipids will only occur in the fed state. Thus, depolarisation may signal the fed 
state. This concept is supported by the fact that lipid administration to the basomedial 
hypothalamus results in decreased feeding and decreased glucose production by the 
liver (Lam et al, 2005b).  
Glucose sensing neurones are also sensitive to lactate. ICV lactate infusion results in 
hypoglycaemia due to reduced hepatic glucose output and lipid production (Lam et al, 
2005a;Lam et al, 2007). This is believed to occur as a result of activation of GE 
neurones and possibly inhibition of GI neurones.   
Astrocytes are a major endogenous source of lactate in the brain and it has been 
suggested that glucose-sensing in the brain is dependent on astrocytes as proposed in the 
“astrocyte-neurone shuttle hypothesis” (Pellerin et al, 2000). This hypothesis proposes 
that glucose is taken up by astrocytes where it is metabolised via glycolysis to pyruvate 
and next converted to lactate. Lactate is released by the astrocyte and taken up by the 
neurone via the monocarboxylate transporter (MCT1). Once transported across the cell 
membrane lactate is converted back to pyruvate by lactate dehydrogenase (LDH). 
Pyruvate is a late stage glycolytic intermediate and its metabolism results in an increase 
in ATP/ADP ratio, closing ATP-sensitive K+ channels (Penicaud et al, 2006). This idea 
is supported by the finding that specific pharmacological inhibition of astrocytes results 
in loss of ARC glucose-sensing following glucose infusion. However, it is not 
supported by the fact that manipulation of GK in neurones influences their glucose-
sensing ability. The metabolism of lactate is downstream of GK. If glucose-sensing 
occurred purely via lactate, manipulation of GK would not be expected to influence it.  
Some glucose-sensing neurones are also sensitive to leptin, insulin and ghrelin. In the 
hypothalamus, leptin and insulin suppress AMPK activity (Minokoshi et al, 2004) while 
ghrelin activates it (Andersson et al, 2004). Since AMPK regulates ACC this offers a 
potential mechanism by which glucose-sensing in neurones may interact with the 
response to endocrine hormones. Equally, since AMPK activity is affected by glucose, 
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fatty acids and a host of endocrine hormones, it suggests that integration between these 
factors may occur in intracellular signalling pathways and may be important in nutrient 
sensing (Penicaud et al, 2006).    
While the term “glucose-sensing” may be something of a misnomer, it is the term used 
most frequently in the literature. For the sake of convention and clarity it will also be 
used in this thesis.   
 
1.5 Summary  
 
A considerable body of literature exists which suggests that glucose-sensing neurones of 
the hypothalamus play important physiological roles, particularly in feeding behaviour 
and glucose homeostasis. However, at present, their exact physiological role and their 
nutrient sensing mechanisms are not clear. Glycolysis appears to be important to 
glucose-sensing and may also be involved in lactate, fatty acid and leptin induced 
signalling via modulation of AMPK, especially in GE neurones. Since GK is central to 
the glucose-sensing mechanism, modulating its expression may help to elucidate the 
physiological role of glucose-sensing neurones. rAAV offers a safe and robust method 
of gene transfer which, by stereotaxic injection into adult animals, avoids problems 
associated with embryonic compensation. With stereotaxic injection of rAAV 
glucokinase (rAAV-GKS) and rAAV glucokinase antisense (rAAV-GKAS) it will be 
possible to modulate glucose sensing in specific hypothalamic nuclei, without reliance 
on nuclei specific promoters. This is attractive, since it is possible, if not probable, that 
glucose-sensing neurones perform different functions depending on location.    
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Chapter 2 
rAAV: Production and testing 
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2.1 Introduction  
 
2.1.1 Studying appetite and neuroendocrinology using molecular approaches 
  
The fields of neuroendocrinology and appetite regulation have benefited greatly from 
advances in molecular biology. Transgenic methods allow the expression of endogenous 
genes to be increased, decreased or completely knocked out. It is also possible to 
introduce genes into species and areas of the body in which they are not normally 
expressed. Such methods offer insight into gene functions that were not previously 
possible.  
Prior to these molecular advances the field of appetite regulation relied heavily on 
administration of compounds via cannulation of a desired location (e.g. the third 
cerebral ventricle or specific hypothalamic nuclei). CNS injection of substances, 
including neuropeptides and nutrients (such as glucose), have greatly increased the 
understanding of neuroendocrinology and appetite regulation (Zarjevski et al, 
1993;Davis et al, 1981).  
Daily ICV injections can be tolerated for a period of one to two weeks. However, ICV 
administrations of compounds can produce non-specific effects because the third 
cerebral ventricle bathes a number of hypothalamic and extra hypothalamic structures. 
Intranuclear injections increase specificity and localisation but daily injections are only 
tolerable for short periods (less than one week) due to destruction of tissue at the 
injection site. The presence of an indwelling cannula and repeated injection also 
increases the risk of infection. Finally, repeated injection protocols cause disruption to 
the normal behavioural patterns of research animals (including feeding behaviour) and 
increase stress.  
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2.1.2 Transgenic animals  
 
In 1985, Gordon et al described a method in which purified plasmid DNA, containing 
segments of the herpes simplex virus and simian virus 40 genome, were microinjected 
into pronuceli of fertilized mouse oocytes. The fertilized oocytes were transferred to the 
oviducts of pseudopregnant host mice and allowed to develop to term. In the initial 
study, injection of several hundred embryos resulted in 78 viable young. Of these 
animals only two were positive for the plasmid DNA (Gordon et al, 1980).  In the 
present day, the majority of transgenic animals are produced using similar methodology 
to that outlined by Gordon et al. Although the techniques have been refined the 
production of transgenic animals remains inefficient (Niemann & Kues, 2003).  
A major limitation associated with knockout mice is the phenomenon of embryonic or 
developmental compensation. Embryonic compensation describes the ability of a fetus 
to adapt to the absence of a knocked out/in gene and develop phenotypically normal. An 
example of embryonic compensation is the AgRP/NPY double knockout mouse. NPY 
and AgRP are orexigenic neuropeptides.  Knockout of NPY and AgRP would be 
expected to produce a phenotype displaying reduced energy intake and low bodyweight. 
Surprisingly, AgRP/NPY KO mice are normal with regard to food intake and 
bodyweight gain (Qian et al, 2002).  
The developmental root of this phenotype is elegantly demonstrated by a transgenic 
mouse model in which AgRP/NPY neurones can be ablated in a temporally controlled 
manner using diphtheria toxin. Ablation of AgRP/NPY in neonatal mice has little effect 
on feeding behaviour. However, ablation of the same neurones in adult animals 
produces rapid starvation showing that early loss of certain pathways can be 
compensated for during development and early life (Luquet et al, 2005).  There is a high 
degree of redundancy in the CNS pathways that regulate feeding behaviour, so 
embryonic knockout models are not ideal for the study of appetite circuits.  
A further potential problem effecting KO animals is early life or embryonic lethality. 
Early life or embryonic lethality occurs when a gene is knocked out that is vital for pre 
or perinatal development. The glucokinase homozygote KO mouse is an example of an 
early life lethal KO. GK KO homozygotes die postnatally between days three and five, 
are markedly diabetic and do not feed (Yang et al, 2007).  Replacing the pancreatic 
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form of glucokinase but not the hepatic form partially rescues the phenotype and 
animals survive into adulthood (Grupe et al, 1995). However, the pancreatic form of 
GK is expressed in the hypothalamus so this approach would not be applicable to the 
present work (Roncero et al, 2000).  
Localising transgenesis to a specific region of the body is another hurdle associated with 
KO models. GK is expressed in various parts of the body including the central nervous 
system, liver and pancreas (Roncero et al, 2000 ;Iynedjian et al, 1986). Global GK KO 
heterozygotes have impaired β-cell response to glucose and are hypoglycaemic and 
hyperphagic (Yang et al, 2007). However, it is impossible to extrapolate the 
involvement of GK expressing cells in any one region of the body from this model.  
By using tissue specific promoters it is possible to alter gene expression in distinct 
regions of the body or in a specific cell type. An example of this is the VMH specific 
leptin receptor KO mouse. These mice are produced by crossing two mouse lines. The 
first, the Sf1-Cre mouse expresses Cre recombinase only in cells that express Sf1. The 
second mouse is a Lepr flox/flox mouse in which the leptin receptor is flanked by lox-p 
sites. Cre recombinase excises DNA that is found between lox-p sites. Crossing these 
mouse lines produces mice in which Cre recombinase and lox-p are expressed together 
in Sf1 expressing cells. The result is a mouse with VMH specific KO of the leptin 
receptor because the VMH is the only region of the hypothalamus that expresses both 
the leptin receptor and Sf1 (Dhillon et al, 2006).  
Unfortunately, this approach is not applicable to the present work because there is no 
ARC-specific promoter that would target all ARC neurones. The ARC is composed of a 
variety of cell populations and at present it is unclear exactly which cells express GK 
(Wang et al, 2004;Muroya et al, 1999;Ibrahim et al, 2003).  For this reason and others 
discussed above, traditional transgenic methods do not lend themselves to the current 
project.  
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2.1.3 Gene transfer 
 
Gene transfer offers a number of advantages over traditional transgenic approaches. 
Using stereotaxic injection of an appropriate vector it is possible to target specific 
hypothalamic nuclei in adult animals and a chosen gene of interest can be over or under 
expressed for the duration of the host‟s life. This negates the requirement for a site 
specific promoter and circumvents the problems associated with embryonic lethality 
and embryonic compensation. As such, gene transfer is a preferable method to 
traditional transgenic methods for this work.  
 
2.1.4 Choice of Gene Transfer Vector  
 
Desirable characteristics in a gene transfer vector include; ease of production, sustained 
transgene expression, unlimited insert size, the ability to target specific tissues and the 
ability to tranduce post-mitotic cells. It is also desirable that the vector of choice evokes 
a low host immune response and it may be desirable for transgene expression to be 
reversible (Park et al, 2008). At present, no single perfect gene transfer vector exists but 
there are a wide variety of vectors available each with desirable and undesirable 
attributes.  
Gene transfer vectors may be broadly divided into two categories; viral and non-viral. In 
general, viral vectors are a more efficient method of gene transfer, especially in vivo. 
However, the introduction of viral proteins during gene transfer using viruses can 
activate innate and acquired immune responses which can limit gene expression and 
negatively affect the health of the host (Wells, 2004). 
Recombinant viral vectors are extremely useful in animal research because they are; 
able to recognise host cells, are transported across cells membranes and transfer genetic 
material to the cell nucleus. They are also able to produce sustained transgene 
expression by effectively high-jacking cellular protein synthesising machinery. At 
present, their use in humans is limited due to toxicity and immunogenic reaction. 
However, a number of different viral vectors have been used successfully in animal 
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research and a great deal of effort is focused on creating gene vectors that will be better 
tolerated by humans.  
 
2.1.4.1  Adenoviruses 
 
Adenoviruses are double stranded DNA viruses with a 36kb genome. In nature, 
adenoviruses cause infections of the respiratory tract and most humans come into 
contact with various serotypes during early life. In laboratory settings most recombinant 
adenoviruses are derived from serotypes 2 and 5 (Snyder et al, 2010).  
First generation replication-deficient adenoviruses were produced by deleting the E1a 
and E1b genes, leaving 90% of the viral genome intact. These viruses are capable of 
carrying large transgenes and produce high levels of infection. In organisms that have 
not previously been exposed to adenoviruses transgene expression is sustained. 
However, pre-existing immunity to adenoviruses severely limits duration of transgene 
expression (Kaplan et al, 1997).   
High capacity, or gutless, adenoviruses have recently been developed which contain 
only the minimum proportion of the viral genome required for infection. Due to the 
removal of most of the viral genome high capacity adenoviruses are capable of 
producing sustained transgene expression in animals that have been previously 
immunized against adenovirus (Barcia et al, 2007).  
 
2.1.4.2  Retroviruses and Lentiviruses 
 
Retroviruses are small single stranded RNA viruses with a carrying capacity of 
approximately 7-12kb. Following infection of a host cell the viral genome must first be 
converted to double stranded DNA by reverse transcriptase. Next, the double stranded 
DNA integrates randomly into the host genome (Temin & Baltimore, 1972). The 
random integration of the newly formed double stranded DNA is problematic in both 
clinical and research settings because of the possibility of insertional mutagenesis of 
host genes. Retroviruses are also limited in their uses because they are only able to 
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tranduce dividing cells and transgene expression can only occur in cells that are actively 
replicating (Miller et al, 1990).     
Lentiviruses are a subgroup of retroviruses which include human immunodeficiency 
virus type I and II. Unlike other retroviruses, they are able to tranduce non-dividing 
cells and produce sustained transgene expression. As such, they can be suitable vectors 
for gene transfer into tissues including the brain, eye, lungs and pancreas (Naldini et al, 
1996;Miyoshi et al, 1997). Many lentiviruses are extremely pathogenic and cause a 
number of slow-progress disease states. For this reason, safety is an important concern 
when working with lentiviruses.  
 
2.1.4.3 Herpesviruses  
 
Herpes viruses are enveloped double-stranded DNA viruses. They are responsible for a 
number of human diseases including; herpes labialis and genitalis (Nishiyama, 2004). 
Herpes viruses are naturally neurotropic and have the capacity to carry large trangenes 
and infect a broad range of cell types. As such, they are an attractive vector for research 
and clinical trials involving the nervous system.  
 Replication-defective herpes vectors, which lack viral replication genes including 
thymidine kinase, have been shown to be effective in rodents when introduced into the 
CNS. Recently, herpes viral vectors have been tested in a phase I clinical trial in 
humans (Wolfe et al, 2009).  
The large and complicated nature of the herpes genome makes the virus complicated 
and potentially dangerous to use. In addition, the virus can be strongly immunogenic 
and cytotoxic.  
 
 
  
55 
 
2.1.4.4 Adeno-associated virus 
 
Adeno-associated virus (AAV) is a small non-enveloped dependovirus measuring 
approximately 20-25nm. The AAV genome comprises a single strand of linear DNA of 
approximately 4.7kb. Human infection with AAV is extremely common; 90% of 
humans produce antibodies against at least one AAV serotype. However, AAV is 
considered non-pathogenic because it has not been associated with any human disease. 
In addition, as a dependovirus, AAV viruses are replication deficient and do not possess 
innate lytic ability (Atchison & Casto, 1965). Because of these qualities, AAV is 
extremely safe to work with and with modification is a safe viral vector. In addition, 
AAV is very stable and is resistant to repeat freeze thawing, temperatures up to 65˚C 
and certain proteases. 
An AAV viral particle is composed of 26% DNA and 74% protein. Each virion contains 
one copy of the viral genome which may be packaged as positive-sense (5‟-3‟) or 
negative-sense (3‟-5‟) (Berns & Adler, 1972). The AAV serotype 2 genome is 
comprised of two open reading frames that are flanked by inverted terminal repeats 
(ITRs) (Srivastava et al, 1983). ITRs are 145 base pair sequences that are required for 
viral DNA replication, viral packaging and host genome integration. Each ITR contains 
a 125 base pair palindromic sequence which forms a hairpin structure and acts as the 
origin of replication and as a primer for host-cell mediated second strand DNA 
synthesis (Lusby et al, 1980;Bohenzky et al, 1988).  
In addition to the ITRs, the AAV genome contains the Rep and Cap genes. The Rep 
gene is under the control of two promoters (p5 and p19) and encodes four overlapping 
proteins Rep78, Rep68, Rep52 and Rep40 (Kyostio et al, 1994). Wild type AAV 
integrates in a site specific manner into human chromosome 19. In the absence of the 
Rep gene, AAV remains episomal or integrates into the host genome randomly 
(Weitzman et al, 1994). Rep proteins are also involved in viral DNA packaging and 
have endonuclease and helicase activity (Im & Muzyczka, 1990) (figure 2.1). 
The Cap gene is under the control of the p40 promoter and encodes the structural 
proteins VP1, VP2 and VP3 which form the viral protein coat (figure 2.1). AAV possess 
an icosahedral protein coat that is formed of 60 capsid proteins with 85% of protein 
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mass being made up by the smallest of the coat proteins VP3 (Rose et al, 1971;Jay et al, 
1981).  
 
Figure 2.1: Schematic of wild-type AAV-2 serotype genome.  
 
 
2.1.4.5 Recombinant adeno-associated virus 
 
Recombinant adeno-associated viruses (rAAV) are a commonly used viral vector, Rep 
and Cap genes are removed from the packaged genome leaving only the ITRs. Since the 
ITRs are not translated rAAV does not produce any viral proteins (Samulski et al, 
1989). This means that host immune response to rAAV is extremely low and trangene 
expression is sustained. Although rAAV administration does not result in inflammation 
it has been shown that antibodies are formed against the capsid proteins. This is not 
problematic if the virus is only introduced on a single occasion to a host that does not 
have pre-existing immunity. However, repeat administration or administration to an 
immune primed host can result in inflammatory responses and limited trangene 
expression (Zaiss & Muruve, 2005).  
rAAV serotype 2 has a strong neurotropism. So, when injected into the brain, rAAV-2 
infection is largely neurone specific (Mandel et al, 1998). The neurotropism of serotype 
2 is dependent  on specific cell surface proteins. Heparan sulphate proteoglycan, a 
member of the ubiquitously expressed protoglycan family, is necessary for efficient 
attachment and infection of neurones (Summerford & Samulski, 1998). In addition, it 
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has been shown that infection is further improved by the expression of the fibroblast 
growth receptor and the alphaVbeta5 integrin receptor which are both found on the 
neurone cell surface (Qing et al, 1999;Summerford et al, 1999). However, the role of 
the alphaVbeta5 integrin receptor has been disputed and the methods utilized in the 
work of Summerford et al have been criticised (Qiu & Brown, 1999).    
Upon infection, rAAV travels to the cell nucleus where its single stranded viral genome 
is converted to double stranded DNA before gene transcription can occur. The 
production of the second DNA strand delays transcription and is considered a rate-
limiting step in transgene expression (Afione et al, 2000;Ferrari et al, 1996). Within the 
nucleus, the rAAV genome can exist episomally or randomly integrated into the host 
genome (Duan et al, 1998).  
rAAV has been used to investigate the role of a number of neuropeptides in the CNS of 
adult animals. Gardiner et al utilized a rAAV vector encoding antisense neuropeptide Y 
targeted at the ARC. Infection with rAAV antisense NPY resulted in decreased food 
intake and bodyweight weight compared to rAAV-eGFP injected controls (Gardiner et 
al, 2005). This study and others like it demonstrate the potential of rAAV as a tool for 
the study of hypothalamic energy regulation. To date, no studies have been published 
that utilize rAAV to chronically over express GK in the CNS.  
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2.2 Aims and Objectives  
 
I aim to investigate the role of hypothalamic glucose-sensing in the regulation of energy 
balance and glucose homeostasis.  In order to do this I will: 
  
1. Modify pTR-CGW plasmid to contain GK (GKS) and antisense GK (GKAS) 
cassettes.  
2. Test the efficacy of the GKS-pTR-CGW and GKAS-pTR-CGW plasmids by 
transfecting cultured cells and subsequently performing enzymatic GK activity 
assay. 
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2.3 Materials and methods 
 
Unless stated otherwise all chemicals were purchased from Sigma, Poole, Dorset, UK. 
 
2.3.1 Production of GKAS using polymerase chain reaction (PCR) 
 
2.3.1.1 Reverse transcription 
 
Materials 
Rat hypothalamic RNA (5mg/ml)  
 10mM dNTPs (GE Healthcare, Buckinghamshire, UK) 
 5x Reverse transcriptase buffer (Promega, Madison, WI)  
 Avian myoblastoma virus reverse transcriptase (RT) 10U/µl (Promega) 
 Oligo dT (12-18) 200ng/µl (GE Healthcare) 
 
Method 
The reaction was set up in a final volume of 20µl containing the following: 1mg/ml 
RNA, 1x reverse transcriptase buffer, 1mM dNTPs and 10mg/ml oligo dT. The solution 
was heated to 65ºC for 5 minutes and allowed to cool at room temperature for 30 
minutes, 10U RT were then added and the reaction was incubated at 42ºC for 1 hour. 
The reaction was then used in PCR. 
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2.3.1.2 PCR 
 
Materials   
 10x Taq buffer  
 20µM oligonucleotide primers (Oswel DNA service, Southampton, UK) 
 Taq DNA polymerase (5U/µl) 
 10mM dNTPs (GE Healthcare) 
 Reverse Transcriptase Reaction (RTr) 
 pCMV4.GKB1 encoding full length GK (gift from M.Magnuson, Vanderbilt 
University) 
Method 
For glucokinase antisense (GKAS), cDNA fragments from the RT reaction were 
amplified using primers corresponding to sequences on the glucokinase gene 
(nucleotides 1-185, figure 2.2). Half of the reverse transcription reaction was added to a 
tube containing 1x taq buffer, 0.2mM dNTPs, 200nM oligonucleotide primers. The 
reaction was heated to 95ºC for 5 minutes and then 5U taq DNA polymerase were 
added. The reaction was then cycled thirty times through the following temperatures: 
95ºC for thirty seconds, 55ºC for thirty seconds and 72ºC for thirty seconds. After 
completion of the reaction, 10µl of the PCR products were visualised by gel 
electrophoresis on a 1% TAE/agarose gel. 
For glucokinase sense (GKS), the above method was repeated with the exception that 
1ul pCMV4.GKB1 was added to the reaction in the place of the reverse transcriptase 
reaction and amplification was achieved using primers corresponding to sequences on 
the pCMV4.GKB1 plasmid (nucleotides 787-2247, figure 2.2). 
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Figure 2.2 PCR primers used for amplification of GK gene sequences.  
 
 
 
 
 
 
 
 
  
Primer Sequence 
GKS forward  5‟-ACGTACCGGTATTCACATCTGGTACCTGGG -3‟ 
GKS reverse  5‟-AGCTCGTACGTATTAGGACAAGGCTGGTGG-3‟ 
GKAS forward 5‟-AGCTTGTACAGGGGGTCCCAGTTCACCTGG-3‟ 
GKAS reverse 5‟-AGCTGGATCCTGGGTCTCCAGGCCCAGGCC-3‟ 
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2.3.1.3 Visualisation of PCR products 
 
Materials 
Agarose, type II-A medium EEO 
 50x TAE: (appendix I) 
 2M Tris-Acetate pH 8.5  
 0.05M EDTA pH 8.0  
 Ethidium Bromide (10mg/ml) (VWR International Ltd, Poole, UK) 
DNA marker (BRL 1Kb plus ladder, Invitrogen , Paisley, UK) 
 Gel loading buffer (appendix I) 
   
 
Method 
A 1% (w/v) agarose gel was prepared by dissolving the agarose in 1x TAE using a 
microwave oven. The gel was cooled to 45ºC and ethidium bromide added to a final 
concentration of 0.5µg/ml. Once set the gel was placed into an electrophoresis tank 
containing 0.5 TAE with 0.5µg/ml ethidium bromide. Three microlitres of gel loading 
buffer was added to 10µl PCR product, 1µl of DNA marker was added to 9µl GDW and 
treated in the same way. The samples were loaded onto the gel and electrophoresed at 
10V/cm. The DNA was visualised by illumination with UV light (300nm). 
 
2.3.2 Insertion of GK and GKAS into pTR-CGW 
 
One of the most important advances in the field of molecular biology was the ability to 
cut DNA at specific sites and to ligate the cut ends. Restriction endonucleases (isolated 
from bacteria) recognise specific target sites within double stranded DNA and cleave it. 
Ligating cut fragments relies on the use of a virus-derived enzyme that catalyses the 
formation of phosphodiester bonds between a free 5‟ phosphate and a free 3‟ hydroxyl 
group (Sambrook et al, 1989) 
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2.3.2.1 Restriction endonuclease digestion of PCR products and pTR-CGW 
 
Materials 
PCR products 
 pTR-CGW (rAAV plasmid)  (gift from Dr. Verhaggen, Amsterdam) 
Restriction endonucleases: BamHI, BsrGI, BsiWI, AgeI (New England Biolabs, 
Hitchin, Hertfordshire, UK) 
10x Restriction buffer (as supplied) (appendix I)  
10x Bovine serum albumin (BSA) (New England Biolabs)  
Phenol/Chloroform pH8 (VWR)  
5M Sodium acetate, pH 5.2 (appendix I) 
Shrimp alkali phosphatase (SAP) 4U/µl (GE Healthcare) 
 
Method 
In separate reactions the PCR products and pTR-CGW were diluted in autoclaved glass 
distilled water (GDW), restriction buffer and BSA added to give a final concentration of 
1x. Forty units of each restriction endonuclease (for GKAS BamHI and BsrGI. For GKS 
AgeI and BsiWI) were added; the total volume of enzyme added was kept below 10% 
of the final volume. The reaction was incubated for at least one hour at 37ºC. In the 
digestion of pTR-CGW, 8U SAP was added 30 minutes before the end of the 
incubation. SAP removes 5‟ phosphate groups preventing self-ligation of the plasmid. 
The reactions were extracted with an equal volume of phenol/chloroform and the phases 
separated by centrifugation for 3 minutes at 13,000xg. The DNA was ethanol 
precipitated with 0.1 volumes sodium acetate pH5.2 and 2.5 volumes absolute ethanol 
and was incubated at -20ºC for at least one hour. The DNA was recovered by 
centrifugation for 7 minutes at 13,000xg. 
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2.3.2.2 Electroelution of DNA fragments 
 
Following restriction digestion it is advantageous to purify the DNA fragment of 
interest and remove any contaminating fragments. This is especially true for plasmids as 
restriction digests are not 100% efficient and a small amount of closed plasmid DNA 
can produce a high background during transformations. The DNA was therefore size 
fractionated by electrophoresis on an agarose gel and the bands of interest electroeluted. 
Materials 
50x TAE  
 Dialysis tubing (VWR) 
 Gel loading buffer (appendix I) 
 DNA marker (Invitrogen) 
 
Method 
A 1% agarose gel was prepared (as described in section 2.3.1.2). The precipitated DNA 
was dissolved in 20µl GDW and 6µl loading buffer added. One microlitre of DNA 
marker was added to 9µl GDW and 3µl loading buffer added. Samples were loaded 
onto the gel and electrophoresed at 10V/cm.  
The DNA was visualised by illumination with UV light, the band of interest was cut out 
from the gel using a scalpel and placed into dialysis tubing sealed at one end with a clip. 
Four hundred microlitres of 0.5x TAE was added to the gel slice, air excluded from the 
end of the tubing and the other end sealed with a clip. The DNA was eluted from the gel 
by electrophoresis at 20V/cm for 20 minutes. The TAE was removed from the tubing, 
phenol/chloroform extracted and the DNA was recovered by ethanol precipitation (as 
described in section 2.3.2.1). The DNA was dissolved in GDW and quantified visually 
by running 1µl on a 1% agarose gel. 
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2.3.2.3 Ligation of PCR product into pTR-CGW 
 
Materials 
T4 DNA ligase, 6U/µl (New England Biolabs) 
 10x Ligase buffer (as supplied)   
 Digested PCR products  
 Digested pTR-CGW 
 
Method 
DNA ligation was used to insert the digested GKAS and GK into pTR-CGW plasmid. 
Twenty nanograms of plasmid DNA were dissolved in GDW and a fourfold molar 
excess of PCR product added. Ligase buffer was added to a final concentration of 1x 
and 6U T4 DNA ligase added to give a final volume of 10µl. The reaction was 
incubated at 16ºC overnight.  
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2.3.3 Preparation of GKS-pTR-CGW-plasmid and GKAS-pTR-CGW-
plasmid   
 
2.3.3.1 Transformation of competent bacteria by electroporation 
 
Competent bacteria can be induced to take up DNA via the process of electroporation. 
Passing a voltage across a bacteria/plasmid mixture opens transient pores in the bacteria 
plasma membrane allowing the plasmid to move into the cell. pTR-GCW contains an 
ampillicin resistance gene. Subsequent incubation allows the expression of the 
resistance genes before exposure to antibiotic. 
Materials 
Ligation reaction 
LB (appendix I) 
LB(amp) plates  
JC811 bacteria (ATCC, Middlesex, UK) 
Glyercol (VWR) 
 
Method 
Prior to transformation, all salts must be removed from the reaction mixture to prevent 
arcing during electroporation. One microliter of glycogen was added to the ligation 
reaction to act as a carrier and the reaction ethanol precipitated for at least one hour (as 
described in section 2.3.2.1). DNA was recovered by centrifugation for 7 minutes at 
13000xg. The DNA was then dissolved in 10 µl GDW.  
An aliquot of frozen bacteria (JC811 cells) was thawed on ice, 10ng of plasmid (5µl 
ligation reaction) added and the mixture transferred to an electrocuvette with an intra-
electrode distance of 1mm. A voltage of 1.4 kilovolts was then passed across the 
cuvette. Eight hundred microlitres of warmed LB was then added and the reaction 
incubated at 37ºC for an hour. Agar plates (supplemented with 100µg/ml ampicillin) 
were warmed and 150µl of the transformed bacteria added to the plate. The bacteria 
were spread over the surface of the agar, the plate inverted and incubated at 37ºC 
overnight.  
67 
 
2.3.3.2 Small scale preparation of plasmid 
 
Plasmids are isolated on a small scale to allow several clones to be analysed 
simultaneously (Sambrook et al, 1989). To isolate the plasmids from bacteria it is 
necessary to disrupt the cell wall to release the plasmid and at the same time 
contaminants (proteins, genomic DNA and RNA) must be removed. Treatment with 
alkaline SDS disrupts the cell wall and bacterial debris is then precipitated using 
potassium acetate. This step also removes most of the genomic DNA, RNA is removed 
later by treatment with RNase A.  
Materials 
LB(amp) 
GTE (appendix I) 
0.2M sodium hydroxide 1% SDS (v/v) (appendix I) 
5M potassium acetate (appendix I) 
5M sodium acetate (appendix I) 
Phenol/Chloroform  
Propan-2-ol (VWR) 
 
Method 
A single bacterial colony was placed in 2ml LB supplemented with ampicillin. This was 
incubated overnight at 37°C with vigorous shaking.  From this 1.5ml was removed and 
centrifuged at 13,000xg for 3 minutes, the remainder was stored at 4°C for future use. 
The supernatant was removed and the bacterial pellet resuspended in 100µl GTE. Two 
hundred microliters of alkaline SDS were added to the bacteria and the mixture left on 
ice for 5 minutes, 150µl 5M KAc was then added and the mixture left on ice for a 
further 5 minutes. The mixture was centrifuged at 13,000xg for 5 minutes and 350µl 
supernatant was removed to a fresh tube. Phenol chloroform extraction was carried out 
and the DNA precipitated by the addition of 0.6 volume propan-2-ol and incubation at 
room temperature for 10 minutes. This was centrifuged at 13,000xg for 7 minutes to 
pellet the DNA. Following removal of the supernatant, DNA was dissolved in 100µl 
GDW. The DNA was recovered by ethanol precipitated with 0.1 volumes sodium 
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acetate pH5.2 and 2.5 volumes absolute ethanol and was incubated at -20ºC for at least 
one hour.   
Restriction endonuclease digestion was carried out (as described in 2.3.2.1) to identify 
which clones contained an insert of the correct size. Purified DNA was dissolved in 
10µl GDW; GKS plasmid was digested by AgeI and BsiWI and GKAS plasmid was 
digested by BamHI and BsrGI. Both plasmids were also digested by XmaI to check for 
presence of inverted terminal repeats (ITRs) and visualised by gel electrophoresis. 
Clones containing the correct insert and ITRs were selected for large scale preparation. 
 
2.3.3.3 Large scale preparation of plasmid 
 
Materials 
 LB(amp) 
 GTE 
Lysozyme  
 0.2M sodium hydroxide/1% (w/v) SDS 
 5M potassium acetate (KAc) 
 Propan-2-ol 
100x TE (appendix I) 
DNase free RNase A 10mg/ml in GDW (GE Healthcare) 
 Phenol/Chloroform (VWR) 
 
Method 
A small quantity of bacteria containing pTR-CGW with the correct size insert was 
inoculated into 500ml LB(amp) and incubated at 37ºC overnight with vigorous shaking. 
The bacteria were recovered by centrifugation for 8 minutes at 3000xg (4000rpm in HS-
4 rotor in RC-5B superspeed centrifuge, Du Pont, Bristol, UK) at 4ºC. The pellet was 
resuspended in 25ml GTE supplemented with 2mg/ml lysozyme and the sample 
incubated at room temperature for 5 minutes. Fifty millilitres of SDS/NaOH were 
added, the sample mixed by inversion and incubated on ice for 5 minutes. Then 38ml 
5M KAc were added, the sample mixed by inversion and incubated on ice for 10 
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minutes. Bacterial debris was removed by centrifugation for 15 minutes at 9000xg 
(7000rpm in HS-4 rotor in RC-5B superspeed centrifuge, Du Pont) at 4ºC. The 
supernatant was transferred to a clean tube and 0.6 volumes propan-2-ol added. The 
sample was incubated on ice for 15 minutes and the DNA recovered by centrifugation 
for 15 minutes at 9000xg at 4ºC. The pellet was dissolved in 10ml GDW to which 100µl 
100x TE was added. RNase A was added at a concentration of 0.1mg/ml and the 
reaction incubated at 37ºC for 30 minutes. The reaction was extracted with an equal 
volume of phenol/chloroform and the phases separated by centrifugation for 20 minutes 
at 10000xg and 4ºC. The DNA was recovered by addition of 0.1 volumes 2M sodium 
acetate pH 5.2 and one volume propan-2-ol and incubation at -20ºC for at least one 
hour. The DNA was then purified by caesium chloride gradient.  
 
2.3.3.4 Caesium chloride gradient purification 
 
Large scale plasmid purification was carried out using a caesium chloride gradient 
(Sambrook et al, 1989). This purification method depends on the decrease in density of 
nucleic acids when bound to ethidium bromide. Because ethidium bromide binds by 
intercalation into the DNA, it causes unwinding of the helix. In closed circular DNA 
this increases supercoiling of the plasmid so binding of ethidium bromide is limited and 
the plasmid has a higher buoyant density than linear or nicked plasmids. The difference 
in buoyant density allows separation of the plasmid on a caesium chloride density 
gradient. 
Materials 
 TES:  
         50mM Tris-HCL, pH 8.0 (appendix I) 
         50mM sodium chloride 
         5 mM EDTA 
 Caesium chloride (Boehringer, Berkshire, UK) 
 10mg/ml ethidium bromide 
 Caesium chloride-saturated propan-2-ol (appendix I)  
Method 
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DNA obtained from large scale plasmid purification was recovered by centrifugation for 
20 minutes at 24,000xg (12,000rpm in HBS rotor in RC5B superspeed centrifuge, Du 
Pont) and 4ºC. The DNA was then dissolved in 8.25ml TES. Eight point four grams of 
caesium chloride were dissolved in the DNA solution and 150µl of ethidium bromide 
added and the solution mixed. The sample was divided into two polyallomer tubes 
(Ultracrimp, Du Pont), balanced, and overlaid with mineral oil. The tubes were sealed 
and centrifuged for 16 hours at 20ºC and 216,518xg (60,000rpm in a T-8100 rotor in a 
Sorvall 100SE centrifuge, Fisher Scientific, Loughborough, UK). 
After centrifugation, DNA bands were visualised by UV illumination and the band 
containing the closed pTR-CGW DNA removed using a 20-gauge needle and a 2ml 
syringe. Ethidium bromide was removed from the plasmid by repeated extraction with 
an equal volume of caesium chloride saturated propan-2-ol, until both phases were 
colourless. The DNA was precipitated by addition of two volumes of GDW and six 
volumes of room temperature absolute ethanol. DNA was recovered by centrifugation at 
24,000xg and 20ºC for 15minutes. The DNA pellet was dissolved in 0.4ml GDW, 
ethanol precipitated and recovered by centrifugation for 7 minutes at 13,000xg. The 
DNA was then dissolved in 1ml GDW. 
pTR-CGW was then quantified spectrophotometrically, 10µl DNA was diluted 1:100 
and placed into a quartz cuvette. Absorbance was read at 260 and 280nm UV 1101 
spectrophotometer (WPA, Cambridgeshire, UK). The reading at 280nm gives an 
indication of the purity of the sample as phenol absorbs more strongly at 280nm than 
DNA. The concentration of the DNA was calculated using the following formula:  
 
Concentration (µg/ml) = (A260 x dilution factor) x 50 
 
Samples were subjected to endonuclease digestion. GKAS-pTR-CGW was digested by 
BamHI and BsrGI. GKS-pTR-CGW was digested AgeI and BsiWI. Both plasmids were 
digested by XmaI to confirm the presence of ITRs. 
Insert sequences were confirmed by DNA sequencing (Genomics Core Laboratory, 
Imperial College London, UK).  
71 
 
2.3.3.5 DNA sequencing  
 
 Sequencing of GKS-pTR-CGW and GKAS-pTR-CGW plasmids was performed by the 
Imperial College Genomics Core Laboratory. Prior to sequencing each plasmid was 
diluted and mixed with either the forward or reverse primer that was used during the 
PCR reaction (see figure 2.2). Each reaction was 10ul and contained 200ng of plasmid 
DNA and 3.2pmole of primer. In total four reactions were produced; GKS-pTR-CGW 
plus forward primer, GKS-pTR-CGW plus reverse primer, GKAS-pTR-CGW plus 
forward primer and GKAS-pTR-CGW plus reverse primer. Samples were cycle 
sequenced using BigDye v3.1 (Applied Biosystems Ltd, Warrington, UK).  
Sequencing results were analysed for homology to known rat GK gene sequences using 
the Basic Local Alignment Search Tool (BLAST) on the National Centre for 
Biotechnology Information (NCBI) internet site.  
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2.3.4 Cell Culture 
 
2.3.4.1 Maintenance of cells 
 
Materials 
Unless otherwise stated all cell-culture materials were purchased from Invitrogen  
Human embryonic kidney cells (HEK293T. ATCC) 
 Human hepatocellular carcinoma (HEPG2. ATCC) 
Dulbeccos modified eagle medium (DMEM) 
Foetal Bovine Serum, heat inactivated (FBS) 
2.5% Trypsin in hanks balanced salt solution 
Versene: (appendix I) 
0.14M sodium chloride 
2.7mM potassium chloride 
8mM di-sodium hydrogen orthophosphate 
3mM EDTA 
1.5mM potassium di-hydrogen orthophosphate 
0.1%(v/v) phenol red 
 
Method 
Human embryonic kidney cells (HEK 293T) and human hepatocellular carcinoma cells 
(HEPG2) were  cultured in DMEM containing 4.5mg/ml glucose and 1mM sodium 
pyruvate supplemented with 10% (v/v) FBS at 37
o
C in a 5% carbon dioxide 
atmosphere.  Medium was changed every three days and the cells sub-cultured when 70-
80% confluent using 0.25% trypsin in versene.  Briefly, the medium was aspirated and 
the cells incubated at 37
o
C with fresh versene/trypsin until they detached from the 
flask.  The trypsin was inactivated by the addition of 10ml of fresh medium and the 
cells recovered by centrifugation for 5 minutes at 100xg.  The cells were resuspended in 
fresh medium and transferred to a new flask at a 1:10 dilution.  
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2.3.4.2 Transfection of cells with GKS and GKAS pTR-CGW plasmids 
 
Untreated mammalian cells, in contrast to bacteria, absorb naked DNA from 
solution.  However, the rate of absorption is slow and the proportion of cells transfected 
is low.  Such transfection also requires the use of large quantities of the exogenous 
DNA.  Several techniques have been developed to increase the efficiency of the process 
including chemical, membrane disruption (e.g. electroporation) and receptor 
mediated.  In this work, calcium phosphate co-precipitation was used. HEK293T cells, 
which do not express GK, were transfected with GKS plasmid. HEPG2 cells, which 
express large quantities of GK, were transfected with GKAS plasmid. In both cases, 
pTR-CGW was transfected as a control.   
Materials 
2x HEPES-buffered saline (HBS) (appendix I) 
280mM sodium chloride 
10mM potassium chloride 
 1.5mM di-sodium hydrogen orthophosphate 
 12mM dextrose 
50mM HEPES, pH7.05 
             2M calcium chloride (appendix I) 
 0.1xTE: 
1mM Tris-HCl, pH 8.0  
 0.1mM EDTA, pH 8.0 
 DNA in 0.1 x TE: 
  40µg/ml plasmid DNA 
  DMEM 
    
Method: transient transfection 
Twenty four hours before transfection, cells at approximately 60% confluence were sub-
cultured and plated at a density of 1x10
4
cells/cm in 90mm Petri dishes.  The following 
day media was replaced with fresh media.  A co-precipitate was formed by mixing 
300µl 10xHBS with 28µg plasmid DNA in 2.5ml of GDW and then slowly adding 
180µl 2M calcium chloride, while gently mixing using air expelled from a pipette 
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aid.  The solution was incubated at room temperature for 5 minutes to allow formation 
of the precipitate.  The precipitate was added to the cells and they were incubated at 
37
o
C in 5% carbon dioxide for 18 hours.  The medium containing the precipitate was 
replaced with fresh media, cells were incubated for 48 hours after which time cells were 
lysed in GK extraction buffer and enzymatic assay was performed for GK activity as 
described in below.  
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2.3.5 Glucokinase activity assays 
 
2.3.5.1 Standard glucokinase activity assay 
 
The glucokinase assay is a coupled spectrophotometric assay.  The first step is that 
catalysed by glucokinase in which glucose is phosphorylated to form glucose -6-
phosphate (G-6-P) in the presence of ATP.  
In the second step the G-6-P produced in step one is converted to 6–phospho-D-
gluconate by glucose-6-phosphate dehydrogenase with a concomitant conversion of 
NADP to NADPH. The reactions are summarised below. 
 
 
 
 
This increase in NADPH concentration can be quantified spectrophotometrically by a 
change in absorbance at 340nm. Thus the change in absorbance at 340nm can be used as 
an indirect measurement of GK activity. 
Both GK and hexokinase (Hx) phosphorylate glucose, however GK has a relatively low 
affinity and high Km for glucose when compared to Hx. In order to differentiate GK 
from Hx activity the assay is performed in a reaction containing either 100mM or 
0.5mM glucose as a substrate. At 0.5mM glucose GK activity should be low whereas 
Hx activity should be near maximal. At 100mM activity for both enzymes should be 
near maximal. Therefore GK activity for each sample can be calculated as: 
  
   
Glucose 
Glucose-6-
Phosphate 
6-Phospho-
D-Gluconate   
  
ATP ADP NADP NADPH 
Glucokinase 
Glucose-6-Phosphate 
Dehydrogenase 
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A(100mM glucose) – A(0.5mM glucose) = GK activity  
This figure can then be compared to a standard curve for GK activity (For calculations 
see appendix III).  
                          
Materials 
 GK extraction buffer (appendix I) 
 glucokinase (0.25µg/ml) 
 100mM adenosine 5‟trisphosphate 
 2M and 0.01M D-glucose 
 100mM Gly-Gly, pH8 (appendix I) 
 12.5mM NADP 
 1M MgCl2 (appendix I) 
 2U glucose-6-phosphate dehydrogenase 
 
 
Method 
Punch biopsies of various hypothalamic nuclei or HEK293T cells were homogenised in 
200µl GK extraction buffer using a handheld homogeniser. The homogenate was 
centrifuged for 40 minutes at 13000xg at 4ºC. The supernatant was then removed. In 
order to calculate glucokinase activity in samples a standard curve for GK activity was 
used containing: 0.025µg GK, 0.02µg, 0.0175µg, 0.015µg, 0.01µg, 0.0075µg, 0.005µg 
and 0.001µg of glucokinase.  
Assay reactions were set up in a total volume of 1ml, containing: 500µl 100mM Gly-
Gly, 7.5µl 1M MgCl2, 50µl 100mM ATP, 60µl 12.5mM NADP, 0.002µg glucose-6-
phosphate dehydrogenase, and 50µl of either 2M or 10mM glucose. The reaction was 
initiated by the addition of either glucokinase standard or hypothalamus homogenate.  
The reaction was incubated at 37˚C for 1 hour. Absorbance at 340nm was measured for 
each sample using a UV 1101 spectrophotometer (WPA, UK).  
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2.3.5.2 Optimized glucokinase activity assay 
 
The optimized GK assay is similar to the standard assay with the exception of the 
addition of 5-thio-d-glucose-6-phosphate (5TG) (at a final concentration of 45 µM) and 
3-O-methyl-N-acetylglucosamine (3OMG) (at a final concentration of 0.5mM).  5TG 
inhibits Hx activity without effecting GK, while 3OMG inhibits N-acetylglucosamine 
kinase, which phosphorylates glucose at high glucose concentrations. The addition of 
these agents is believed to increase the accuracy of the assay.   
 
Materials 
GK extraction buffer  
 glucokinase (0.25µg/ml) 
 100mM adenosine trisphosphate 
 2M D-glucose 
 100mM Gly-Gly, pH8  
 12.5mM NADP 
 1M MgCl2  
 2U glucose-6-phosphate dehydrogenase 
3-O-methyl-N-acetylglucosamine 
5-thio-d-glucose-6-phosphate 
 
Method 
The assay is performed (as described in 2.3.5.1) except that 3-O-methyl-N-
acetylglucosamine and 5-thio-d-glucose-6-phosphate are added to the reaction mixture 
prior to the addition of the GK standard or cell/hypothalamic homogenate. In addition, 
since Hx activity is inhibited there is no requirement for an assay carried out with 
0.01M D-glucose as the substrate. 
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2.3.5.3 Comparison of GK assay methodologies  
 
 The two GK assay methodologies were compared using HEK293T cell which were 
maintained as described in 2.3.4.1. Prior to the assay, cells were washed twice in 1x 
PBS before being resuspended in GK extraction buffer. Cells were lysed using a 
handheld homogeniser and assay were performed as described in 2.3.5.1 and 2.3.5.2.        
 HEK293T cell do not express glucokinase but do express other hexokinases. Since both 
assays are expected to be specific for GK activity the NADPH production in both 
should be zero. Assays were performed via the standard method and the optimized 
method and where compared against an assay performed without HX inhibition. Assays 
were performed in triplicate and absorbance was read at 340nm.  
NADPH production was calculated using the millimolar extinction coefficient 6.27 
(ξmM) at 340nm using the following equation   
A340nm/6.27ξmM= mM concentration of NADPH   
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2.3.6 Production of rAAV-GKS, GKAS-rAAV and rAAV-eGFP particles 
 
2.3.6.1 Production of rAAV 
 
Adeno-associated virus was produced by Dr. J. Gardiner (Division for Diabetes, 
Endocrinology and Metabolism) using the two plasmid system. Briefly, host cells 
(HEK293) are co-transfected with the rAAV plasmid pTR-CGW and a helper plasmid 
pDG using calcium phosphate. There is no homology between the two plasmids so they 
cannot recombine and form wild-type virus. This results in the production of rAAV 
particles. To release the particles cells are lysed by freeze thawing and the rAAV 
produced is purified. 
HEK293 cells were maintained in DMEM containing 4500µg/ml glucose and 1mM 
sodium pyruvate supplemented with 10% (v/v) FBS.  
 
2.3.6.2 Calcium phosphate transfection 
 
Materials 
HEK293 cells 
Plasmids 
pTR-CGW (containing transgene) 
pDG 
10x HEBS buffer: 
          1.36M NaCl 
          0.05M KCl 
0.007M Na2HPO4.2H20 
0.2M HEPES  
0.125M glucose 
 2M CaCl2 
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Methods 
Cells were plated into a 10 chamber cell factory (L x W x H (mm): 335 x 205 x 190, 
culture area: 6320cm
2
). Cells were incubated in 2000ml DMEM with 10% FBS. After 
24 hours, when cells were 50% confluent, the culture medium was replaced (250ml 
culture medium was retained for transfection) and transfection performed 2 hours later.  
Transfection mix was prepared for the cell factory, consisting of 560µg pTRCGW, 
1.68mg pDG, 7.2ml 2M CaCl2 and 52ml GDW. Immediately before transfection 12ml 
10x HEBS buffer in 48ml GDW was added and mixed gently. After standing at room 
temperature for 1 minute the mixture was added slowly to 250ml DMEM supplemented 
with 10% FBS and added to the cell factory.  
 
2.3.6.3 Recovery and purification of rAAV 
 
Materials 
 
0.01M PBS  
DNaseI  
Sepharoes column (GE Healthcare)  
Iodixanol (Life Sciences Technology, Eggenstein, Germany) 
0.3x PBS/0.1M NaCl 
0.3x PBS/2mM EDTA 
2M MgCl2  
Benzonase (Novagen, Nottingham, UK) 
Lysis buffer (appendix I) 
 
Methods 
Forty-eight hours after transfection, cell medium was removed and cells were washed 
using 500ml PBS and then harvested using 1 L PBS/2mM EDTA. Cells were then 
recovered by centrifugation at 5000xg for 10 minutes, washed in 150ml PBS and 
recovered by centrifugation at 5000xg for 10 minutes. Cells were then resuspended in 
60ml lysis buffer and aliquoted into four falcon tubes. Cells were subjected to three 
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cycles of 10 minutes in dry ice/ethanol followed by 10 minutes in a 37ºC waterbath. 
Seven point three microlitres of 2M MgCl2 and 1.2µl Benzonase were then added to 
each falcon tube and incubated at 37ºC for 30 minutes. The reactions were then 
centrifuged at 2000xg for 10 minutes to pellet cell debris. The supernatant was removed 
and loaded into four 50ml polyallomer tubes (Beckman Coulter (U.K.), 
Buckinghamshire, UK) under layered with 100ml iodixanol gradient. The tubes were 
then topped up with lysis buffer, heat sealed and subjected to centrifugation at 69,000xg 
for 1 hour at 18ºC (in a Type 70 Ti rotor in a Sorvall 100SE centrifuge, Fisher 
Scientific). The top of each tube was punctured with an 18G needle and rAAV collected 
by puncturing the bottom of the tube and collecting 5ml of iodixanol gradient from the 
60/40% interface. The fractions from the four tubes were pooled, added to 20ml PBS 
and loaded onto a Sepharose column which had been pre-washed with 25ml 0.1M 
NaCl/0.3x PBS and 50ml 0.3x PBS. The column was then washed with 50ml 0.3x PBS 
and the virus was eluted using 15ml 350mM NaCl/0.3xPBS. The elutant was transferred 
to an Apollo Concentrator containing 10ml PBS and subjected to centrifugation at 
4000xg for 5 minutes. The flow through was discarded and 5ml PBS was added below 
the filter and 19.5ml PBS above. The tube was then subjected to centrifugation at 
4000xg for 5 minutes and the 0.5ml remaining in the filter (which contained the rAAV) 
was aliquoted into eppendorf tubes.  The viral titre was quantified by dot blot analysis. 
 
2.3.7 Statistical analysis 
 
Unpaired two tail t-test was used for experiments with two groups and analysis of 
variance (ANOVA) followed by Bonferroni post hoc analysis was used for experiments 
with more than two groups. p<0.05 was considered statistically significant throughout. 
Data analysis was performed using GraphPad Prism 4 software (CA, USA). 
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2.4 Results 
 
2.4.1 PCR products  
 
2.4.1.1 GKS  
 
Following PCR, 10µl of GKS PCR product was visualised by gel electrophoresis. 
Comparison of the PCR product with a 1kb DNA ladder (Invitrogen) confirmed the 
presence of a band of between 1400-1600bp. The expected product size of this reaction 
was 1460bp.The presence of this band suggests that the reaction was successful.     
 
2.4.1.2 GKAS 
 
Following PCR, 10µl of GKAS PCR product was visualised by gel electrophoresis. 
Comparison of the PCR product with a 1kb DNA ladder confirmed the presence of a 
band of between 100-200bp. The expected product size of this reaction was 185bp. The 
presence of this band suggests that the reaction was successful.    
 
2.4.2 Restriction endonuclease digestion of small scale plasmid preparation 
 
DNA from small scale plasmid preparation was subjected to restriction endonuclease 
analysis to identify which clones contained the correct plasmid insert and retained their 
ITR‟s. GKS plasmid was digested by AgeI and BsiWI which should yield two bands; 
the cut plasmid of 4912bp and the GKS insert of 1460bp. GKAS plasmid was digested 
by BamHI and BsrGI and should yield two bands; the cut plasmid of 4892bp and the 
GKAS insert of 185bp. Both plasmids were also digested by XmaI to check for 
presence of ITR‟s. All products were visualised by gel electrophoresis. For both GKS 
and GKAS samples with the correct sized bands and strong ITRs were selected and 
used for large scale plasmid preparation.  
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2.4.3 Restriction endonuclease digestion of large scale plasmid preparation 
 
2.4.3.1 GKS  
 
Restriction endonuclease digestion of purified DNA from large scale GKS plasmid 
preparation using AgeI and BsiWI produced a band of between 1400-1600bp (figure 
2.3, b). Digestion with XmaI showed strong ITR‟s (figure 2.3, a). Taken together this 
indicates that the plasmid contains the correct insert and the ITR‟s to allow expression 
of the viral DNA in host cells.  
 
 
Figure 2.3 Gel electrophoresis of large scale plasmid production of GKS: Purified 
DNA was digested by AgeI and BsiWI and produced a band of ~1450bp (b). Digestion 
with XmaI showed strong ITR’s (a). Compared to Invitrogen 1kb ladder (c).    
 
 
 
1018bp 
1636bp 
2036bp 
A B C 
84 
 
2.4.3.2 GKAS  
 
Restriction endonuclease digestion of purified DNA from large scale GKAS plasmid 
preparation using BamHI and BsrGI produced a band of between 100-200bp (figure 2.4, 
b). Digestion with XmaI showed strong ITR‟s (figure 2.4, a). Taken together this 
indicates that the plasmid contains the correct insert and the ITR‟s to allow expression 
of the viral DNA in host cells. 
 
 
 
Figure 2.4 Gel electrophoresis of large scale plasmid production of GKAS: Purified 
DNA was digested by BamHI and BsrG1 and produced a band of ~180bp (b). Digestion 
with XmaI showed strong ITR’s (a).Compared to Invitrogen 1kb ladder (c).   
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85 
 
2.4.4 DNA sequencing  
 
2.4.4.1 GKS 
 
Sequencing results produced by the Imperial College Genomics Core laboratory were 
analysed using the nucleotide BLAST tool on the NCBI internet site. BLAST analysis 
of the GKS-pTR-CGW sequencing data revealed that the plasmid contained a full 
length copy of the glucokinase gene with 100% homology to pCMV4.GKB1 plasmid 
gifted from Vanderbilt University. As shown in figure 2.5.  
 
Query  1     CTGGGCTGGTGGCTGCGCAGATGCTGGATGACAGAGCCAGGATGGAGGCCACCAAGAAGG  60   
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||                                                
Sbjct  1     CTGGGCTGGTGGCTGCGCAGATGCTGGATGACAGAGCCAGGATGGAGGCCACCAAGAAGG  60 
 
Query  61    AAAAGGTCGAGCAGATCCTGGCAGAGTTCCAGCTGCAGGAGGAAGACCTGAAGAAGGTGA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    AAAAGGTCGAGCAGATCCTGGCAGAGTTCCAGCTGCAGGAGGAAGACCTGAAGAAGGTGA  120 
 
Query  121   TGAGCCGGATGCAGAAGGAGATGGACCGTGGCCTGAGGCTGGAGACCCACGAGGAGGCCA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   TGAGCCGGATGCAGAAGGAGATGGACCGTGGCCTGAGGCTGGAGACCCACGAGGAGGCCA  180 
 
Query  181   GTGTAAAGATGTTACCCACCTACGTGCGTTCCACCCCAGAAGGCTCAGAAGTCGGAGACT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   GTGTAAAGATGTTACCCACCTACGTGCGTTCCACCCCAGAAGGCTCAGAAGTCGGAGACT  240 
 
Query  241   TTCTCTCCTTAGACCTGGGAGGAACCAACTTCAGRGTGATGCTGGTCAAAGTGGGAGAGG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   TTCTCTCCTTAGACCTGGGAGGAACCAACTTCAGRGTGATGCTGGTCAAAGTGGGAGAGG  300 
 
Query  301   GGGAGGCAGGGCAGTGGAGCGTGAAGACAAAACACCAGATGTACTCCATCCCCGAGGACG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   GGGAGGCAGGGCAGTGGAGCGTGAAGACAAAACACCAGATGTACTCCATCCCCGAGGACG  360 
 
Query  361   CCATGACGGGCACTGCCGAGATGCTCTTTGACTACATCTCTGAATGCATCTCTGACTTCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   CCATGACGGGCACTGCCGAGATGCTCTTTGACTACATCTCTGAATGCATCTCTGACTTCC  420 
 
Query  421   TTGACAAGCATCAGATGAAGCACAAGAAACTGCCCCTGGGCTTCACCTTCTCCTTCCCTG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   TTGACAAGCATCAGATGAAGCACAAGAAACTGCCCCTGGGCTTCACCTTCTCCTTCCCTG  480 
 
Query  481   TGAGGCACGAAGACCTAGACAAGGGCATCCTCCTCAATTGGACCAAGGGCTTCAAGGCCT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   TGAGGCACGAAGACCTAGACAAGGGCATCCTCCTCAATTGGACCAAGGGCTTCAAGGCCT  540 
 
Query  541   CTGGAGCAGAAGGGAACAACATCGTAGGACTTCTCCGAGATGCTATCAAGAGGAGAGGGG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   CTGGAGCAGAAGGGAACAACATCGTAGGACTTCTCCGAGATGCTATCAAGAGGAGAGGGG  600 
 
Query  601   ACTTTGAGATGGATGTGGTGGCAATGGTGAACGACACAGTGGCCACAATGATCTCCTGCT  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   ACTTTGAGATGGATGTGGTGGCAATGGTGAACGACACAGTGGCCACAATGATCTCCTGCT  660 
 
Query  661   ACTATGAAGACCGCCAATGTGAGGTCGGCATGATTGTGGGCACTGGCTGCAATGCCTGCT  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   ACTATGAAGACCGCCAATGTGAGGTCGGCATGATTGTGGGCACTGGCTGCAATGCCTGCT  720 
 
Query  721   ACATGGAGGAAATGCAGAATGTGGAGCTGGTGGAAGGGGATGAGGGACGCATGTGCGTCA  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   ACATGGAGGAAATGCAGAATGTGGAGCTGGTGGAAGGGGATGAGGGACGCATGTGCGTCA  780 
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Query  781   ACACGGAGTGGGGCGCCTTCGGGGACTCGGGCGAGCTGGATGAGTTCCTACTGGAGTATG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   ACACGGAGTGGGGCGCCTTCGGGGACTCGGGCGAGCTGGATGAGTTCCTACTGGAGTATG  840 
 
Query  841   ACCGGATGGTGGATGAAAGCTCAGCGAACCCCGGTCAGCAGCTGTACGAGAAGATCATCG  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   ACCGGATGGTGGATGAAAGCTCAGCGAACCCCGGTCAGCAGCTGTACGAGAAGATCATCG  900 
 
Query  901   GTGGGAAGTATATGGGCGAGCTGGTACGACTTGTGCTGCTTAAGCTGGTGGACGAGAACC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   GTGGGAAGTATATGGGCGAGCTGGTACGACTTGTGCTGCTTAAGCTGGTGGACGAGAACC  960 
 
Query  961   TTCTGTTCCACGGAGAGGCCTCGGAGCAGCTGCGCACGCGTGGTGCTTTTGAGACCCGTT  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   TTCTGTTCCACGGAGAGGCCTCGGAGCAGCTGCGCACGCGTGGTGCTTTTGAGACCCGTT  1020 
 
Query  1021  TCGTGTCACAAGTGGAGAGCGACTCCGGGGACCGAAAGCAGATCCACAACATCCTAAGCA  1080 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  TCGTGTCACAAGTGGAGAGCGACTCCGGGGACCGAAAGCAGATCCACAACATCCTAAGCA  1080 
 
Query  1081  CTCTGGGGCTTCGACCCTCTGTCACCGACTGCGACATTGTGCGCCGTGCCTGTGAAAGCG  1140 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1081  CTCTGGGGCTTCGACCCTCTGTCACCGACTGCGACATTGTGCGCCGTGCCTGTGAAAGCG  1140 
 
Query  1141  TGTCCACTCGCGCCGCCCATATGTGCTCCGCAGGACTAGCTGGGGTCATAAATCGCATGC  1200 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1141  TGTCCACTCGCGCCGCCCATATGTGCTCCGCAGGACTAGCTGGGGTCATAAATCGCATGC  1200 
 
Query  1201  GCGAAAGCCGCAGTGAGGACGTGATGCGCATCACTGTGGGCGTGGATGGCTCCGTGTACA  1260 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201  GCGAAAGCCGCAGTGAGGACGTGATGCGCATCACTGTGGGCGTGGATGGCTCCGTGTACA  1260 
 
Query  1261  AGCTGCACCCGAGCTTCAAGGAGCGGTTTCACGCCAGTGTGCGCAGGCTGACACCCAACT  1320 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1261  AGCTGCACCCGAGCTTCAAGGAGCGGTTTCACGCCAGTGTGCGCAGGCTGACACCCAACT  1320 
 
Query  1321  GCGAAATCACCTTTCATCGAATCAGAGGAGGGCAGCGGCAGGGGAGCCGCRCTGGTCTCT  1380 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1321  GCGAAATCACCTTTCATCGAATCAGAGGAGGGCAGCGGCAGGGGAGCCGCRCTGGTCTCT  1380 
 
Query  1381  GCGGTGGCCTGCAAGAAGGCTTGCATGCTGGCCCAGTGAAATCCAGGTCATATGGACCGG  1440 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1381  GCGGTGGCCTGCAAGAAGGCTTGCATGCTGGCCCAGTGAAATCCAGGTCATATGGACCGG  1440 
 
Query  1441  GACCTCTAG  1449 
             ||||||||| 
Sbjct  1441  GACCTCTAG  1449 
 
 
Figure 2.5 BLAST analysis of sequencing results for GKS-pTR-CGW vs. 
pCMV4.GKB1 sequence:  Analysis of GKS-pTR-CGW compared to pCMV4.GKB1 
revealed 100% homology and showed that the sequence contained start and stop 
codons (highlighted in red).  
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2.4.4.2 GKAS  
 
BLAST analysis of the GKAS-pTR-CGW sequencing data revealed that the plasmid 
contained a 185bp sequence with 100% homology to the rat pancreatic GK sequence 
(GenBank: M25807.1) as shown in figure 2.6.  
 
 
Query  1    GGGGGTCCCAGTTCACCTGGGCTGGTGGCTGCGCAGATGCTGGATGACAGAGCCAGGATG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    GGGGGTCCCAGTTCACCTGGGCTGGTGGCTGCGCAGATGCTGGATGACAGAGCCAGGATG  60 
 
Query  61   GAGGCCACCAAGAAGGAAAAGGTCGAGCAGATCCTGGCAGAGTTCCAGCTGCAGGAGGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   GAGGCCACCAAGAAGGAAAAGGTCGAGCAGATCCTGGCAGAGTTCCAGCTGCAGGAGGAA  120 
 
Query  121  GACCTGAAGAAGGTGATGAGCCGGATGCAGAAGGAGATGGACCGTGGCCTGAGGCTGGAG  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACCTGAAGAAGGTGATGAGCCGGATGCAGAAGGAGATGGACCGTGGCCTGAGGCTGGAG  180 
 
Query  181  ACCCA  185 
            ||||| 
Sbjct  181  ACCCA  185  
 
Figure 2.6 BLAST analysis of GKAS-pTR-CGW sequencing results vs. rat pancreatic 
GK sequence: Comparison of GKAS-pTR-CGW to published sequence revealed 100% 
homology.   
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2.4.5 Comparison of GK assays methodologies   
 
GK assays were performed on extracts of HEK 293T cells which express hexokinase 
(Hx) but not GK. In the standard and optimized assays HX activity and NADPH 
production should be zero.   
In the standard GK assay NADPH production was reduced by 56% (0.057 +/-0.001 
mM, n=3) compared to control (0.131 +/-0.002 mM, n=3, P<0.0001). The optimised 
assay reduced NADPH production by 81% (0.025 +/-0.0002 mM, n=3. P<0.0001) 
compared to controls. Compared to the standard assay the optimised assay reduced 
NADPH by 56% (P<0.0001) (figure 2.7). Therefore, the optimized assay was used in all 
subsequent analysis.   
 
 
Figure 2.7 Comparing GK assays: NADPH production in GK assays on HEK293T cell 
lysate using three different methodologies 1). No hexokinase inhibitor (yellow bar). 2) 
Optimised GK assay (red bar). 3) Standard GK assay (blue bar). Values are shown in 
mM, n=3. ***= P<0.001. 
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2.4.6 Effect of GKAS-pTR-CGW plasmid transfection on GK activity in 
HEK293T cells  
 
Transfection of HEK293T cells with GKS-pTR-CGW plasmid resulted in increased 
glucokinase activity compared to controls (controls 0.11 +/- 0.048 vs GKS 0.34 +/-0.02 
units/mg protein, n=4, P<0.05) as shown in figure 2.8. 
 
 
 
Figure 2.8 Effect of GKS-pTR-CGW plasmid transfection on GK activity in 
HEK293T cells: GKS activity in HEK293T cells 48hr after transfection with either 
GKS-pTR-CGW plasmid (blue bar) or pTR-CGW plasmid (green bar). Values are 
shown in units of enzymatic activity per mg of protein +/- SEM n=4 * P<0.05.  
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2.4.7 Effect of GKAS-pTR-CGW plasmid transfection on GK activity in 
HEPG2 cells 
 
Transfection of HEPG2 cells with GKAS-pTR-CGW plasmid resulted in decreased GK 
activity compared to controls (control 0.31 ± 0.024 vs. GKAS 0.19 ± 0.011 units/mg 
protein, n=4, P<0.05) (figure 2.9).  
 
 
 
 
Figure 2.9 Effect of GKAS-pTR-CGW plasmid transfection on GK activity in HEPG2 
cells: GK activity in HEPG2 cells 48hr after transfection with either GKAS-pTR-CGW 
plasmid (blue bar) or pTR-CGW plasmid (green bar). Values are shown in units of 
enzymatic activity per mg of protein +/- SEM n=4 * P<0.05. 
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2.5 Discussion  
 
Prior to the production of GK and GKAS AAV particles, the efficacy of the plasmids 
was tested in vitro. At present, there is no assay that directly measures GK activity. The 
assays used in this thesis estimate the activity of GK based on two coupled reactions. 
The first reaction, glucose to glucose-6-phosphate, is catalysed by GK. In the next 
reaction glucose-6-phosphate dehydrogenase catalyses the conversion of glucose-6-
phosphate to 6-phospho-D-gluconate with the production of NADPH which is measured 
spectrophotometrically.  
However, GK is not the only enzyme expressed in the rat brain that phosphorylates 
glucose to give G-6-P. The rat brain expresses a variety of hexokinases, with 
hexokinase I being expressed at high levels (Shinohara et al, 1991). As such, the 
production of G-6-P cannot be fully attributed to GK. This in turn means that NADPH 
production during the assay is also not fully attributable to GK. To ensure that the AAV 
plasmids were having a specific effect on GK expression I first had to choose an assay 
that was sufficiently sensitive and accurate.  
In the standard GK assay, the interfering effect of hexokinases is partially controlled for 
based on the known enzymatic properties of GK and other hexokinases. GK has a low 
affinity and high Km for glucose compared to other hexokinases (Meglasson & 
Matschinsky, 1984). This means that it is possible to partially differentiate between the 
effect of GK and other hexokinases by altering the glucose concentration in the reaction 
media. At glucose concentrations of 0.5mmol/l glucose hexokinase activity is near 
maximal whereas glucokinase activity is low (Liu et al, 1991). At glucose 
concentrations of 100mmol/l the activity of both enzymes should be maximal. To 
calculate GK activity in a sample the assay is performed in both 0.5mmol/l and 
100mmol/l glucose and the result of the former is subtracted from the latter.  
The optimized GK assay utilizes enzymatic inhibition to control for hexokinase 
interference. 5-thio-D-glucose is a structural analogue of glucose that inhibits others 
hexokinases but not GK (Wilson & Chung, 1989). 3-O-methyl-N-acetylglucosamine 
inhibits N-acetylglucosamine kinase which catalyses the reaction N-acetylglucosamine 
to N-acetylglucosamine-6-phosphate. At high glucose concentrations, N-
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acetylglucosamine kinase will also phosphorylate glucose to give G-6-P (Miwa et al, 
1995).  For this reason, it is also necessary to inhibit the actions of N-acetylglucosamine 
kinase in the GK assay.   
To test the efficacy of the GK assay methods I performed the GK assays on HEK293T 
cell lysate. HEK293T cells express hexokinase but do not express GK. Since there is no 
GK in HEK293T cells GK activity and NADPH production should be zero.  
Using the standard assay method, the production of NADPH was 0.057mmol/l. This 
suggests that the standard GK assay does not accurately measure GK activity. It is 
possible that one of the reasons this assay is unreliable is that it does not control for the 
activity of N- acetylglucosamine kinase at high glucose concentrations.  
Using the optimized GK assay NADPH production was 0.025mmol/l. While this 
method did not give a perfect result it is a significant improvement on the standard 
method. For this reason, the optimized GK assay was chosen for subsequent analysis of 
GK activity.  
Next it was necessary to investigate the efficacy of pTR-CGW-GKS plasmid in vitro. 
To do this, HEK293T cells were transiently transfected with the plasmid. After 48 
hours, cells were lysed and assayed for GK activity using the optimized method. 
Following transfection with pTR-CGW-GKS plasmid GK activity in HEK293T cells 
was increased three-fold compared to controls. Thus, demonstrating the efficacy of the 
GKS -pTR-CGW plasmid in vitro. 
A similar protocol was used to investigate the efficacy of the antisense plasmid. In this 
case HEPG2 cells, which express GK, were transfected with GKAS-pTR-CGW. 
Transfection of HEPG2 cells with the antisense plasmid decreased GK activity by 
approximately one third compared to controls. This level of knockdown is comparable 
to the results of Gardiner et al who reported  approximately 50% knockdown of NPY 
expression from cultured RIN 56 NPY cells using antisense AAV (Gardiner et al, 
2005).  
Having established the efficacy of both plasmids the AAV viral particles were produced 
and in vivo experiments commenced.  
 
93 
 
 
 
3. Chapter 3 Effect administration on food intake 
and body weight  
 
 
Chapter 3 
Effect of iArc rAAV-GKS 
administration on food intake and 
body weight 
 
 
 
  
94 
 
3.1 Introduction  
3.1.1 The Glucostatic hypothesis 
 
Jean Mayer‟s 1953 “Glucostatic hypothesis” proposed that short-term food intake was 
regulated by glucose metabolism in critical brain regions. At the centre of the 
hypothesis was the concept that a reduction in arteriovenous (AV) difference in blood 
glucose is met with hunger and feeding, with an increase in AV glucose difference 
having the opposite effect. As part of the hypothesis, Mayer predicted the existence of 
glucose-sensing neurones (which were not discovered until 1961) and predicted that 
glucose-sensing neurones in the ventromedial hypothalamus would be of importance in 
the regulation of feeding (Mayer, 1955;Mayer, 1953).  
Mayer argued that glucose-sensing was the likely mechanism that regulated short-term 
feeding because a) glucose is utilized preferentially by most tissues and in the fed state 
the CNS uses it exclusively b) glucose is usually the first substrate to become depleted 
(bodily stores being very low) and c) prevention of low level of glucose is necessary to 
avoid “death through incapacitation of the central nervous system”(Mayer, 1953).   
 
3.1.2 Experimental evidence 
 
In the years following the publication of the glucostatic hypothesis a number of 
investigators attempted to demonstrate the hypothesis experimentally. Manipulation of 
glucose levels in various regions of the body including the general circulation (Smith & 
Epstein, 1969) and portal circulation (Tordoff et al, 1989) have been shown to alter 
feeding behaviour. However, some investigators have found that manipulation of 
plasma glucose does not influence feeding behaviour. For example, in an experiment 
conducted by Bernstein et al, hyperglycemia was shown to have no effect on feeding 
behaviour in humans. Nine healthy men received a glucose solution either intravenously 
or intragastrically in a dose sufficient to induce hyperglycemia. The study was run in a 
cross over design with each participant acting as his own control on separate days. 
Thirty minutes following treatment subjects were offered ad libitum access to a buffet 
meal and food intake and appetite (via questionnaire) were recorded. Treatment with 
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glucose was not shown to alter food intake or appetite significantly compared with 
intravenous or intragastric saline treatment (Bernstein & Grossman, 1956).  
By contrast in rodents, glucose and 2-deoxy-glucose (2DG) have been shown to alter 
feeding when administered i.p., ICV and or intra-VMH. Pre-prandial ICV infusion of 
glucose at doses of 6 to 24μmol/l decreases subsequent meal size in a dose dependent 
manner in rats (Kurata et al, 1986). While infusion of glucose directly into the VMH for 
a period of 6 days results in decreased food intake and bodyweight gain (Panksepp & 
Rossi III, 1981).  
ICV infusion of 2DG, which specifically inhibits glucose metabolism, results in a potent 
increase in food intake (Tsujii & Bray, 1990). This effect is also observed when 2DG is 
infused directly into the VMH (Lenin Kamatchi et al, 1986). Interestingly, infusion of 
glucose epimers including D-mannose, D-allose and D-galactose does not affect food 
intake or bodyweight (Kurata et al, 1986). Taken together, these data suggest a specific 
role for VMH glucose-sensing in the regulation of short-term feeding, as predicted by 
Mayer.         
 
3.1.3 Mechanism of glucose-induced regulation of feeding 
 
The mechanism by which hypothalamic glucose-sensing affects feeding behaviour is 
not well characterised although it is thought to involve the POMC/CART and 
NPY/AgRP expressing neurones of the ARC. It is well accepted that POMC/CART and 
NPY/AgRP neurones are glucose sensitive. However, there is a degree of disagreement 
regarding their exact electrophysiological characteristics. For example, subpopulations 
of NPY expressing neurones have been shown to be GI by Fioramonti et al and GE by 
Claret et al (Fioramonti et al, 2007 ;Claret et al, 2007). 
In support of the results of Fioramonti et al, systemic glucoprivation caused by i.p. 
administration of 2DG has been shown to increase mRNA levels of both NPY and 
AGRP (Sergeyev et al, 2000). A decrease in plasma glucose would be expected to 
activate GI neurones and increase their peptide release. Thus, the increase in NPY with 
glucoprivation suggests that at least some NPY neurones are GI. Intraperitoneal 2DG 
administration has also been shown to increase NPY peptide levels in the ARC 
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(Akabayashi et al, 1993). Interestingly, glucoprivic feeding as a result of i.p. 2DG is 
largely attenuated in rats that are pre-treated with NPY-antiserum in the PVN (He et al, 
1998). Feeding response to 2DG is also attenuated in NPY KO mice and food intake in 
these mice is not significantly increased by insulin-induced hypoglycaemia (Sindelar et 
al, 2004). This suggests that an NPY-dependent mechanism underlies at least part of the 
feeding response to hypoglycaemia and also that NPY neurones are responsive to 
decreasing plasma glucose.    
Glucose-sensing in POMC neurones might also be important in the regulation of 
feeding behaviour. POMC mRNA is decreased in streptozotocin (STZ)-induced 
diabetes. POMC levels are normalised with insulin treatment and normalisation of 
plasma glucose levels (Kim et al, 1999).  
Glucose has been shown to increase POMC release in a dose dependent manner from 
hypothalamic explants taken from lean mice. This effect, is absent in explants taken 
from diet-induced obese mice (Parton et al, 2007), suggesting that glucose-sensing in 
POMC neurones is lost in obesity. In addition, the sensitivity of POMC neurones to 
leptin appears to be dependent on local glucose concentration. At high glucose levels 
(11mM) leptin excites POMC neurones and increases their firing rate. At low glucose 
concentrations (5mM) leptin has the opposite effect, hyperpolarising POMC neurones 
and decreasing their action potential firing rate (Ma et al, 2008). 
 
3.1.4 Blood glucose and spontaneous feeding 
 
Despite the preponderance of evidence linking neuronal glucose-sensing with the 
regulation of food intake it has been difficult to demonstrate a role for VMH glucose-
sensing in spontaneous feeding. It has also been suggested that many of the experiments 
linking neural glucose-sensing to food intake do so using supraphysiological glucose 
concentrations. For example in the experiments of Parton et al, glucose concentration of 
5mM and 11mM were used to alter the sensitivity of POMC neurones to leptin ex vivo 
(Parton et al, 2007). Glucose levels in the VMH have been recorded over a range of 
0.73-4.23mM with ambient concentrations of 1.43mM in fed rats (Mayer et al, 2006;de 
Vries et al, 2005). Since the “low” glucose concentration used by Parton et al is above 
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the highest physiological level recorded in the VMH it is possible that the results 
achieved do not reflect normal physiology.  
In both humans and rats, a high proportion of spontaneous meals are preceded by a 5-
12% decrease in plasma glucose levels (Campfield et al, 1985;Melanson et al, 1999). In 
a recent study conducted by Dunn-Meynell et al, the pre-prandial decrease in plasma 
glucose was confirmed. However, there was no consistent relationship between changes 
in VMH glucose levels and spontaneous feeding. Altering VMH glucose-sensing, by 
decreasing mRNA, caused a reduction in glucoprivic feeding but had no effect on 
spontaneous feeding, bodyweight or adiposity (Dunn-Meynell et al, 2009). Thus, the 
results of this study would appear to suggest that VMH glucose-sensing is important in 
glucoprivic feeding but not in the day to day regulation of energy balance. In addition, 
spontaneous feeding is associated with a decrease in plasma glucose but not a decrease 
in VMH glucose. This raises the possibility that feeding behaviour may be regulated by 
glucose-sensing in a region of the body other than the VMH, perhaps in the periphery. 
This is also in opposition to the “Glucostatic hypothesis” since Mayer predicted that 
VMH glucose sensors regulate feeding behaviour.  
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3.2 Hypothesis and Aims 
 
3.2.1 Hypothesis 
 
GK is expressed in a number of hypothalamic nuclei and an important step in this work 
is to establish which nucleus/nuclei are quantitatively most important in feeding 
behaviour.  Fasting has been shown to increase GK mRNA expression in the ARC. It is 
hypothesised that fasting will also increase GK enzymatic activity in a nucleus specific 
manner. Based on the results of the fasting studies I will choose a hypothalamic nucleus 
as the primary target for rAAV induced increase in GK. It is hypothesised that 
intranuclear injection of rAAV-GKS will increase GK activity local to the injection site 
and will affect food intake, bodyweight and glucose homeostasis.   
 
3.2.2 Aims and Objectives  
 
I aim to investigate the role of hypothalamic glucose-sensing neurones in the regulation 
of energy intake and glucose homeostasis.  In order to do this I will:  
1. Measure the effect of fasting on GK activity in the ARC, PVN and VMN to               
establish which nuclei are quantitatively most important in the regulation of 
glucose homeostasis and feeding behaviour 
2. Examine the physiological effect of up regulation of GK mRNA in specific 
hypothalamic nuclei on food intake and glucose homeostasis 
3.  Examine the effect of up regulation of GK mRNA on hypothalamic gene 
expression 
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3.3 Methods  
3.3.1 Animals 
 
Male Wistar rats (specific pathogen free, Charles River UK Ltd, Margate, Kent, UK) 
were maintained under a controlled environment (temperature 21-23ºC, 12 hour light-
dark cycle, lights on at 07:00) with ad libitum access to food (RM1 diet, Special Diet 
Services UK Ltd, Witham, Essex, UK) and water. All animal procedures were approved 
under the British Home Office Animals (Scientific Procedures) Act 1986 (Project 
licence no. 70/6377). Prior to all experiments animals were acclimatised to the Imperial 
College animal unit for 7 days. In all experiments animals were randomised to treatment 
and control groups as described in appendix III. 
 
3.3.2 Isolation of specific hypothalamic nuclei by punch biopsy from coronal 
sections 
 
Rats were killed by decapitation, and brains removed. Brains were then placed on filter 
paper with the ventral surface facing upwards so that the hypothalamus was visible, and 
sections caudal and rostral to the hypothalamus were cut away using a razorblade. The 
brain was then frozen using isopentane cooled on dry ice. Frozen brains were then 
mounted upon a freezing sled microtome (Shandon Southern Products Ltd, Runcorn, 
UK). Eight hundred micrometre sections from the rostro-caudal extent of the 
hypothalamus were then cut and mounted on poly-lysine slides. Slides were kept on dry 
ice to re-freeze sections and the ARC, PVN and VMN were identified using a rat brain 
atlas (Paxinos & Watson C, 2007) and removed using a 22 gauge neuropunch (Fine 
Science Tools, Linton, UK). 
 
  
100 
 
3.3.3 Isolation of specific hypothalamic nuclei by punch biopsy from sagittal 
sections 
 
Rats were killed by decapitation, and brains removed. Brains were then placed on filter 
paper with the ventral surface facing upwards so that the hypothalamus was visible, and 
sections lateral to the hypothalamus on either side were cut away using a razorblade. 
The remaining block of brain was then frozen using isopentane cooled on dry ice. 
Frozen brains were mounted upon a freezing sled microtome (Shandon Southern 
Products Ltd). Sagittal sections of 1.2mm containing the ARC, VMH and PVN were 
then cut and mounted on slides. Slides were kept on dry ice to re-freeze sections and 
nuclei were identified and removed using a 22 gauge neuropunch (Fine Science Tools). 
 
3.3.4 Quantification of glucokinase activity in the hypothalamic nuclei of fed 
and fasted rats  
 
Punch biopsies from the ARC, VMN and PVN were taken from three groups of rats; 
group 1 (n=8) was allowed ad libitum access to standard chow during a 48 hour period, 
group 2 (n=8) was fasted for 24 hours and group 3 (n=9) fasted for 48 hours. Animals 
were killed by decapitation 2 hours after lights-on on the final day of the study and 
hypothalamic nuclei were isolated (as in section 3.3.2) and optimized glucokinase assay 
was performed on homogenised hypothalamic nuclei (as described in 2.3.5.2). 
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3.3.5 Protein assay on punch biopsy samples 
 
There is inherent variability in the amount of hypothalamic tissue collected by punch 
biopsy. In order to compensate for this the protein content of the punch biopsy 
homogenate must be calculated in order to standardise the results of the GK activity 
assay. 
Homogenate protein content was measured using a well-established modified Lowry 
protein assay. This method involves reaction of proteins with cupric sulphate and 
tartrate in an alkaline solution to form tetradentate copper-protein complexes. These 
copper-protein complexes produce a peak in absorbance at 750nm and can be measured 
spectrophotometrically to quantify the amount of protein in a sample. 
Materials 
  Lowry protein assay kit (Pierce, Rockford, IL, USA) 
  Bovine serum alblumin (BSA) stock solution 
  2X Folin-Ciocalteu reagent 
Method 
BSA stock solution was diluted in GDW to make up nine standard solutions of 1, 5, 25, 
125, 250, 500, 750, 1,000, and 1,500 μg/ml. One times Folin-Ciocalteu reagent was 
prepared by diluting the supplied 2X reagent 1:1 with ultra-pure water. All other 
reagents were supplied ready to use.  
Fifty microlitres of BSA standard and 50µl of sample were added to microfuge tubes. 
One millilitre of modified Lowry reagent was then added to each tube at 15 second 
intervals, mixed, and incubated for 10 minutes. One hundred microlitres of the prepared 
1X Folin-Ciocalteu reagent was then added and the solution was vortexed. The tubes 
were covered and incubated at room temperature for 30 minutes. The A750 of the 
samples was then measured in a spectrophotometer. Absorbance values of the blank 
readings were subtracted from the absorbance readings of all samples and a standard 
curve plotted. The protein concentration of each of the unknown samples was 
determined by comparison to the standard curve.  
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3.3.6 Injection of GKS-AAV in the rat brain  
 
Adult male Wistar rats were anaesthetized by intraperitoneal (i.p.) injection of ketamine 
60mg/kg (Parke-Davis, Pontypool, UK) and xylazine 12mg/kg (Bayer UK Ltd, Bury St. 
Edmunds, UK) and immobilised on a stereotaxic frame (David Kopf Instraments, 
California, USA).  The incisor bar was set at 3.0mm below the interaural plane.  The 
surgical area was shaved, and cleaned with 10% w/v povidine-iodine solution 
(Betadine).  A small (<2cm) rostro-caudal incision was made in the scalp.  Animals 
were injected bilaterally into the ARC using coordinates -3.4mm caudal, +/-0.5mm 
lateral to the bregma, and 10.5mm below the skull, determined from the rat brain atlas 
of Paxinos and Watson (Paxinos & Watson C, 2007).  A stereotaxically mounted drill, 
was used to make a 0.65mm burr hole in the skull.  Each animal was injected via a 33 
gauge steel injector (Plastics-One, Roanoke, Virginia, USA) inserted into, and 
projecting 1mm below, the tip of a guide cannula. Animals received either 1µl rAAV-
GKS at a titre of 2.96x10
12 
genome particles/ml or 1µl rAAV-eGFP at a titre of 
5.04x10
12 
genome particles/ml injected bilaterally into the ARC.  The pressure was 
removed from the injector and the cannula/injector unit was maintained in situ for 5 
minutes before being slowly extracted to minimise backflow. The incision was sutured 
with two mattress sutures with 6.0 proline thread.  The animal was removed from the 
frame, re-hydrated with 5ml normal saline, revived with 50μl antisedan (Animalcare 
Ltd, Dunnington, UK) and placed in a heated box for recovery. Once the rat had 
regained the righting reflex it was housed individually and monitored for a recovery 
period of 7 days.  The animals were given ad libitum access to food (unless pair fed to 
another group) and food intake and body weight were measured at least 3 times per 
week following the 7 day post-operative recovery period.  
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3.3.7 Confirmation of gene transfer by in situ hybridisation 
 
In situ hybridisation is a method for the detection and quantification of mRNA whilst 
maintaining the structural integrity of the tissue. It relies on the hybridisation of a 
complementary probe, usually radiolabelled RNA, to the target mRNA in tissue 
mounted on poly-lysine slides. 
Following rAAV-GKS injections transgene expression was confirmed in brains taken 
from three animals using an 
35
S labelled riboprobe specific for GK. The 
35
S GK 
riboprobe was labelled as described below using pBluescript-GK as a template. The 
pBluescript-GK plasmid was created by endonuclease digestions of pBluescript and full 
length GK using BamHI and PstI (as described in 2.3.2.1). Following endonuclease 
digestion pBluescript and GK were ligated and the plasmid was amplified and purified. 
 
3.3.7.1 Production of radiolabelled RNA probe for in situ hybridisation 
 
Materials 
Linearised template (pBluescript-GK (200ng/µl) linearised by digestion with 
BamHI for antisense probe) 
100M DTT  
RNase inhibitor, 30U/µl 
10x nucleotide mix: 10mM of each ATP, UTP, GTP; 
T7 RNA polymerase, 20U/µl (Promega) 
10x RNApolymerase buffer (Promega) 
DNase I, 7.5 U/µl (GE Healthcare) 
10x DNase buffer 
5M Ammonium  acetate (appendix I)  
[
35S]CTPαS, 30TBq/mmol, 1.5GBq/ml (GE Healthcare) 
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Method 
Radioactively labelled RNA was produced using an in vitro transcription reaction. Two 
hundred nanograms of template were added to a reaction buffer containing 10mM DTT, 
1x nucleotide mix, 1x polymerase buffer, 30U RNase inhibitor and 3.75MBq 
[
35S]CTPαS in a total volume of 9µl. To this 20U of T7 RNA polymerase was added 
and the reaction incubated for at least 2 hours at 37ºC. After incubation, 6µl GDW, 1µl 
DNase I and 3µl DNase buffer was added. This was followed by a 15 minute incubation 
at 37ºC. Ammonium acetate was added to a final concentration of 2M and 2.5volumes 
ice cold absolute ethanol was added and the mixture left at -20ºC for at least an hour for 
the RNA to precipitate. RNA was recovered by centrifugation at 8,000xg for 7 minutes 
and the pellet was dissolved in 100µl GDW. To measure the activity or the radiolabelled 
probe, 1µl was counted on a microbeta counter (Wallac, Waltham, MA). 
 
  
105 
 
3.3.7.2 In situ hybridisation 
 
Materials 
 4% (v/v) formaldehyde in 0.1M phosphate buffered solution (PBS)  
 100% acetic anhydride (VWR) 
 0.1M triethanolamine pH 8.0 
 20x SSC (appendix I)  
 70% ethanol in distilled water 
 Chloroform (VWR) 
 Hybridisation buffer (appendix I)  
   50% (v/v) Formamide 
   600mM sodium chloride 
   80mM Tris-HCl, pH 7.5 
   4mM EDTA 
   100mM DTT 
0.1 mg/ml yeast tRNA 
2% (w/v) Dextran sulphate, mw ~500,000 
   1x RNase buffer 
   10mM Tris pH 8 
   1mM EDTA 
   0.5M sodium chloride 
 
Method 
Twelve micrometre brain sections were cut on a cryostat at -25ºC (Bright instrument 
Company, Huntingdon, Cambridgeshire, UK). The sections were mounted onto poly-
lysine coated slides and stored at -20ºC until hybridisation. In situ hybridisation was 
carried out on every third slide. The sections were fixed in 4% (v/v) formaldehyde in 
0.1M PBS for 20 minutes. Slides were washed twice in 0.1MPBS, for 5 minutes. 
Sections were then incubated in 0.1M TEA for 2 minutes and acetylated in 0.25% (v/v) 
acetic acid anhydride in 0.1M TEA for 10 minutes. Sections were washed twice in 
0.01M PBS for 2 minutes and then dehydrated by immersion in 70% ethanol for 3 
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minutes. Finally, slides were delipidated in chloroform for 5 minutes and allowed to air 
dry. All steps were performed at room temperature unless otherwise stated.  
Hybridisation buffer was supplemented with the 
35
S labelled probe (1 x 10
6
 Bq) and 
80µl added to each slide. A coverslip was placed over each slide and the slides were 
hybridised at 60ºC overnight. Next, the slides were washed in 4x SSC with gentle 
agitation to remove coverslips and then washed four times in 4x SSC for 5 minutes. 
Slides were then RNase treated by incubation for 30 minutes at 37ºC in 1x RNase buffer 
containing 100µg/ml RNase A. This was followed by two 5 minute washes in 10mM 
DTT/2x SSC at room temperature. Slides were washed in 10mM DTT/1x SSC followed 
by 10mM DTT/0.5x SSC for 10 minutes each. Slides were then washed in 10mM 
DTT/0.1x SSC at 60ºC for 30 minutes. Finally, slides were rinsed in 10mM DTT/0.1x 
SSC and dehydrated in 70% ethanol for 3 minutes before being allowed to air dry. After 
washing and dehydration, the slides were exposed to Bio-Max film (Kodak, Hemel 
Hempstead, Herts, UK) at room temperature. After three days exposure the film was 
developed and transgene expression determined by observation of specific 
hybridisation. 
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3.3.8 Cohort One 
 
3.3.8.1 Effect of iARC rAAV-GKS on food intake and bodyweight  
 
Male Wistar rats were injected bilaterally into the ARC with 1µl of either rAAV-GKS 
(n=25) or rAAV-eGFP (n=16). Intake of RM1 diet (standard chow) and body weight 
were measured three times per week for a period of 40 days. Three rats from the rAAV-
GKS group were killed 3 week post injection and brains were removed and used for in 
situ hybridization.  
 
3.3.8.2 Effect of iARC rAAV-GKS on GK activity in the ARC and PVN   
 
On day 40 animals were killed by decapitation and the ARC and PVN were isolated 
and homogenized (as described in 3.3.3). Optimized glucokinase assay was then 
performed on homogenised hypothalamic nuclei (as described in 2.3.5.2). 
 
3.3.8.3 Effect of iARC rAAV-GKS on body composition  
 
Body composition analysis was required to establish the ratio of fat mass to lean body 
mass. The principle behind this practice involves dissolving the carcass in a 
saponification reaction using a strong alkali. The component fats and proteins from the 
resultant solution can then be analysed using standard assay procedures. To determine 
carcass protein content a modified Lowry protein assay was performed (as described in 
3.3.5). Fat mass was determined by glycerol assay (as described in 3.3.8.4). Rats had 
previously been decapitated and brains had been collected for GK assay. Heads and 
remaining brain matter where returned to the carcasses before saponification.   
Carcasses were weighed and placed into separate containers. Carcasses were dissolved 
using 3M KOH in 65% ethanol (appendix I) in equal volumes to carcass weight. The 
carcasses were incubated in the alkali solution at 70˚C for five days. The resultant liquid 
was made up to 1L with absolute ethanol and stored at room temperature until required. 
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3.3.8.4 Glycerol assay 
 
In order to determine the total fat mass of rats, a glycerol assay was used. Glycerol 
concentrations were determined using reagents and methods from Randox Laboratories 
Ltd, UK. All buffers were supplied ready to use with the exception of reagent 2 which 
was reconstituted with 15ml of buffer 1.  1M glycerol stock solution was diluted in 
GDW to provide standard glycerol concentrations of 5mM, 2mM, 1mM, 0.5mM, 
0.2mM, 0.1mM, and 0.05mM. Ten microlitres dissolved carcass sample was diluted 
1:100 with GDW. To start the assay, 1ml reagent 2 was transferred into fresh eppendorf 
tubes. To this 30μl of sample, standard, or buffer (for blank value) was added and left to 
incubate at room temperature for 10 minutes. Two hundred microlitres from each tube 
was transferred into a well on a 96-well. The glycerol concentration of each sample was 
determined by measuring absorbance at 520nm and reading from the standard curve.  
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3.3.9 Cohort 2 
 
3.3.9.1  Effect of iARC rAAV-GKS on food intake and bodyweight, effect of 
pair feeding 
 
Male Wistar rats were injected iARC with 1µl rAAV-GKS (n=30) or rAAV-eGFP 
(n=15).  Following recovery rats injected with rAAV-GKS were divided into two group; 
Group 1 (n=15) received ad libitum access to standard chow. Group 2 (n=15) were pair 
fed standard chow to the food intake of the rAAV-eGFP (n=16) of the previous day. 
Food intake and bodyweight were recorded at 2-3day intervals for a period of 33days. 
The food hoppers of the pair fed GKS group were refilled daily.  
 
 
 
3.3.9.2 Effect of iARC rAAV-GKS on 24hr food intake following fast 
  
To  further elucidate the role of ARC GK in feeding behaviour rAAV-GKS (n=12), 
rAAV-eGFP (n=14) and rAAV GKS rats pair fed to rAAV-eGFP (n=10) were fasted for 
24hr hours after which time they were allowed ad libitum access to standard chow. 
Body weight was measure before fasting, after 24hr fast and 24hr post re-feed starting 
on day 35. Food intake was measure at 1,2,4,8 and 24hr post re-feed.  Chow was 
returned at the onset of the dark phase. 
 
3.3.9.3 Body composition 
 
At the termination of the study (day 40) rats were killed by decapitation. Trunk blood 
was collected and assayed for insulin and glucose. Epididymal WAT and interscapular 
BAT were removed and weighed. Brains were removed and hypothalami were 
dissected, frozen in liquid nitrogen and stored at -80°C.  
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3.3.9.4 Glucose homeostasis  
 
Following decapitation trunk blood was collected in tubes coated with heparin and 
200µl aprotinin (Trasylol).  Plasma was separated by centrifugation and frozen on liquid 
nitrogen. Plasma insulin was assayed by ELISA. Plasma glucose was assayed using an 
enzymatic oxidation reaction (described below). 
 
3.3.9.5 Glucose assay  
 
Materials 
Glucose assay kit (Randox Laboratories Ltd. UK) 
Methods  
Plasma glucose concentrations were determined using reagents and methods from 
Randox Laboratories Ltd. This assay involves two linked reactions which are shown 
below. In the first reaction glucose is oxidised by glucose oxidase (GOD) to give 
gluconic acid and hydrogen peroxide. In the second reaction hydrogen peroxide reacts 
with 4-aminophenazone and phenol under catalysis of peroxidise (POD). The products 
of the second reaction are water and quinoneimine. 
 
                                          GOD 
Glucose + O2 + H2O                      gluconic acid + H2O2 
 
                                                                    POD 
2 H2O2+ 4-aminophenazone+phenol                      quinoneimine + 4 H2O 
 
All buffers were supplied ready to use and the GOD-PAP reagent was reconstituted 
using one vial R1b buffer. Plasma samples were thawed on wet ice and diluted 1:5 in 
normal saline. Standard glucose concentrations were produced using standard glucose 
solution and methods provided by Randox. On a 96 well plate 5µl of sample or standard 
was mixed with 280µl of reconstituted GOD-PAP reagent and incubated for 10 
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minutes at 37˚C.  The A500 of the samples was then measured in a 
spectrophotometer. Absorbance values of the blank readings were subtracted from the 
absorbance readings of all samples and standards, and a standard curve plotted. The 
glucose concentration of each of the unknown samples was determined by comparison 
to the standard curve. For full calculations see appendix III. 
 
3.3.9.6 Plasma insulin ELISA 
 
Material 
Rat insulin ELISA kit (Linco Research, Missouri, USA)  
Methods   
Plasma insulin concentrations were determined using reagents and methods from Linco 
Research. All reagents were provided ready to use with the exception of 10X wash 
buffer that was diluted 1:10 in GDW. Prior to setting up the reaction all wells were 
washed three times with 300µl of 1X wash buffer and residual buffer was removed by 
tapping the plate on absorbent towels. Ten microlitres of sample, premixed rat insulin 
standard or quality control were added to wells followed by 80µl detection antibody 
(pre-titered biotinylatd anti-insulin antibody). Plates were sealed and incubated at room 
temperature for 2 hours on a plate shaker at 400rpm. Following incubation, solution was 
decanted from wells as previously described and wells washed three times with 300µl 
wash buffer. Next, 100µl of enzyme solution containing streptavidin-horseradish 
peroxidise was added and the plate was sealed and agitated for 30 minutes at 400rpm. 
Following incubation solution was decanted and wells washed six times with wash 
buffer. One hundred microlitres of substrate reagent was added, containing 3,3‟,5,5‟-
tetramethylbenzidine, and was  incubated for 15 minute. The A590 of the samples was 
then measured in a spectrophotometer. Absorbance values of the blank readings were 
subtracted from the absorbance readings of all samples and standards, and a standard 
curve plotted. The insulin concentration of each of the unknown samples was 
determined by comparison to the standard curve.  
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3.3.9.7 Quantification of Hypothalamic mRNA by QPCR 
 
Quantitative PCR (QPCR) was used to analyse the expression of a range of mRNA 
species in order to assess their involvement in the perceived phenotype. 
 
3.3.9.7.1  RNA Extraction 
 
Materials 
Tri-reagent (Helena Biosciences, Sunderland, UK) 
Method 
RNA was extracted from whole hypothalami using the Tri-reagent method according to 
the manufacturer‟s protocol. Hypothalamic tissue was ground under liquid nitrogen with 
a pestle and mortar before being homogenised in 1ml Tri-reagent and subsequently 
transferred to 1.5ml eppendorfs to incubate at room temperature for 5 minutes. 
 
3.3.9.7.2  RNA Purification 
 
In order to accurately analyse mRNA levels by TaqMan assay sample RNA must not be 
contaminated with DNA. To achieve this, RNA samples were treated with DNase 
solution.
 
Materials 
Purelink RNA Mini kit (Invitrogen)  
Purelink DNase 
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Method 
Chloroform was added to each sample in a ratio of 0.2ml:1ml of Tri-reagent before 
vigorous agitation by hand and incubation at room temperature for 3 minutes. Samples 
were subjected to centrifugation at 12000xg for 15 minutes at 4°C to facilitated phase 
separation. The upper aqueous phase of each sample was transferred to a fresh tube and 
an equal volume of 70% ethanol added. Seven hundred microlitres of the resulting 
mixture was transferred to a spin cartridge before centrifugation at 12000xg for 15 
seconds at room temperature. This was repeated until the total sample volume had been 
processed. The sample RNA was now bound to the spin cartridge, which was subjected 
to centrifugation at 12000xg for 15 seconds at room temperature with 350µl of wash 
buffer 1. Eighty microlitres of Purelink DNase was then added directly to the spin 
cartridge membrane the cartridge incubated at room temperature for 15 minutes. The 
centrifugation step using wash buffer I was repeated before washing twice with wash 
buffer II and subsequent centrifugation at 12000xg for 15 minutes. The RNA was then 
dissolved in RNase-free GDW and stored before its yield was determined 
spectrophotometrically according to the following equation: 
RNA (µg) = dilution factor x 40 x 260nm  
 
3.3.9.7.3  Reverse Transcription of Hypothalamic mRNA 
 
RNA was converted into its complementary cDNA sequence by reverse transcription in 
order to allow its amplification by PCR. The High Capacity cDNA Reverse 
Transcription Kit uses the random primer scheme for initiating cDNA synthesis. 
Materials 
RNA Samples 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
96 Well Assay Plate 
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Method 
Ten microlitres of each RNA sample was added in triplicate to reaction wells containing 
1X RT buffer, 4mM dNTP mix, 1X RT random primers, and Multiscribe reverse 
transcriptase. The plate was then foil-sealed before being incubated in a thermal cycler 
programmed to the following conditions: 25°C for 10 minutes, 37°C for 120 minutes, 
85°C for 5 minutes. Following cycle completion, cDNA templates were stored at -20°C. 
 
3.3.9.7.4  QPCR Analysis of Hypothalamic cDNA 
 
TaqMan QPCR assay allows accurate quantification of gene expression by 
incorporating a fluorescent reporter-tagged probe into the amplification reaction. During 
PCR, the probe anneals to its complementary sequence, however fluorescence of the 
tagged reporter is suppressed by the presence of a quencher dye. Taq DNA polymerase 
cleaves only probes that are hybridised to the target. This separates the quencher from 
the reporter, producing fluorescence. The increase in fluorescence is relative to the 
concentration of the target gene in the sample. 
Materials 
Sample cDNA template (50µg/ml) 
Endogenous control cDNA template (5µg/ml) 
TaqMan
 
 Gene Expression Assay (Applied Biosystems) 
TaqMan
 
 Gene Expression Master Mix 
384 Well Assay Plate 
 
Method 
Each QPCR reaction contained: 50ng of the target gene assay, 1µl of cDNA template, 
10µl master mix, and GDW to give a final volume of 20µl. To quantify total RNA, a 
gene expression assay targeting the 18S ribosomal subunit and 10ng target gene were 
used. cDNA was diluted 1:10 prior to use. Each reaction was mixed and the plate was 
sealed. 
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The sealed plate was loaded onto a thermal cycler and processed under the following 
conditions: 50°C for 2 minutes, 95°C for 10 minutes, 95°C for 15 seconds and 60°C for 
1 minute. The cycle was repeated for 40 cycles. The amplification data for each sample 
was corrected against its respective endogenous control. 
 
3.3.10 Cohort 3  
 
3.3.10.1 Effect of iARC rAAV-GKS on food intake and bodyweight: High 
energy diet 
 
Male Wistar rats were injected iARC with 1µl rAAV-GKS (n=15) or rAAV-eGFP 
(n=15).  Prior to surgery animals were given ad libitum access to high energy chow 
(D12266B, Research Diets Inc., New Brunswick, USA) for a 3 day acclimatisation 
period. Following surgery, rats were allowed to recover for a period of 7 days and were 
given ad libitum access to high energy chow. Intake of high energy chow and 
bodyweight were measured three times per week for a period of 37 days.  
 
3.3.11 Statistical analysis 
 
All longitudinal data (growth curves/cumulative food intake) were analysed using the 
population-averaged general estimating equation (GEE). For all other data, unpaired t-
test was used for experiments with two groups and analysis of variance (ANOVA) 
followed by Bonferroni post hoc analysis was used for experiments with more than two 
groups. P<0.05 was considered statistically significant throughout. Data analysis was 
performed using GraphPad Prism 4 software (CA, USA) and Stata 9.    
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3.4 Results  
3.4.1 Glucokinase activity in the hypothalamic nuclei of fed and fasted rats  
 
Glucokinase activity was significantly increased in the ARC of rats fasted for 24hr and 
48hr compared to controls (controls 0.0059+/-0.0011 vs 24hr fast 0.0087+/-0.0001 
units/mg protein, n=8, P=<0.05; 48hr fast 0.009+/-0.0001 units/mg protein, P=<0.05 
n=9)(figure 3.1). In the PVN glucokinase activity was unchanged following 24hr and 
48hr fast compared to controls (controls 0.01+/-0.0013 vs 24hr fast 0.011+/-0.0008 
arbitrary units, n=8; 48hr fast 0.01+/-0.001 units/mg protein, n=9)(figure 3.2). In the 
VMN glucokinase activity was unchanged following 24hr fast and 48hr fast compared 
to controls (controls 0.011+/-0.0012 vs 24hr fast 0.009+/-0.0008 units/mg protein, n=8;  
48hr fast 0.01+/-0.001 units/mg protein, n=9) (figure 3.3).  
 
 
Figure 3.1 Glucokinase activity in ARC of fed and fasted rats: GK activity in ARC of 
fed (yellow bar), 24hr fasted (orange bar) and 48hr fasted (red bar) male Wistar rats. 
Data are expressed as mean units of enzymatic activity per mg protein +/- SEM, n=8-9, 
*=P<0.05 vs fed.  
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Figure 3.2 Glucokinase activity in the PVN of fed and fasted rats: GK activity in PVN 
of fed (yellow bar), 24hr fasted (orange bar) and 48hr fasted (red bar) male Wistar rats. 
Data are expressed as mean units of enzymatic activity per mg protein +/- SEM, n=8-9. 
 
Figure 3.3 Glucokinase activity in the VMN of fed and fasted rats: GK activity in 
VMN of fed (yellow bar), 24hr fasted (orange bar) and 48hr fasted (red bar) male 
Wistar rats. Data are expressed as mean units of enzymatic activity per mg protein +/- 
SEM, n=8-9.  
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3.4.2 Cohort 1: Effect of iARC rAAV-GKS on food intake and bodyweight 
  
3.4.2.1 Confirmation of gene transfer by in situ hybridisation  
 
Three weeks post injection three rats from the GKS group were killed and in situ 
hybridisation was performed to confirm transgene expression.  Transgene expression 
was demonstrated in all three brains and was localized to the ARC. For a representative 
image of in situ hybridisation see figure 3.4. 
 
 
 
 
 
Figure 3.4 Confirmation of gene transfer by in situ hybridisation: GK mRNA 
expression in brains of male Wistar rats a) endogenous expression b) GK expression in 
the ARC 3 weeks post injection with rAAV-GKS.  
 
 
 
  
a) b) 
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3.4.2.2 Effect on bodyweight and bodyweight gain 
 
At the termination of the experiment (day 40 post recovery), there was a pronounced 
and significant difference in bodyweight (eGFP 424.9 +/- 12.9g vs GKS 449.4 +/- 6.5g, 
n=12-16, P=<0.05) and bodyweight gain (eGFP 151.7 +/- 8.9g vs GKS 171.6 +/- 5.9g, 
n=12-16, P=<0.05) between the eGFP group and the GKS group (figure 3.5). 
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Figure 3.5 Effect of iARC rAAV-GKS on bodyweight and bodyweight gain: a) 
Bodyweight and b) bodyweight gain following bilateral injection of 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Male Wistar rats were fed normal chow. Data 
are expressed as mean +/- SEM for both groups, n=12-16, *=P<0.05. 
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3.4.2.3 Effect on food intake  
 
At day 40, when the experiment was terminated, there was a significant increase in 
cumulative food intake in the GKS group compared to the eGFP group (eGFP 1094.3+/-
22.4g vs GKS 1183.2 +/- 25.7g, n=12-16, P=<0.01) (figure 3.6).                     
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Figure 3.6 Effect of iARC rAAV-GKS on food intake: Food intake following bilateral 
injection of 1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Male Wistar rats 
were fed normal chow. Data are expressed as mean +/- SEM for both groups, n=12-16, 
**=P<0.01.  
 
 
122 
 
3.4.2.4 Body composition  
 
At the termination of the study (day 40) body composition was analysed by carcass 
dissolution followed by protein and glycerol assays. Glycerol concentration was 
significantly higher in samples taken from GKS animals compared to controls (eGFP 
0.66+/-0.05mM vs. GKS 0.88+/-0.07mM, n=12-16, P=<0.05) and body fat percentage 
was 4.8% higher in GKS animals (eGFP 23.2+/-1.7% vs. GKS 27.9+/-1.6%, n=12-16) 
(figure 3.7). There was no difference in mean protein concentration of samples (eGFP 
71.1+/-2.1mg/ml vs. GKS 75.9+/-2.7mg/ml, n=12-16) or percentage bodyweight as 
protein (eGFP 16.9 +/-0.4% vs. GKS 16.9+/-0.5%, n=12-16) (figure 3.7). 
 
 
 
Figure 3.7 Effect of iARC rAAV-GKS on glycerol concentration and adiposity: (a) 
Glycerol concentration of saponification reaction samples and (b) body fat percentage 
of male Wistar rats after bilateral injection with either 1ul rAAV-eGFP (green bars) or 
1ul rAAV-GKS (blue bars) 40 days post surgical recovery. Data are expressed as mean 
+/- SEM for both groups, n=12-16, *=P<0.05. 
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a) 
 
 
 
Figure 3.8 Effect of iARC rAAV-GKS on protein concentration and lean body mass: 
(a) Protein concentration of saponification reaction samples and (b) percentage 
bodyweight as protein of male Wistar rats injected with either 1ul rAAV-eGFP (green 
bar) or 1ul rAAV-GKS (blue bar) 40 days post surgical recovery. Data are expressed as 
mean +/- SEM for both groups, n=12-16. 
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3.4.2.5 Effect of iARC rAAV-GKS on GK activity in the ARC and PVN 
 
Punch biopsies from the ARC and PVN of animals in the study group were 
homogenised and optimised GK assay was performed. GK activity increased slightly 
but not significantly in the GKS group compared to eGFP controls (eGFP 0.0048+/-
0.0007 vs GKS 0.0056+/-0.0006 units/mg protein, n=8-11) (figure 3.9a). In the PVN 
there was no difference between the groups (eGFP 0.0052+/-0.0011 vs GK 0.0052+/- 
0.0004 units/mg protein, n=8-11) (figure 3.9b).  
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Figure 3.9 Effect of iARC rAAV-GKS on GK activity in the ARC and PVN: GK 
activity in the a) ARC and b) PVN of male Wistar rats 40 days post surgical recovery 
following iARC injection of either 1ul rAAV-eGFP (green bars) or 1ul rAAV-GKS (blue 
bars). Data are expressed as mean units of enzymatic activity per mg protein +/- SEM, 
n=8-9, n=8-11. 
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3.4.3 Cohort 2: Effect of iARC rAAV-GKS on food intake and bodyweight, 
effect of pair feeding 
 
3.4.3.1 Effect on bodyweight and weight gain   
 
At the termination of the experiment (day 33 post recovery) there was a significant 
difference in bodyweight (eGFP 399.4 +/- 4.7g vs GKS 419.0 +/- 5.5g, n=11-13, 
P=<0.01 and weight gain (eGFP 123.4 +/- 2.6g vs GKS 145.5 +/- 6.5g, n=11-13, 
P=<0.01) in the GKS compared to the eGFP group. There was also a significant 
difference between the bodyweight (GKS 419.0 +/- 5.5g vs GKPF 393.2 +/- 5.5g, n=13-
15, P=<0.001) and weight gain (GKS 145.5 +/- 6.5g vs GKPF 114.5 +/- 5.9g, n=13-15, 
P=<0.001) of the GKS group and the GKPF group. There was no significant difference 
between the bodyweight or weight gain of the eGFP group and the GKPF group (figure 
3.10). 
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Figure 3.10 Effect of iARC rAAV-GKS on bodyweight and weight gain; effect 
of pair feeding: a) Bodyweight and b) weight gain following bilateral injection of 1ul 
rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line) and animals receiving 1ul rAAV-
GKS pair fed to rAAV-eGFP (black line).  Male Wistar rats were fed normal chow. 
Data are expressed as mean +/- SEM for all groups, n=11-15,**=P<0.01, 
***=P<0.001.  
a) b) 
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3.4.3.2 Effect on food intake  
 
At the termination of the experiment (day 33) there was a small difference between the 
food intake of the GKS group (963.0 +/-13.9g, n=13) and the eGFP group (932.0 +/-
6.4g, n=11) but this did not reach significance (figure 3.11).  
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Figure 3.11 Effect of iARC rAAV-GKS on food intake, effect of pair feeding: 
Food intake following bilateral injection of 1ul rAAV-eGFP (green line) or 1ul rAAV-
GKS (blue line). Male Wistar rats were fed normal chow.  Data are expressed as mean 
+/- SEM for both groups, n=11-13.   
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3.4.3.3 Effect of iARC rAAV-GKS on 24hr food intake and bodyweight 
following 24hr fast   
 
3.4.3.3.1 Food intake  
 
Food intake was not different between the groups until the 8-24hr period post re-feeding 
when the GKPF group and the GKS group consumed significantly more chow 
compared to the eGFP group (eGFP 9.6+/-0.82g vs GKPF 14.9 +/- 0.87g, n=10-14, 
P=<0.001; GKS 12.5+/- 0.64g, n=12, P=<0.05 vs eGFP) (figure 3.12e). Cumulative 
24hr food intake was significantly different between the GKPF group and the eGFP 
group (eGFP 35.5+/- 0.59g vs rAAV-GKPF 39.9 +/-1.38g, n=10-14, P=<0.05) but 
neither were significantly different from the rAAV-GKS groups (36.7+/- 0.75g, n=12) 
(figure 3.12f).  
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Figure 3.12 Effect of iARC rAAV-GKS on 24hr food intake following 24hr fast: 
24hr food intake of male Wistar rats injected with 1ul rAAV-eGFP (green bars), 1ul 
rAAV-GKS (blue bars) and rats injected with 1ul rAAV-GKS and pair fed to rAAV-
eGFP animals throughout life (red bars). All groups were fasted for 24hr and allowed ad 
libitum access to standard chow for a 24hr period at the start of the dark phase day 35 
post recovery.  Data are expressed as mean +/- SEM for all groups, n=10-14,*=P<0.05, 
***=P<0.001.  
e) f) 
d) c) 
a) b) 
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3.4.3.3.2 Bodyweight 
 
Following 24hr fast the GKPF group lost significantly less weight (16.7 +/-0.7g, n=14) 
than the GKS group (24.9+/-0.68g, n=12, P=<0.05) and eGFP group (23.1+/-0.67g, 
n=10, P=<0.05) (figure 3.13a). Following 24hr re-feed the GKS group gained 
significantly more weight than the eGFP group (eGFP 16.6+/- 1.22g vs GKS 19.5+/-
0.46g, n=10-12,P=<0.05), as did the GKPF group (20.9 +/-1.61g, n=14, P=<0.05). The 
GKPF group gained significantly more weight than the GKS group (P=<0.05) (figure 
3.13b). 
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Figure 3.13 Effect of iARC rAAV-GKS on 24hr weight gain following 24hr fast 
and re-fed: 24hr a) bodyweight loss and b) bodyweight gain of male Wistar rats 
injected with 1ul rAAV-eGFP (green bar), 1ul rAAV-GKS (blue bar) and rats injected 
bilaterally with 1ul rAAV-GKS and pair fed to rAAV-eGFP animals throughout life (red 
bar). All groups were fasted for 24hr and allowed ad libitum access to standard chow 
for a 24hr period at the start of the dark phase on day 35 post recovery. Bodyweight 
was measured post 24hr fast (a) and 24hr after re-feeding (b).  Data are expressed as 
mean +/- SEM for all groups, n=10-14, *=P<0.05 
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3.4.3.4 Effect of iARC rAAV-GKS on body composition and plasma hormones  
 
At the termination of the study (day 40 post recovery) rats were killed by decapitation 
and tissues were collected. 
3.4.3.4.1 BAT weight  
 
Intrascapular brown adipose tissue (BAT) was removed and weighed. BAT weight was 
not different between the GKS group and the eGFP group (eGFP 0.55+/- 0.03g vs GKS 
0.62+/-0.04g, n=10-12). BAT weight was lower in the GKPF group compared to GKS 
(GKS 0.62+/-0.04g vs GKPF 0.47+/-0.03g, n=10-14, P=<0.05). BAT weight was also 
lower in the GKPF group compared to the eGFP but this did not reach significance 
(eGFP 0.55+/- 0.03g vs GKPF 0.47+/-0.03g, n=10-14) (figure 3.14). 
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Figure 3.14 Effect of iARC rAAV-GKS on BAT weight: BAT weight of male Wistar 
rats injected bilaterally with 1ul rAAV-eGFP (green bar), 1ul rAAV-GKS (blue bar) and 
rats injected with 1ul rAAV-GKS and pair fed to rAAV-eGFP animals throughout life 
(red bar).  Data are expressed as mean +/- SEM for all groups, n=10-14, *=P<0.05. 
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3.4.3.4.2 Epididymal WAT weight  
 
Epididymal white adipose tissue (WAT) was removed and weighed. Epididymal WAT 
weight was not significantly different between the groups (eGFP 6.89+/- 0.44g vs GKS 
8.38+/-0.84g vs GKPF 7.64+/- 0.53 n=10-14) (figure 3.15). 
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Figure 3.15 Effect of iARC rAAV-GKS on epididymal WAT weight: Epididymal 
WAT weight of male Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar), 
1ul rAAV-GKS (blue bar) and rats injected with 1ul rAAV-GKS and pair fed to rAAV-
eGFP animals throughout life (red bar).  Data are expressed as mean +/- SEM for all 
groups, n=10-14. 
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3.4.3.4.3 Fed blood glucose  
 
In the fed state blood glucose levels were not different between the groups (eGFP 4.7+/- 
0.2g vs GKS 4.7+/-0.1g vs GKPF 4.8+/- 0.1 n=10-14) (figure 3.16). 
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Figure 3.16 Effect of iARC rAAV-GKS on fed blood glucose: Blood glucose 
measured in fed male Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar), 
1ul rAAV-GKS (blue bar) and rats injected with 1ul rAAV-GKS and pair fed to rAAV-
eGFP animals throughout life (red bar).  Data are expressed as mean +/- SEM for all 
groups, n=10-14. 
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3.4.3.4.4 Fed plasma insulin  
 
In the fed state plasma insulin was significantly higher in the GKS group compared to 
eGFP controls (eGFP 301.2+/- 16.7pmol/l vs GKS 388.0+/-40.8pmol/l, n=10-12, 
P=<0.05) and compared to GK animals pair fed to controls (GKS 388.0+/-40.8pmol/l vs 
GKPF 254.8+/-13.9pmol/l, n=10-14, P=<0.01) (figure 3.17). 
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Figure 3.17 Effect of iARC rAAV-GKS on fed plasma insulin: Plasma insulin 
measured in fed male Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar), 
1ul rAAV-GKS (blue bar) and rats injected with 1ul rAAV-GKS and pair fed to rAAV-
eGFP animals throughout life (red bar).  Data are expressed as mean +/- SEM for all 
groups, n=10-14, *=P<0.05, **=P<0.01. 
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3.4.3.5 Hypothalamic gene expression  
 
3.4.3.5.1 GK 
 
Hypothalamic GK mRNA expression was significantly increased in GKS treated 
animals compared to control at the termination of the study (eGFP 3.93+/- 1.19 vs GKS 
53.9+/-12.16 arbitrary units, n=10-12, P=<0.05). Hypothalamic GK mRNA was also 
significantly increased in the pair fed GK group compared to controls (eGFP 3.93+/- 
1.19 vs GKPF 58.47+/- 14.6 arbitrary units, n=10-14, P=<0.01) (figure 3.18). 
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Figure 3.18 Effect of iARC rAAV-GKS on hypothalamic GK mRNA expression: 
GK mRNA expression measured in whole hypothalami from fed male Wistar rats 
injected bilaterally with 1ul rAAV-eGFP (green bar), 1ul rAAV-GKS (blue bar) and rats 
injected with 1ul rAAV-GKS and pair fed to rAAV-eGFP animals throughout life (red 
bar).  Data are expressed as mean +/- SEM for all groups, n=10-14, *=P<0.05, 
**=P<0.01. 
 
136 
 
3.4.3.5.2 AMPK  
 
Hypothalamic AMPK mRNA expression was not significantly different between the 
groups (eGFP 0.66+/- 0.09 vs GKS 0.64+/-0.08 arbitrary units, n=10-12) (figure 3.19). 
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Figure 3.19 Effect of iARC rAAV-GKS on hypothalamic AMPK mRNA 
expression: AMPK mRNA expression measured in whole hypothalami from fed male 
Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar)or 1ul rAAV-GKS (blue 
bar).  Data are expressed as mean +/- SEM for all groups, n=10-12. 
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3.4.3.5.3 CART 
 
Hypothalamic CART mRNA expression was not significantly different between the 
groups (eGFP 0.59+/-0.09 vs GKS 0.52+/-0.06 arbitrary units, n=10-14) (figure 3.20). 
 
rA
A
V-
eG
FP
rA
A
V-
G
K
S
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
H
y
p
o
th
a
la
m
ic
 C
A
R
T
 m
R
N
A
 (
A
rb
. 
u
n
it
s
)
 
 
Figure 3.20 Effect of iARC rAAV-GKS on hypothalamic CART mRNA 
expression: CART mRNA expression measured in whole hypothalami from fed male 
Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar)or 1ul rAAV-GKS (blue 
bar).  Data are expressed as mean +/- SEM for all groups, n=10-12. 
 
 
 
 
  
138 
 
3.4.3.5.4 FAS  
 
Hypothalamic FAS mRNA expression was not significantly different between the 
groups (eGFP 0.45+/-0.09 vs GKS 0.58+/-0.08 arbitrary units, n=10-12) (figure 3.21). 
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Figure 3.21 Effect of iARC rAAV-GKS on hypothalamic FAS mRNA expression: 
FAS mRNA expression measured in whole hypothalami from fed male Wistar rats 
injected bilaterally with 1ul rAAV-eGFP (green bar)or 1ul rAAV-GKS (blue bar).  Data 
are expressed as mean +/- SEM for all groups, n=10-12. 
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3.4.3.5.5 NPY 
 
Hypothalamic NPY mRNA expression was not significantly different between the 
groups (eGFP 0.66+/-0.1 vs GKS 0.63+/-0.04 arbitrary units, n=10-12) (figure 3.22). 
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Figure 3.22 Effect of iARC rAAV-GKS on hypothalamic NPY mRNA expression: 
NPY mRNA expression measured in whole hypothalami from fed male Wistar rats 
injected bilaterally with 1ul rAAV-eGFP (green bar)or 1ul rAAV-GKS (blue bar).  Data 
are expressed as mean +/- SEM for all groups, n=10-12. 
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3.4.3.5.6 POMC 
 
Hypothalamic POMC mRNA expression was not significantly different between the 
groups (eGFP 0.59+/-0.11 vs GKS 0.64+/-0.11 arbitrary units, n=10-12) (figure 3.23).   
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Figure 3.23 Effect of iARC rAAV-GKS on hypothalamic POMC mRNA 
expression: POMC mRNA expression measured in whole hypothalami from fed male 
Wistar rats injected bilaterally with 1ul rAAV-eGFP (green bar)or 1ul rAAV-GKS (blue 
bar).  Data are expressed as mean +/- SEM for all groups, n=10-12. 
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3.4.4 Cohort 3: Effect of iARC rAAV-GKS on food intake and bodyweight: 
High energy diet  
3.4.4.1 Effect on bodyweight gain   
At the termination of the experiment (day 37), there was no significant difference 
between the mean bodyweights of the groups (eGFP 313.1+/-13.3g vs GKS 345.2+/- 
14.8g, n=9-11). However, weight gain was significantly different between the eGFP 
group and the GKS group (eGFP 81.8+/-5.5g vs GKS 105.4+/- 7.4g, n=9-11, P=<0.05) 
(figure 3.24).  
                          a) 
b)
0 10 20 30 40
200
250
300
350
400
rAAV-eGFP
rAAV-GKS
Time (days post recovery)
B
o
d
y
w
e
ig
h
t 
(g
)
                                                              
0 10 20 30 40
0
50
100
150
rAAV-eGFP
rAAV-GKS
*
Time (days post recovery)
W
e
ig
h
t 
g
a
in
 (
g
)
 
Figure 3.24 Effect of iARC rAAV-GKS on bodyweight and weight gain; high energy 
diet: a) bodyweight and b) weight gain following bilateral injection of 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Male Wistar rats were fed a high energy diet 
for 37 days. Data are expressed as mean +/- SEM for both groups, n=9-11, *=P<0.05. 
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3.4.4.2 Effect on food intake  
 
At the termination of the study (day 37) food intake was significantly higher in the GKS 
group compared to controls (eGFP 803.5+/-14.6g vs GKS 887.0+/- 25.8g, n=9-11, 
P=<0.05) (figure 3.25). 
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Figure 3.25 Effect of iARC rAAV-GKS on intake of high energy diet: Food intake 
following bilateral injection of 1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue 
line). Male Wistar rats were fed a high energy diet for 37 days. Data are expressed as 
mean +/- SEM for both groups, n=9-11, *=P<0.05. 
 
 
 
 
143 
 
3.5 Discussion 
 
3.5.1 Identifying a primary target for rAAV-GKS injection 
 
Glucose-sensing neurones are found in numerous hypothalamic nuclei including the 
ARC, PVN, LHA and VMN (Lynch et al, 2000). For this reason, the first task was to 
identify which nucleus/nuclei might be quantitatively most important in feeding 
behaviour. To achieve this GK assay was performed on punch biopsies taken from the 
ARC, PVN and VMN of fed rats and rats subjected to a fast of either 24 or 48 hours. 
Fasting, for 24 or 48 hours, resulted in an increase in GK activity in the ARC compared 
to fed controls with no difference observed in the VMN or PVN. This finding is in line 
with previously published material which shows that GK mRNA is increased with 
fasting (Kang et al, 2008).  These findings are also in agreement with a large body of 
evidence which shows that insulin induced hypoglycaemia results in increased GK 
mRNA expression and activity in the VMH (which comprises the ARC and VMN) 
(Dunn-Meynell et al, 2002;Kang et al, 2008;Tkacs et al, 2000).  
The ARC is located at the base of the hypothalamus and possesses a highly fenestrated 
blood brain barrier. This allows access to circulating factors including glucose, fatty 
acids, leptin and ghrelin (Cone et al, 2001). It is likely that the supply of glucose to the 
ARC, and perhaps the VMN, is greater than in deeper regions of the brain (Mountjoy & 
Rutter, 2007). Furthermore, the ARC contains the orexigenic NPY/ AgRP neurones and 
the anorexic POMC/CART neurones, some of which are believed to be glucose 
sensitive (Cone et al, 2001;Ibrahim et al, 2003;Muroya et al, 1999).  As such, ARC 
glucose-sensing neurones are well placed to act as primary central “metabolic sensors” 
and it is also possible that due to their co-localisation and/or close proximity to 
NPY/AgRP and POMC/CART neurones glucose sensing neurones may also act as 
“metabolic effectors” by influencing feeding behaviour and glucose homeostasis. Taken 
together with the results of the fasting study, these data suggest that ARC glucose 
sensing may be of particular importance in the regulation of energy balance. For this 
reason, the ARC was chosen as the primary target for rAAV-GKS microinjection.  
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3.5.2 Ex-vivo GK assay 
 
In testing the efficacy of the plasmids used in the production of the rAAV-GKS, it was 
found that treating HEK293T cells with pTR-CGW-GKS increased NADPH production 
3-fold in the GK assay.  In this assay, GK activity is linked to the production of 
NADPH (described in 2.3.5.2). The increase in NADPH production suggests that the 
sense plasmid (pTR-CGW-GKS) was producing functioning GK enzyme that was able 
to phosphorylate glucose and initiate glycolysis via the GK pathway.   
The primary objective of this work has been to alter the sensitivity of hypothalamic 
glucose-sensing neurones by increasing GK activity via rAAV mediated gene transfer. 
While in situ hybridisation confirmed increased GK mRNA in the GKS treated animals 
the GK activity assay failed to show a significant increase in activity in the GK group 
compared to eGFP controls. This may have occurred for a number of reasons. Firstly, it 
is possible that the GK assay was not sufficiently sensitive to detect the changes in 
activity resulting from treatment. In testing this assay in vitro, a cell type was selected 
that does not express GK therefore, no NADPH should be produced during the reaction. 
Since the cell lysate was highly diluted in the reaction mixture NADPH produced by the 
cell prior to the reaction should be minimal. In light of this, the fact that NADPH was 
detected suggests that hexokinase activity may not have been fully inhibited; this would 
interfere with the results of the assay and could reduce its sensitivity.   
It is also possible that the punching technique used was inaccurate. In the study 
investigating the effect of fasting on ARC GK activity a difference was observed 
between GK activity in the fasted and fed states. During this study, brains were sliced in 
the coronal plane and each nucleus was excised bilaterally by two punch biopsies. In the 
study investigating the effect of iARC rAAV-GKS treatment an alternative method was 
used. In the rAAV studies the brains were sliced in the sagittal plain and both sides of 
the desired nucleus were excised by a single punch. During this study, the nuclei of 
interest were identified using land marks on the brain in the sagittal plain.  
The majority of work conducted on the rat brain by this group has dealt with brain slices 
in the coronal plane and numerous anatomical markers are available for identification of 
specific hypothalamic nuclei. In slicing the brains in the sagittal plain, I hoped to isolate 
a greater proportion of the desired nucleus than would be possible in the coronal plain. 
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Unfortunately, preparing sagittal brain sections and identifying nuclei using sagittal 
markers proved to be challenging. It is possible that the failure to observe a difference in 
GK activity using this method may have resulted from inaccuracy in the localisation of 
biopsies taken.    
 
3.5.3 Effect of iARC rAAV-GKS; Cohort one  
 
In the initial feeding study, injection of rAAV-GKS into the ARC resulted in a 
significant increase in food intake accompanied by significantly increased bodyweight.  
The divergence in food intake between the treatment group and control group began 
early (approximately 9 days post injection) and continued to diverge until the 
termination of the study. The increase in bodyweight gain in the GKS group also began 
early but reached a plateau at day 22. After this time the difference in bodyweight 
between the groups was maintained such that at the termination of the study the GKS 
group were 6% heavier than controls. At the termination of the study carcass analysis 
was performed. Carcass analysis revealed that the difference in bodyweight observed 
between the groups resulted from a significant increase in percentage body fat in the 
GKS group. There was no difference in lean mass between the groups. 
The results of the first feeding study were unexpected as they apparently disagreed with 
available literature.  Glucose infusion ICV decreases food intake acutely (Kurata et al, 
1986).  Whereas, ICV infusion of the glucoprivic agent 2DG into the 3
rd
 cerebral 
ventricle results in increased feeding (Tsujii & Bray, 1990). It could therefore be 
hypothesized that increasing GK expression in the ARC (which is hypothesised to 
increase glucose metabolism therein) would result in a reduction in food intake. As this 
was not the case, the feeding study was repeated in a second cohort of animals with the 
addition of a GKS group pair-fed to controls to help clarify the role of feeding in the 
increased bodyweight observed. 
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3.5.4 Effect of iARC rAAV-GKS; Cohort two  
 
In the second feeding study, the bodyweight gain of the GKS group was again 
significantly greater than controls. The pair-fed GKS group and the control group were 
not different in weight, suggesting that the increased bodyweight of the GKS animals in 
the previous study was primarily due to increased food intake. However, the food intake 
of the ad libitum fed GKS group in cohort two was only slightly, and not significantly, 
higher than the eGFP controls. 
 At the termination of the feeding study (day 33) cumulative food intake in the GKS 
group was 31g higher than controls. This equates to an increase in energy intake of 
482kJ across the duration of the study. Approximately 34kJ are required to store 1g of 
adipose tissue so it is unlikely that the 22g difference in bodyweight between the groups 
can be accounted for solely by food intake. That said, the 20g difference between the 
bodyweights of the GKS group and the controls in the first cohort could be explained by 
the 1,309kj difference in their energy intake.   
To further investigate the observed differences between the groups I measured food 
intake and bodyweight gain for a period of 24 hours following a 24 hour fast. Upon re-
feeding, there was no difference in food intake between the groups until the 8-24 hours 
period when both the GKS group and the pair fed GKS group consumed significantly 
more chow than eGFP controls. There was no significant difference in cumulative food 
intake between the ad libitum fed GKS group and their controls over the total 24hr 
period. Interestingly, despite the fact that food intake was not different both GKS 
groups gained significantly more weight than the eGFP group. Combined with the 
results of the long term feeding study these data suggest that increasing GK mRNA in 
the ARC may have additional effects on metabolism beyond those on food intake. For 
example it is possible that the treatment might decrease energy expenditure.    
At the termination of the study, tissues were harvested. BAT weight was not different 
between the GKS group and the eGFP controls. BAT weight was significantly lower in 
the pair fed GKS group compared to the ad libitum fed GKS group. BAT metabolism 
and mass are reduced by fasting and this result is likely to reflect the fact that the pair 
fed GKS group are calorie restricted compared to the ad libitum GK group (Rothwell et 
al, 1984). During the 24 hour fast the pair fed GKS group lost significantly less weight 
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than both other groups. It is possible that this result is related to the reduction in BAT 
weight observed in this group. 
To confirm the successful increase of GK mRNA expression in the treatment groups I 
harvested whole hypothalami and performed quantitative PCR (QPCR) for GK mRNA. 
GK mRNA was increased 15-fold in the pair fed GKS group and 14-fold in the ad 
libitum GKS group compared to controls. Taken together with the results of the in situ 
hybridization these data suggest that GK mRNA was successfully increased by 
treatment. In addition to GK, I performed QPCR for AMPK, CART, FAS, NPY and 
POMC mRNA. Other than GK, there was no significant difference in mRNA 
expression of any gene assayed.  
 Glucose sensing in the VMH has been shown to be involved in the regulation of 
glucose homeostasis. For this reason, I performed assays for plasma glucose and insulin 
in non-fasted animals at the termination of the study. There was no significant 
difference in plasma glucose between the groups. The plasma glucose levels recorded in 
this experiment are close to values reported in the literature (Dunn-Meynell et al, 2009; 
da Vries et al, 2005; Anderson, 2011). This suggests that the assay method used 
provided an accurate measure of true plasma glucose values. Plasma insulin was 
significantly higher in the GKS group compared to the pair fed GKS group and 
compared to the eGFP controls. The fact that the pair fed GKS group had lower plasma 
insulin compared to the ad libitum GKS group again suggests that the pair fed group 
were calorie restricted because calorie restriction has a well-accepted insulin lowering 
effect. The increased plasma glucose in the GKS group compared to the eGFP group 
could be interpreted in a number of ways. Firstly, since the GKS group were larger and 
more adipose than the controls, it could be suggested that increased insulin is the result 
of peripheral insulin resistance as observed in type II diabetes mellitus. Another 
possibility is that the increased GK mRNA expression within the ARC has had a 
specific effect on pathways that regulate pancreatic insulin release. The release of 
insulin from the pancreas is under significant neural influence and lesioning of the 
VMH has been shown to enhance insulin secretion, which suggests that VMH signalling 
is important in the regulation of insulin secretion (Hahn et al, 1981;Gerich et al, 1976).  
At present, there is considerable interest in the use of GK activators in the treatment of 
type II diabetes. Oral administration of the GK activator RO-28-1675 has been shown to 
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decrease plasma glucose and increase plasma insulin levels in mice (Grimsby et al, 
2003). In addition, it has been hypothesised that a GK activator that could cross the 
blood brain barrier could be used to reduce food intake and thus treat obesity (Al-Hasani 
et al, 2003). The data presented in this chapter are important because they indicate that 
increasing GK mRNA in the ARC could have the opposite effect, increase food intake 
and weight gain.   
 
3.5.5 Effect of iARC rAAV-GKS; High energy diet   
 
The results of my work so far have demonstrated that increasing GK mRNA in the ARC 
using rAAV results in increased bodyweight gain and food intake. However, the 
standard chow diet is low in both fat and sugar (see appendix II) and does not contain 
nutrient levels similar to the diet of westernized human populations. Considering the 
proposed use of GK activators in the treatment of diabetes and obesity it was important 
to assess the effect of increased ARC GK mRNA on intake of a high energy western-
style diet.  
As observed on standard chow, there was a significant increase in both food intake and 
bodyweight gain in the GKS group compared to controls on the high energy diet. The 
difference in food intake started early (at day 9) and continue to diverge until the 
termination of the study at day 37 by which time the GKS group had gain 23.6g more 
than controls. Despite the difference in weight gain there was no difference in mean 
bodyweight between the groups. 
The work in this chapter demonstrates that increasing GK mRNA expression in the 
ARC results in a robust and reproducible increase in food intake and bodyweight gain 
on standard chow and a high energy western style diet. From the results of the 24 hour 
food intake study it would also appear that feeding patterns are altered by treatment as 
food intake in the GKS groups was only different in the 8-24 hour period. There was no 
significant difference in the expression of any of the feeding related hypothalamic genes 
assayed so at present there is no proposed hypothalamic mechanism of action. 
Interestingly, plasma insulin levels in the fed state were significantly higher in the GKS 
group compared to controls despite no difference in plasma glucose levels. Further 
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experiments including glucose tolerance test and insulin tolerance test are required to 
assess the effect of treatment on glucose homeostasis.   
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4. Chapter 4Effect GKS administration on intake 
of sugars and glucose homeostasis 
 
Chapter 4 
Effect iArc rAAV-GKS 
administration on intake of sugars 
and glucose homeostasis 
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4.1 Introduction  
 
4.1.1 The role of sugars in the regulation of food intake 
 
Manipulation of glucose levels in numerous regions of the body have been shown to 
affect feeding behaviour (see section 1.1.10.1).  The effect of manipulation of glucose 
metabolism on feeding behaviour normally follows a reasonably predictable pattern. 
Manipulations that increase glucose levels tend to decrease feeding acutely while those 
that decrease glucose metabolism (such as 2DG infusion) increase feeding. When 
glucose and other sugars are provided either as a pre load prior to a meal or in addition 
to chow the effects are less predictable.   
 In rats, provision of a 32% (w/v) solution of sucrose, fructose or glucose in addition to 
standard chow results in a significant increase in energy intake and fat pad mass 
compared to standard chow fed controls. Daily energy intake was greatest in the group 
provided sucrose, followed by the fructose group with the glucose group consuming the 
least. In all cases, increased energy intake was a result of intake of sugar solution rather 
than increased intake of standard chow (Kanarek & Orthen-Gambill, 1982).    
Glucose and fructose have also been shown to alter feeding behaviour when consumed 
as a preload before a meal. However, the results of studies of this nature are 
inconsistent. Rodin et al 1998, fasted human participants overnight before providing a 
solution containing 50g of either glucose or fructose. Two and a quarter hours after 
consumption of the solution participants were presented with a buffet meal and calorie 
intake was measured. In this study, the fructose preload group consumed fewer calories 
at the buffet than the glucose preload group suggesting that fructose has a greater 
inhibitory effect on food intake. Plasma glucose and plasma insulin were significantly 
increased in the glucose group compared to the fructose group and calorie intake was 
correlated to plasma insulin levels such that higher plasma insulin was associated with 
increased food intake. The authors hypothesise that the difference between the groups 
may have resulted from the rapid storage and utilization of glucose following the 
glucose load. Two hours after a glucose load, plasma glucose levels have been shown to 
fall below baseline, an effect not observed with fructose (Rodin et al, 1988). It is 
plausible that a transient fall in plasma glucose following a glucose load may result in 
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an increased drive to feed. The majority of spontaneous meals in rats and humans are 
preceded by fall in plasma glucose (Dunn-Meynell et al, 2009).  
Using a similar study protocol to that of Rodin, Shafer et al 1987, found that glucose 
decreased food intake to a greater extent than fructose when delivered as a preload. In 
this study, participants were fasted and offered a solution containing either 25g of 
fructose or glucose 1 hour prior to a buffet meal. Calorie intake was significantly 
reduced by glucose and fructose compared with water and the glucose group consumed 
less than the fructose group (Shafer et al, 1987).  
It is possible that the differences between the results of these studies might involve both 
the time at which the meal was presented after the preload and the amount of sugar 
provided in the preload. Although plasma glucose and insulin levels were not recorded 
during the Shafer study it is likely that the magnitude of the increase in plasma glucose 
would not be as great as in the Rodin study because the glucose dose was half the size. 
In addition, in the Shafer study, the buffet meal was provided one hour after the preload, 
whereas in the Rodin study the meal was provided after two and a quarter hours. One 
hour after an oral glucose load plasma glucose would be expected to be higher than 
baseline. Thus, in the Shafer study, it is possible that plasma glucose was increased 
when the meal was presented. In the Rodin study, plasma glucose was lower than 
baseline when the meal was presented, this might potentially explain the observed 
differences.  
 
4.1.2 Fructose metabolism in the brain and food intake  
 
The pathways by which fructose and glucose are metabolised differ; both in the 
periphery and the central nervous system (CNS). In the CNS, glucose infusion has a 
well-accepted effect of decreasing food intake. Interestingly, ICV infusion of fructose 
has been shown to increase food intake (Miller et al, 2002). It is believed that the 
differential effects of ICV fructose and glucose on food intake result from the manner in 
which they are metabolised.  
Glucose and fructose are both ultimately metabolised via glycolysis in the CNS and the 
liver. However, the early steps in the metabolism of glucose and fructose differ. Glucose 
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metabolism is regulated by a rate limiting step in which fructose-6-phosphate is 
converted to fructose-1-6-bisphosphate by phosphofructokinase (PFK).  The first step in 
fructolysis is the phosphorylation of fructose to fructose-1-phosphate by 2-keto-
hexokinase. Following this step, fructose enters glycolysis at the triose level and thus 
fructose metabolism by-passes regulation by PFK. Phosphorylation of fructose by 2-
keto-hexokinase is unregulated and rapidly utilizes ATP. Indeed, while ICV infusion of 
glucose increases hypothalamic ATP levels, infusion of fructose does the opposite and 
decreases hypothalamic ATP (Cha et al, 2008).  
Increased ATP as a result of glucose infusion reduces levels of phosphorylated AMPK 
(pAMPK). This in turn increases the activity of acetyl-CoA carboxylase (ACC) 
resulting in increased levels of malonyl-CoA. Malonyl-CoA is a potent inhibitor of the 
mitochondrial transporter CPT-1 and increased levels of malonyl-CoA have been shown 
to decrease food intake via increased expression of POMC and CART mRNA (Cha et 
al, 2008).  
Following ICV fructose infusion, hypothalamic ATP levels fall and levels of pAMK are 
increased. This decreases the activity of ACC, resulting in a reduction in malonyl-CoA, 
increased feeding  and decreased POMC mRNA (Cha et al, 2008). 
The majority of dietary fructose is metabolised by the liver before it can enter general 
circulation. However, at higher doses, dietary fructose increases plasma fructose 
concentrations. Fasting plasma fructose is usually lower than 1mg/dL. Following 
ingestions of 18-100g of fructose plasma levels increase in a dose dependent manner 
from 4.5-13.0mg/dL within 60 minutes (Cook, 1969). Combined with the fact that the 
CNS expresses enzymes that are specific to fructolysis this suggests that post-prandial 
fructose metabolism occurs in the CNS. When considered with the results of Cha et al, 
this further suggests the possibility that central fructose metabolism might be an 
important regulator of food intake.  
The effects of sugars on food intake are complex and dependent on a number of factors 
including type of sugar, size of dose and timing of administration. The fact that central 
administration of glucose and fructose produces different effects highlights the 
importance of specific nutrient sensing pathways in the regulation of feeding behaviour. 
The correlation between plasma insulin and food intake also suggests the intriguing 
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possibility that at least part of the effect of sugars on food intake might be secondary to 
their effect on glucose homeostasis.  
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4.2 Hypothesis and Aims 
4.2.1 Hypothesis 
 
In earlier chapters, increasing GK mRNA in the ARC was shown to increase food 
intake and bodyweight gain. It is hypothesised that increasing GK mRNA in the ARC 
will also alter the intake of sugar solutions and intake of standard chow when a sugar 
solution is available. Furthermore, it is hypothesised that increasing GK mRNA in the 
ARC will affect glucose homeostasis.   
 
4.2.2 Aims and Objectives 
 
The aims of this chapter are to  
1. Examine the effect of up regulation of ARC GK mRNA on intake of sugars 
2. Examine the effect of up regulation of ARC GK mRNA on preference to sugars 
or standard chow 
      3. Examine the effect of up regulation of ARC GK mRNA on glucose homeostasis 
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4.3 Methods  
4.3.1 Cohort 4: Effect of iARC rAAV-GKS on food intake, intake of glucose 
and bodyweight gain 
 
4.3.1.1 Energy intake calculation 
 
In studies in which food intake and intake of glucose solution were measured, total 
energy intake in kcal was calculated as follows:  
kcal from standard chow= food intake in g x 3.523kcal/g standard chow 
kcal from glucose solution= (glucose solution consumed ml x concentration of glucose 
g/ml)x 4kcal/g glucose 
Total energy intake= kcal from glucose solution + kcal from standard chow  
 
4.3.1.2 Effect of iARC-GKS on intake sugars and standard chow  
 
Animals were maintained as described in 3.3.1 and were randomised to control and 
treatment groups as described in appendix  
Adult male Wistar rats were bilaterally injected in the ARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) and allowed to recover for 7 days (as described in 3.3.6). 
Twenty-one days later they were fasted for 4hr. Following 4hr fast animals were given 
ad libitum access to a solution containing 10% (w/v) glucose at the onset of the dark 
phase. Intake of the glucose solution was measured at 1,2,4,8,12,16 and 24hr. In all 
experiments described in this thesis animals had ad libitum access to water. 
On day 24 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast animals were 
given ad libitum access to a solution containing 10% (w/v) fructose at the onset of the 
dark phase. Intake of the fructose solution was measured at 1,2,4,8,12,16 and 24hr. 
On day 28 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast standard chow 
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was returned at the onset of the dark phase and food was weighed at 1,2,4,8,12,16 and 
24hr.  
4.3.1.3 Effect of iARC rAAV-GKS on 24hr intake of standard chow and 2% 
glucose solution  
 
On day 31 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast standard chow 
was returned and animals were given ad libitum access to a 2% (w/v) glucose solution 
at the onset of the dark phase. Intake of standard chow and glucose solution were 
measured at 1,2,4,8,12,16 and 24hr. Total kcal intake was calculated as described in 
4.3.1.1. 
 
4.3.1.4 Effect of iARC rAAV-GKS on 24hr intake of standard chow and 10% 
glucose solution  
 
On day 40 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast standard chow 
was returned and animals were given ad libitum access to a 10% (w/v) glucose solution 
at the onset of the dark phase. Intake of standard chow and glucose solution were 
measured at 1,2,4,8,12,16 and 24hr. Total kcal intake was calculated as described in 
4.3.1.1. 
 
4.3.1.5 Effect of iARC rAAV-GKS on 24hr intake of standard chow and 20% 
glucose solution  
 
On day 44 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast standard chow 
was returned and animals were given ad libitum access to a 20% (w/v) glucose solution 
at the onset of the dark phase. Intake of standard chow and glucose solution were 
measured at 1,2,4,8,12,16 and 24hr. Total kcal intake was calculated as described in 
4.3.1.1. 
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4.3.1.6 Effect of iARC rAAV-GKS on 24hr intake of standard chow and 40% 
glucose solution  
 
On day 50 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted for 4hr. Following 4hr fast standard chow 
was returned and animals were given ad libitum access to a 40% (w/v) glucose solution 
at the onset of the dark phase. Intake of standard chow and glucose solution were 
measured at 1,2,4,8,12,16 and 24hr. Total kcal intake was calculated as 4.3.1.1. 
 
4.3.1.7 Effect of iARC rAAV-GKS on intake of standard chow and 10% 
glucose solution: long term study  
 
54 days post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were maintained with ad libitum access to RM1 diet 
(standard chow) and a solution containing 10% (w/v) glucose with free access to water. 
Food intake, intake of 10% glucose solution and bodyweight were measured for a 
period of 31 days. In addition, total energy intake from glucose and chow was 
calculated.  
 
4.3.1.8 Effect of iARC rAAV-GKS on plasma glucose following oral glucose 
challenge  
 
At day 85 post injection male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) were fasted over night with free access to water. At the 
onset of the light phase animals were offered a 20% (w/v) D-glucose solution providing 
2.5g/kg glucose which was consumed within 10 minutes. Thirty minutes after the 
glucose solution had been consumed animals were killed by decapitation and trunk 
blood was collected in lithium heparin tubes (Microvette, Sarstedt, Nümbrecht, 
Germany). Plasma was separated by centrifugation at 2,400xg for 5minutes at 4˚C and 
frozen on liquid nitrogen. Plasma glucose was assayed as described in 3.3.9.5 and 
plasma insulin was assayed as described in 3.3.9.6.  
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4.3.2 Group 5  
 
4.3.2.1 Oral glucose tolerance test by gavage (oGTT) 
 
Materials  
20% (w/v) glucose solution (Clintech, Dublin, Ireland) 
Lithium heparin tubes (Microvette) 
 
Method  
Adult male wistar rats were bilaterally injected in the ARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=10) and allowed to recover for 7 days (as described in section 
3.3.6) On day 20 post recovery oGTT was performed. Male Wistar rats injected iARC 
with either 1ul rAAV-GKS (n=10) or rAAV-eGFP (n=9) were fasted over night with 
free access to water. On the day of the procedure rats were cannulated into the lateral 
tail vein (as described in 4.3.3.2). After all rats had been cannulated and cannulae 
checked, baseline blood samples were collected. Rats received glucose (2.5g/kg) via 
oral gavage and blood samples were collected at 15, 30, 60 and 120 minutes post 
gavage. Between blood sampling rats were returned to the home cage with free access 
to water. Blood samples of approximately 120µl were collected at each time point in 
lithium heparin tubes and plasma was separated by centrifugation at 2,400xg for 5 
minutes at 4˚C. Plasma was frozen on liquid nitrogen and plasma glucose was assayed 
as described in 3.3.9.5.  
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4.3.2.2 Tail vein cannulation  
 
Materials 
Warming cabinet (Vet Tech Solutions Ltd, Cheshire,UK) 
Restraining tube (Vet Tech Solutions Ltd) 
25 gauge needles (Tyco Healthcare Ltd, Hampshire, UK) 
24 gauge/19mm Cannulae (Millpledge Veterinary, Nottinghamshire, UK)  
Zinc Oxide surgical adhesive tape (Millpledge Veterinary) 
Ethyl chloride liquid spray (L.E. West, Barking, UK) 
Heparin sodium diluted 1:10 in normal saline (Heparin sodium 1000IU/ml, LEO 
Pharma  Ltd, Bucks, UK)  
Method 
Tail vein cannulation is a technique that allows multiple blood sampling with minimal 
discomfort to the animal. Prior to cannulation rats were warmed in a 39 C warming 
cabinet for 10 minutes to dilate blood vessels. Next, rats were immobilised in a 
restraining tube and ethyl chloride was sprayed on the area of the tail that was to be 
cannulated. The lateral tail vein was visualised and an indwelling cannula inserted. The 
cannula was fixed in place using surgical tape and the cannula covered to prevent its 
removal. Blood flow was confirmed and 100µl of diluted heparin was injected into the 
cannula to prevent clotting. Following cannulation rats were returned to the home cage 
for 45 minutes prior to further procedures to reduce the influence of stress responses on 
experimental results. Blood was collected by inserting a 25 gauge needle into the 
cannula and gently massaging the tail. In all experiments 120µl of fluid was discarded 
prior to collection of blood to decrease sample contamination with heparin.  Following 
each sample collection 100µl of diluted heparin was injected into the cannula to prevent 
clotting. After the final sample collection rats were placed in the restraint tube, cannula 
was removed and the animal returned to its home cage.  
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4.3.2.3 Insulin tolerance test 
 
Materials  
Human insulin, diluted 1:100. (Humulin S, soluble insulin 100 IU/ml, Eli Lilly & Co. 
Ltd, Basingstoke, UK) 
Lithium heparin tubes (Microvette) 
 
Method 
On day 35 post recovery male Wistar rats injected iARC with either 1ul rAAV-GKS 
(n=10) or rAAV-eGFP (n=9) were fasted for 4 hours with free access to water. 
Following fast rats were cannulated into the lateral tail vein (as described in 4.3.3.2). 
After all rats had been cannulated and cannulae checked, baseline blood samples were 
collected. Rats then received an i.p. injection of insulin (2 IU/kg), and blood samples 
were collected at 15, 30, 90, and 150 minutes post-injection.  Between sampling rats 
were returned to the home cage with free access to water. Blood samples of 
approximately 120 µl were collected in lithium heparin tubes and plasma was separated 
by centrifugation at 2,400xg for 5 minutes at 4˚C. Plasma was frozen on liquid nitrogen 
and plasma insulin was assayed as described in 3.3.9.6.     
 
4.3.2.4 Voluntary oral glucose tolerance test (vGTT)   
 
Materials  
20% glucose solution (Clintech) 
Lithium heparin tubes (Microvette, Sarstedt) 
 
Method  
 
On 48 post recovery vGTT was performed. Male Wistar rats injected iARC with either 
1ul rAAV-GKS (n=10) or rAAV-eGFP (n=9) were fasted over night with free access to 
water. Following fast rats were cannulated into the lateral tail vein (as described in 
4.3.3.2). After all rats had been cannulated and cannulae checked, baseline blood 
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samples were collected. Next, animals were offered a 20% (w/v) D-glucose solution 
providing 2.5g/kg glucose which was consumed within 10 minutes. Blood samples were 
collected at 15, 30, 60, and 120 minutes post-glucose. Between sampling rats were 
returned to the home cage with free access to water. Blood samples of approximately 
120µl were collected at each time point in lithium heparin tubes and plasma was 
separated by centrifugation at 2,400xg for 5 minutes at 4˚C. Plasma was frozen on 
liquid nitrogen and plasma glucose was assayed as described in 3.3.9.5.    
 
4.3.2.5 Effect of iARC rAAV-GKS on glucose stimulated insulin release 
 
Materials  
Rat insulin ELISA kit (Linco Research)  
Method  
Plasma collected during the vGTT on day 48 post injection was assayed for insulin as 
described in 3.3.9.6. 
 
4.3.3 Statistical analysis 
 
Longitudinal data (growth curves, cumulative food and glucose intake) was analysed 
using the population-averaged general estimating equation (GEE). For all other data, 
unpaired t-test was used to analyse individual time points and to analyse AUC in 
glucose and insulin tolerance tests. P<0.05 was considered statistically significant 
throughout. Data analysis was performed using GraphPad Prism 4 software (CA, USA) 
and Stata 9.    
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4.4 Results  
 
4.4.1 Cohort 4  
 
4.4.1.1 24 hour intake of 10% glucose 
 
Intake of a 10% glucose solution was measured for 24hr starting at the onset of the dark 
phase (day 21). Intake of 10% glucose solution was significantly greater in the GKS 
animals compared to controls in the 0-2hr period (eGFP 22.3+/- 1.0ml vs GKS 27.0+/-
1.7ml, n=10, p=<0.05) , the 0-4hr period (eGFP 43.1+/- 1.4ml vs GKS 50.5+/-1.8ml, 
n=10, p=<0.05), the 0-8hr period (eGFP 81.5+/- 3.8ml vs GKS 92.8+/-3.3ml, n=10, 
p=<0.05), the 0-12hr period (eGFP 135.0+/- 4.6ml vs GKS 154.1+/-5.3ml, n=10, 
p=<0.05) and the 0-16hr period (eGFP 143.6+/- 4.9ml vs GKS 164.0+/-7.5ml, n=10, 
p=<0.05) (figure 4.1) 
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Figure 4.1 Effect of iARC rAAV-GKS on 24hr intake of 10% glucose solution: 24hr 
intake of 10% glucose solution in male Wistar rats bilaterally injected with 1ul rAAV-
eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were given ad libitum access to a 
10% glucose solution at the onset of the dark phase (day 21). Data are expressed as 
mean +/- SEM for both groups, n=10, *=P<0.05.   
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4.4.1.2 24 hour intake of 10% fructose 
 
Intake of a 10% fructose solution was measured for 24hr starting at the onset of the dark 
phase (day 24). There was no significant difference in the intake of 10% fructose 
solution at any time point. (figure 4.2) 
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Figure 4.2 Effect of iARC rAAV-GKS on 24hr intake of 10% fructose solution: 24hr 
intake of 10% fructose solution in male Wistar rats bilaterally injected with 1ul rAAV-
eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were given ad libitum access to a 
10% fructose solution at the onset of the dark phase (day 24). Data are expressed as 
mean +/- SEM for both groups, n=10, *=P<0.05.   
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4.4.1.3 24 hour food intake without glucose solution   
 
To establish that the feeding pattern of cohort four was similar to that of previous GKS 
groups food intake was measured for 24hr starting at the onset of the dark phase (day 
28). Food intake was significantly higher in GKS animals compared to controls in the 0-
8hr period (eGFP 12.8+/- 1.2g vs GKS 16.0+/-0.6g, n=10, p=<0.05), the 0-12hr period 
(eGFP 20.5+/- 0.6g vs GKS 22.7+/-0.9g, n=10, p=<0.05) and the 0-16hr period (eGFP 
21.3+/-0.7g vs GKS 23.8+/-0.8g, n=10, p=<0.05). Food intake was higher over 24hr but 
this did not reach significance (eGFP 26.4+/- 1.1g vs GKS 29.21+/-1.3g, n=10, 
p=<0.12) (figure 4.3).   
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 Figure 4.3 Effect of iARC rAAV-GKS on 24hr food intake without glucose solution: 
24hr food intake of male Wistar rats bilaterally injected with 1ul rAAV-eGFP (green 
line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow at the onset of the dark 
phase (day 28). Data are expressed as mean +/- SEM for both groups, n=10, 
*=P<0.05.   
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4.4.1.4 24 hour intake of standard chow and 2% glucose solution  
 
Intake of standard chow and a 2% glucose solution were measured in GKS animals and 
their controls over a 24hr period starting at the onset of the dark phase (day 31). Food 
intake was not different between the groups at any time point (figure 4.4). 
 Intake of 2% glucose solution was greater in the GKS group compared to controls in 
the 0-1hr period (eGFP 8.1+/- 2.7ml vs GKS 18.6+/-1.5ml, n=10, p=<0.01), 0-2hr 
period (eGFP 18.6+/-3.7ml vs GKS 34.7+/-3.4ml, n=10, p=<0.01), 0-4hr period (eGFP 
31.6+/-3.3ml vs GKS 61.1+/-5.3ml, n=10, p=<0.001),  0-8hr period (eGFP 59.4+/-
8.5ml vs GKS 110.3+/-8.3ml, n=10, p=<0.001), 0-12hr period (eGFP 82.1+/-11.8ml vs 
GKS 134.6+/-9.6ml, n=10, p=<0.01), 0-16hr period (eGFP 84.3+/-11.9ml vs GKS 
140.0+/-11.3ml, n=10, p=<0.01), and 0-24hr period (eGFP 86.3+/-12.9ml vs GKS 
145.4+/-11.3ml, n=10, p=<0.01) (figure 4.5).  
Total energy intake was not different between the groups at any time point (figure 4.6). 
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Figure 4.4 Effect of iARC rAAV-GKS on 24hr food intake (with 2% glucose 
solution): 24hr food intake of male Wistar rats bilaterally injected with 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad libitum 
access to a 2% glucose solution at the onset of the dark phase (day 31). Data are 
expressed as mean +/- SEM for both groups, n=10.  
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Figure 4.5 Effect of iARC rAAV-GKS on 24hr intake of a 2% glucose solution: 24hr 
intake of 2% glucose solution of male Wistar rats bilaterally injected with 1ul rAAV-
eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad 
libitum access to a 2% glucose solution at the onset of the dark phase (day 31). Data 
are expressed as mean +/- SEM for both groups, n=10, **=P<0.01, ***=P<0.001.   
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Figure 4.6 Effect of iARC rAAV-GKS on total energy intake over a 24hr period (2% 
glucose): Total 24hr energy intake of male Wistar rats bilaterally injected with 1ul 
rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with 
ad libitum access to a 2% glucose solution at the onset of the dark phase (day 31). Data 
are expressed as mean +/- SEM for both groups, n=10. 
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4.4.1.5 24 hour intake of standard chow and 10% glucose solution  
 
Intake of standard chow and a 10% glucose solution were measured in GKS animals 
and their controls over a 24hr period starting at the onset of the dark phase (day 40). 
Food intake was not different between the groups at any time point (figure 4.7). 
Intake of 10% glucose solution was greater in the GKS group compared to controls in 
the 0-8 hour period (eGFP 55.9+/- 2.4ml vs GKS 65.8+/-3.2ml, n=10, p=<0.05) and the 
0-24hr period (eGFP 88.0+/- 6.4ml vs GKS 107.6+/-4.4ml, n=10, p=<0.05) (figure 4.8). 
Total energy intake was not different between the groups at any time point (figure 4.9). 
 
0 10 20 30
0
5
10
15
20
25
rAAV-eGFP
rAAV-GKS
Time (hours)
F
o
o
d
 i
n
ta
k
e
 (
g
)
 
Figure 4.7 Effect of iARC rAAV-GKS on 24hr food intake (with 10% glucose 
solution): 24hr food intake of male Wistar rats bilaterally injected with 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad libitum 
access to a 10% glucose solution at the onset of the dark phase (day 40). Data are 
expressed as mean +/- SEM for both groups, n=10.  
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Figure 4.8 Effect of iARC rAAV-GKS on 24hr intake of a 10% glucose solution: 24hr 
intake of 10% glucose of male Wistar rats bilaterally injected with 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad libitum 
access to a 10% glucose solution at the onset of the dark phase (day 40). Data are 
expressed as mean +/- SEM for both groups, n=10, *=P<0.05.    
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Figure 4.9 Effect of iARC rAAV-GKS on total energy intake over a 24hr period (10% 
glucose): Total 24hr energy intake of male Wistar rats bilaterally injected with 1ul 
rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with 
ad libitum access to a 10% glucose solution at the onset of the dark phase (day 40). 
Data are expressed as mean +/- SEM for both groups, n=10. 
 
 
 
 
 
 
 
 
174 
 
4.4.1.6 24 hour intake of standard chow and 20% glucose solution  
 
Intake of standard chow and a 20% glucose solution were measured in GKS animals 
and their controls over a 24hr period starting at the onset of the dark phase (day 44). 
Food intake was not different between the groups at any time point (figure 4.10). 
Intake of 20% glucose solution was greater in the GKS group compared to controls in 
the 0-1hr period (eGFP 8.8+/- 0.7ml vs GKS 14.6+/-1.9ml, n=10, p=<0.05), 0-16hr 
period (eGFP 62.5+/- 2.9ml vs GKS 71.4+/-2.8ml, n=10, p=<0.05) and the 0-24hr 
period (eGFP 75.3+/-3.8ml vs GKS 88.5+/-3.6ml, n=10, p=<0.05) (figure 4.11). 
Total energy intake was not different between the groups at any time point (figure 4.12).  
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Figure 4.10 Effect of iARC rAAV-GKS on 24hr food intake (with 20% glucose 
solution): 24hr food intake of male Wistar rats bilaterally injected with 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad libitum 
access to a 20% glucose solution at the onset of the dark phase (day 44). Data are 
expressed as mean +/- SEM for both groups, n=10.  
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Figure 4.11 Effect of iARC rAAV-GKS on 24hr intake of a 20% glucose solution: 
24hr intake of 20% glucose of male Wistar rats bilaterally injected with 1ul rAAV-
eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad 
libitum access to a 20% glucose solution at the onset of the dark phase (day 44). Data 
are expressed as mean +/- SEM for both groups, n=10, *=P<0.05.    
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Figure 4.12 Effect of iARC rAAV-GKS on total energy intake over a 24hr period 
(20% glucose): Total 24hr energy intake of male Wistar rats bilaterally injected with 
1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow 
with ad libitum access to a 20% glucose solution at the onset of the dark phase (day 
44). Data are expressed as mean +/- SEM for both groups, n=10. 
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4.4.1.7 24 hour intake of standard chow and 40% glucose solution  
 
Intake of standard chow and a 40% glucose solution were measured in GKS animals 
and their controls over a 24hr period starting at the onset of the dark phase (day 50). 
Food intake was not different between the groups at any time point (figure 4.13). 
Intake of 40% glucose solution was not different between the groups at any time point 
(figure 4.14).  
Total energy intake was greater in the GKS animals compared to controls in the 0-16hr 
period (eGFP 100.0+/-1.7kcal vs GKS 112.0+/-4.9kcal, n=10, p=<0.05) and the 0-24hr 
period (eGFP 125.4+/-2.3kcal vs GKS 137.5+/-5.0kcal, n=10, p=<0.05) (figure 4.15).  
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Figure 4.13 Effect of iARC rAAV-GKS on 24hr food intake (with 40% glucose 
solution): 24hr food intake of male Wistar rats bilaterally injected with 1ul rAAV-eGFP 
(green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad libitum 
access to a 40% glucose solution at the onset of the dark phase (day 50). Data are 
expressed as mean +/- SEM for both groups, n=10.  
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Figure 4.14 Effect of iARC rAAV-GKS on 24hr intake of a 40% glucose solution: 
24hr intake of 40% glucose of male Wistar rats bilaterally injected with 1ul rAAV-
eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow with ad 
libitum access to a 40% glucose solution at the onset of the dark phase (day 50). Data 
are expressed as mean +/- SEM for both groups, n=10. 
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Figure 4.15 Effect of iARC rAAV-GKS on total energy intake over a 24hr period 
(40% glucose): Total 24hr energy intake of male Wistar rats bilaterally injected with 
1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Rats were fed normal chow 
with ad libitum access to a 40% glucose solution at the onset of the dark phase (day 
50). Data are expressed as mean +/- SEM for both groups, n=10, *=P<0.05.    
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4.4.1.8 Effect of iARC rAAV-GKS on food intake, intake of glucose and 
bodyweight gain  
 
Animals were maintained with ad libitum access to standard chow and a 10% glucose 
solution for 31 days from day 54 post recovery. Mean bodyweights of the rAAV-eGFP 
group and rAAV-GKS group on day 54 were 428.6g and 449.3g respectively. This 
difference was not statistically significant (p=0.13). At the termination of the 
experiment there was a significant difference in bodyweight between the groups (eGFP 
489.6 +/- 15.1g vs GKS 521.0 +/- 8.39g, n=10, p=<0.05). Weight gain was not different 
between the groups (eGFP 61.0 +/- 4.2g vs GKS 71.8 +/- 4.5g, n=10) (figure 4.16). 
There was no significant difference in intake of standard chow between the groups 
(eGFP 691.9+/- 19.4g vs GKS 682.1+/-22.8g, n=10) (figure 4.17).The GKS group 
consumed a significantly greater volume of 10% glucose solution than their controls 
(eGFP 691.9+/- 19.4ml vs GKS 682.1+/-22.8ml, n=10, p=<0.05) (figure 4.18). There 
was no significant difference in total energy intake from standard chow and 10% 
glucose solution between the groups (eGFP 3456.9+/- 78.6g vs GKS 3615+/-100.4g, 
n=10) (figure 4.19). 
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Figure 4.16 Effect of iARC rAAV-GKS on bodyweight and bodyweight gain: a) 
bodyweight and b) weight gain following bilateral injection of 1ul rAAV-eGFP (green 
line) or 1ul rAAV-GKS (blue line). Male Wistar rats were fed normal chow with ad 
libitum access to a 10% glucose solution. Data are expressed as mean +/- SEM for both 
groups, n=10. 
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Figure 4.17 Effect of iARC rAAV-GKS on food intake: Food intake following bilateral 
injection of 1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue line). Male Wistar rats 
were fed normal chow with ad libitum access to a 10% glucose solution. Data are 
expressed as mean +/- SEM for both groups, n=10. 
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4.4.1.9 Effect on intake of 10% glucose solution  
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Figure 4.18 Effect of iARC rAAV-GKS on intake of 10% glucose solution: Intake of 
10% glucose solution following bilateral injection of 1ul rAAV-eGFP (green line) or 
1ul rAAV-GKS (blue line). Male Wistar rats were fed normal chow with ad libitum 
access to a 10% glucose solution. Data are expressed as mean +/- SEM for both 
groups, n=10, *=P<0.05. 
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4.4.1.10 Effect on total energy intake  
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Figure 4.19 Effect of iARC rAAV-GKS on total energy intake: Total energy intake 
following bilateral injection of 1ul rAAV-eGFP (green line) or 1ul rAAV-GKS (blue 
line). Male Wistar rats were fed normal chow with ad libitum access to a 10% glucose 
solution. Data are expressed as mean +/- SEM for both groups, n=10. 
 
 
 
 
  
185 
 
4.4.1.11 Effect of iARC rAAV-GKS on plasma glucose following oral glucose 
challenge  
 
At the termination of the study (day 85) GKS animals and controls received a solution 
containing 2.5mg of glucose per kg of bodyweight. The solution was consumed 
voluntarily in less than 10 minutes.  Blood glucose levels were measured prior to 
consumption of glucose and at 30 minutes after consumption when animals were 
euthanized by CO2 inhalation. Plasma glucose prior to consumption of glucose was not 
different between the groups (eGFP 4.2+/-0.2mmol/L vs GKS 4.0+/-0.2mmol/L, n=10). 
At 30 minutes plasma glucose was significantly lower in the GKS group compared to 
controls (eGFP 6.9+/-0.3mmol/L vs GKS 5.0+/-0.2mmol/L, n=10, p=<0.001) (figure 
4.20).  
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Figure 4.20 Effect of iARC rAAV-GKS on plasma glucose response to oral glucose 
challenge: GKS animals and controls received a solution containing 2.5mg/kg of 
glucose. Plasma glucose levels were measured prior to consumption of glucose and 30 
minutes after. Data are expressed as mean +/- SEM for both groups, n=10, 
***=P<0.001.    
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4.4.2 Cohort 5: Glucose homeostasis  
 
4.4.2.1 Oral glucose tolerance test  
 
To assess the role of GK in the ARC in the regulation glucose homeostasis GKS 
animals and their controls were subjected to oral glucose tolerance test at 20 days post 
recovery. Glucose was delivered by oral gavage. Glucose clearance at 30 minutes was 
significantly improved in the GKS group compared to controls (eGFP 7.7+/-0.6mmol/L 
vs GKS 4.6+/-0.3mmol/L, n=9-10, p=<0.001). There was no significant difference at 
any other time point (figure 4.21). Area under the curve (AUC) was significantly lower 
in the GKS group compared to controls (eGFP 614.4+/-21.5 vs GKS 522.4+/-26.3, n=9-
10, p=<0.05).  
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Figure 4.21 Oral glucose tolerance test via gavage: GKS animals and controls 
received a bolus glucose dose (2.5g/kg body weight) via oral gavage and their blood 
glucose response was measured over the course of 2 hours (day 20) .Data are expressed 
as mean +/- SEM for both groups, n=9-10, ***=P<0.001.    
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4.4.2.2 Insulin tolerance test  
 
At 35 days post recovery insulin tolerance test was performed. Plasma glucose was 
significantly lower in the GKS group compared to controls at the 60 minute time point 
(eGFP 2.9+/-0.1mmol/L vs GKS 2.5+/-0.2mmol/L, n=9-10, p=<0.05) and at the 120 
minute time point (eGFP 2.0+/-0.1mmol/L vs GKS 1.7+/-0.1mmol/L, n=9-10, p=<0.05) 
(figure 4.22). AUC was not significantly different between the groups (eGFP 394.3+/-
11.1 vs GKS 370.5+/-13.5, n=9-10). 
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Figure 4.22 Insulin tolerance test: GKS animals and controls received a bolus i.p. 
insulin dose (2.0IU/kg body weight) and their blood glucose response was measured 
over the course of 2.5 hours (day 35) .Data are expressed as mean +/- SEM for both 
groups, n=9-10, *=P<0.05.     
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4.4.2.3 Voluntary oral glucose tolerance test group 5 
 
GKS animals and their controls were subjected to vGTT at 48 days post recovery. 
Plasma glucose was significantly lower in the GKS group compared to controls at the 
15 minute time point (eGFP 7.4+/-0.2mmol/L vs GKS 6.4+/-0.3mmol/L, n=9-10, 
p=<0.05) and the 30 minute time point (eGFP 7.8+/-0.2mmol/L vs GKS 6.9+/-
0.3mmol/L, n=9-10, p=<0.05). There was no significant difference between the groups 
at any other time point (figure 4.23). AUC was not significantly different between the 
groups (eGFP 849.1+/-15.5 vs GKS 805.1+/-23.9, n=9-10). 
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Figure 4.23 Voluntary oral glucose tolerance test: GKS animals and controls 
voluntarily consumed a glucose solution containing 2.5g/kg body weight and their 
blood glucose response was measured over the course of 2 hours (day 48) .Data are 
expressed as mean +/- SEM for both groups, n=9-10, *=P<0.05.    
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4.4.2.4 Plasma insulin during voluntary oral glucose tolerance test  
 
During the vGTT on day 48, plasma was collected at 0,15,30 and 60 minutes and was 
subsequently assayed for insulin. Plasma insulin was significantly higher in the GKS 
group compared to controls at 30 minute (eGFP 0.71+/-0.2ng/mL vs GKS 1.64+/-
0.4g/mL, n=8-9, p=<0.05). There was no significant difference at any other time point 
(figure 4.24). AUC was not significantly different between the groups (eGFP 92.2+/-
20.9 vs GKS 140.7+/-28.4, n=9-10). 
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Figure 4.24 Plasma insulin during voluntary oral glucose tolerance test: GKS animals 
and controls voluntarily consumed a glucose solution containing 2.5g/kg body weight 
and their plasma insulin response was measured for 1hour .Data are expressed as mean 
+/- SEM for both groups, n=8-9, *=P<0.05.    
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4.5 Discussion 
In the last chapter, increasing GK mRNA in the ARC was shown to increase food intake 
and bodyweight gain on both standard chow and high calorie western style diet. In 
addition, the increased fasting plasma insulin in the GKS group suggested that the 
treatment might also affect glucose homeostasis. In this chapter I investigated the effect 
of increased GK mRNA in the ARC on intake of sugars and on glucose homeostasis.  
In the first experiment, rats were offered a solution containing 10% (w/v) D-glucose for 
a period of 24 hours. Intake of the glucose solution was significantly higher in the GKS 
group compared to the controls at all-time points between 0-2 hour and 0-16 hour but 
was not significantly different over 24 hours. 
In contrast, fructose intake between the groups was not different at any time point. 
Fructose enters glycolysis downstream of GK so it would not be expected to be sensed 
via the GK pathway. In addition, fructose intake does not influence plasma glucose 
levels in the fed state (Lee & Wolever, 1998). Taken together with the results of the 
glucose intake study, these data suggest that increasing GK mRNA in the ARC alters 
feeding behaviour via its effect on glucose-sensing rather than causing indiscriminate 
hyperphagia. It is important to note that while the standard chow diet does not contain 
high levels of glucose, it does contain high levels of starch (see appendix II). Starch is 
formed of large numbers of glucose molecules linked by glucosidic bonds. Thus, post 
digestion, the standard chow diet provides a high proportion of its energy from glucose, 
which would be sensed via the GK pathway in ARC neurones.  
The 24 hour intake of standard chow was also measured in the current cohort to ensure 
that food intake followed a similar pattern to that of previous groups. Food intake was 
significantly greater in the GKS group compared to control in the 0-8, 0-12 and 0-16 
hour time points.  In cohort two, the GKS group consumed significantly more standard 
chow than the controls in the 8-24 hour period. In both cohorts, the GKS group 
consumed more chow than controls over the full 24 hour period but this did not reach 
significance in either study. Thus, the feeding patterns of the current cohort were 
comparable to those of previous groups.    
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Next, I examined the effect of increased ARC GK mRNA on preference to glucose over 
standard chow. In separate experiments, rats were given ad libitum access to solutions 
of 2%, 10%, 20% or 40% glucose in addition to standard chow. 
At glucose concentrations of 2% and 10%, intake of glucose was significantly higher in 
the GKS group compared to controls over 24 hours. Interestingly, the increased intake 
of glucose in the GKS groups led to a normalisation of food intake and total energy 
intake compared to controls. These results are striking because, for the first time, energy 
intake was not different between the groups at any time point.   
At 20% glucose, a similar pattern was observed. Food intake was not different between 
the groups and glucose intake was significantly higher in the GKS group compared to 
controls over 24 hours. Total calorie intake was also not different but at the later time 
points (16 and 24 hours) there was a non-significant divergence such that at 24 hours 
the GKS group had consumed 13.8kcal more than controls. At 40% glucose, neither 
food nor glucose intake was significantly different. However, both were non-
significantly higher in the GKS group and this resulted in a significant increase in total 
energy intake at the 0-16 and 0-24 hour time points in the GKS group.  
The fact that low concentration glucose solutions normalised the total energy intake of 
the groups may be due to the energy density of the solutions. In all experiments, the 
GKS group consumed a greater proportion of their total energy intake from glucose 
compared to the controls. This suggests an increased preference for glucose over 
standard chow compared to the control group. 
 In the 2% glucose study, the GKS group consumed 59.1ml more glucose solution than 
the controls over 24 hours. However, this equates to a difference in energy intake of 
only 4.7kcal. In the same study, the controls consumed 0.7g more chow than the GKS 
group, this equates to a difference in energy intake of 2.1kcal. Thus, it does not appear 
that the addition of the glucose solution reduced the appetite of the GKS group. Rather, 
it appears that the increased drive to consume glucose caused the GKS group to 
preferentially consume a vast quantity of a very low energy-density food stuff (the 2% 
glucose solution being 98% water). Gastric dissention has a well-accepted effect of 
reducing appetite (Geliebter et al, 1988), considering the fact that the GKS group 
consumed nearly 60ml more water than the controls, this is likely to be a factor in this 
study. A similar pattern was observed in the 10% glucose study.  
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With increasing glucose concentrations, the difference in total energy intake between 
the groups increased. At 2% glucose the controls consumed 98% of the total energy 
intake of the GKS group over 24 hours. This decreased to 96% in the 10% glucose 
study, 91% in the 20% glucose study and 90% in the 40% glucose study. During the 
study measuring intake of standard chow alone, the 24 hour food intake of the controls 
was also 90% of the GKS group. Thus, during the 40% glucose study the difference in 
energy intake between the groups is the same as it was on standard chow alone. This 
suggests that the effect of the glucose solution on reducing the energy intake of the GKS 
group is concentration dependent. That said, it is of interest that increased ARC GK 
mRNA would increase the drive to consume glucose.    
I was next interested to see whether the effect of a low concentration glucose solution 
on food intake contained beyond 24 hours. To investigate this, the GKS group and 
controls were maintained on standard chow with ad libitum access to a 10% glucose 
solution for a period of 31 days. As was observed during the 24 hour studies glucose 
intake was higher in the GKS groups compared to controls and there was no difference 
in food intake or total energy intake. In addition, bodyweight gain was not different 
between the groups although the weight gain of the groups did appear to be diverging 
towards the end of the study. The bodyweight of the GKS group was significantly 
higher than controls at the termination of the study. However, the mean bodyweight of 
the GKS group was 20g greater than the controls at the beginning of the study. This 
difference in starting bodyweight will have contributed to the difference in bodyweight 
observed at the termination of the study.  
The results of the sugar feeding studies suggest that 1) GK animals have an increased 
drive to consume glucose compared to controls and 2) when offered standard chow and 
glucose GK animals have an increased preference for glucose over standard chow 
compared to controls. As discussed in the introduction to this chapter, the effect of 
sugars on food intake is complex and dependent on many factors including dosage, 
timing of administration and effect on plasma glucose and insulin. At present, it is not 
possible to determine whether the increased intake of glucose in the GK group is the 
result of increased meal size or increased meal number. Accurate analysis of feeding 
patterns might help to elucidate the mechanisms involved in the perceived phenotype.  
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It is also unclear why increasing GK mRNA in the ARC would increase an animal‟s 
preference to glucose over standard chow. Changes in plasma insulin and glucose have 
been shown to influence intake of glucose and to increase the palatability of sweet 
tasting foods (Rodin et al, 1985;Jacobs, 1958). Considering the effects of iARC rAAV-
GKS on glucose homeostasis (discussed below) it is possible that the effects on food 
and glucose intake might be secondary to changes in glucose homeostasis.   
In cohort two, plasma insulin in the fed state was significantly higher in the GKS group 
compared to controls, suggesting that treatment might be affecting glucose homeostasis. 
To investigate this further, rats were offered a glucose solution containing 2.5g/kg 
glucose which was consumed in less than 10 minutes. Plasma was collected prior to 
ingestion of glucose and 30 minutes afterward. The purpose of this experiment was to 
assess the effect of increased GKS on glucose disposal. At baseline, there was no 
difference in plasma glucose between the groups. Thirty minutes after the oral glucose 
load, plasma glucose levels were significantly lower in the GKS group compared to 
controls, demonstrating enhanced post-prandial glucose clearance.     
To further investigate the effect of increased ARC GK mRNA on glucose homeostasis, 
GTTs and ITTs were performed. During GTTs, glucose was delivered using two 
methods. The first method utilized oral gavage to deliver glucose as is commonly 
practised. The second method was novel and involved training rats to voluntarily 
consume a solution containing the desired glucose dose. After a brief period of training, 
all animals consumed the solution within 10 minutes with most doing so in less than 5 
minutes.  
The voluntary oral glucose tolerance test holds a number of advantages over the gavage 
method. Firstly, because the voluntary method is less invasive and requires less animals 
handling, it is likely that levels of stress in the study animals will be decreased. 
Handling animals and oral gavage have both been shown to cause stress to laboratory 
animals and both result in increased plasma glucose (Balcombe et al, 2004). Secondly, 
glucose sensing in the oral cavity is involved in cephalic phase insulin secretion 
(Berthoud et al, 1980;Berthoud & Powley, 1990). The cephalic phase insulin response 
is only responsible for 1-3% of postprandial insulin secretion (Teff & Engelman, 1996). 
Despite this, the small rise in plasma insulin has been shown to be important in post 
prandial glucose tolerance. In an early experiment, rats received a carbohydrate rich 
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meal voluntarily or via an indwelling intragastric cannula. Direct infusion of the meal 
into the stomach resulted in a significant reduction in glucose tolerance compared to 
voluntary feeding suggesting that cephalic phase insulin release is important in the 
regulation of post prandial plasma glucose (Steffens, 1976).    
During the GTT using the oral gavage method, glucose tolerance was significantly 
increased in the GKS group compared to controls. The results of this experiment must 
be interpreted with some caution. At the 0min time point, fasted plasma glucose in both 
groups was close to 2mmol/l. This value is lower than levels reported in the literature in 
similar conditions (Fragloudakis et al, 2008; Dias et al, 2009; Xu et al, 1999). A 
possible explanation for these values is human error. During sample collection, the first 
120μl of fluid must be discarded to avoid contamination with heparin. If this step were 
missed, the concentration of glucose in the collected fluid would be lower than the true 
concentration in the blood.  
Increased glucose disposal during GTT can be the result of either increased peripheral 
insulin sensitivity or increased glucose stimulated insulin release. To help identify the 
source of the increased glucose tolerance in the GKS group I subsequently performed an 
insulin tolerance test (ITT). ITT revealed a small but significant difference in plasma 
glucose at the 60 minute and 120 minute time points. The fact that there was no 
difference in plasma glucose prior to the 60 minute time point suggests that the insulin 
sensitivity of peripheral tissues was not different between the groups.  
The enhanced glucose disposal of the GKS group was confirmed by the voluntary GTT. 
Post prandial plasma glucose levels were significantly lower in the GKS group 
compared to controls at the 15 and 30 minute time points. Plasma collected at the 15, 30 
and 60 minute time points was also assayed for insulin to establish the effect of 
treatment on glucose stimulated insulin release. Plasma insulin was significantly higher 
in the GKS group compared to the controls at 30 minutes. Taken together with the result 
of the ITT, these data suggest that increasing GK mRNA in the ARC results in 
improved glucose tolerance via increased glucose stimulated insulin release.  
ICV glucose infusion has been shown to increase plasma insulin levels, suggesting that 
insulin secretion is regulated by the CNS (Schultz-Klarr et al, 1994). The fact that 
increasing GK mRNA in the ARC resulted in increased plasma insulin in the fed state 
and increased glucose stimulated insulin release is in agreement with this data. 
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Furthermore, it suggests that manipulation of glucose metabolism specifically in the 
ARC is sufficient to alter whole body glucose homeostasis. Ablation of the VMH 
(which contain the ARC) causes hyperinsulinemia, which is reversed by severing the 
vagus nerve (Inoue et al, 1991). This suggests that signals from the VMH and relayed 
via the vagus are important in the regulation of pancreatic insulin secretion. It is 
possible that the effect of increased ARC GK mRNA might also be dependent on relay 
via the vagus nerve.  This could be tested in vagotomised rats injected iARC with 
rAAV-GKS.  
In the last chapter, I showed that increasing GK mRNA in the ARC results in increased 
food intake and bodyweight gain on both standard chow and western style diet. In this 
chapter, I have shown that the effect of treatment on food intake and bodyweight gain 
can be ameliorated by offering animals a solution containing a low concentration of 
glucose; both in the short term and during longitudinal studies. It appears that the GKS 
group have a greater drive to consume glucose than the controls and that increased 
intake of glucose inhibits calorie intake from standard chow. In addition, the effect of 
treatment on glucose sensing seems to be specific because intake of fructose was not 
different between the groups.  
I have also shown that the glucose tolerance of GKS animals is significantly increased 
due to an increase in glucose stimulated insulin release. The increased glucose tolerance 
of the GKS group is of particular interest considering the fact that they are heavier and 
more adipose than the controls. In mice, rats and humans, increased adiposity is usually 
associated with decreased glucose tolerance (Surwit et al, 1988;Martin et al, 
2006;Hayashi et al, 2003).   
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Numerous lines of evidence suggest a role for hypothalamic glucose-sensing neurones 
in energy balance and glucose homeostasis. It is becoming increasingly clear that 
functions that had previously been thought to be controlled peripherally are also subject 
to central regulation (Andersson et al, 2004;Borg et al, 1997;Borg et al, 1995;Burdakov 
et al, 2005b;Daly, 2004;Hardie et al, 1998;Levin et al, 2004). Furthermore, recent 
evidence suggests strong interaction between nutrient sensing in the periphery and 
nutrient sensing in the CNS in the regulation of energy balance. For example, Wang et 
al have shown that intraduodenal lipid infusion decreases hepatic glucose output and 
increases insulin sensitivity. Interestingly, this pathway was shown to involve a gut-
brain-liver axis, which is  on signal relay in the CNS (Wang et al, 2008). Glucose-
sensing neurones in the ARC are ideally placed to integrate central and peripheral 
information. Equally, their action potential firing rates are affected by numerous 
nutrient and nutrient derived signals (Lam et al, 2005b;Tsujii & Bray, 1990;Wang et al, 
2004;Wang et al, 2006). As such, glucose-sensing neurones in the ARC are well placed 
and functionally capable of playing an important role in energy balance and glucose 
homeostasis. The aim of this work was to investigate the physiological function of 
glucose-sensing neurones in the ARC via manipulation of GK using rAAV.  
GK is one of the rate limiting steps in glycolysis and manipulation of GK has been 
shown to alter the electrophysiological properties of glucose-sensing neurones in the 
hypothalamus (Kang et al, 2006). For this reason, GK was chosen as a tool to 
manipulate glucose-sensing neurones during these studies. Glucose-sensing neurones 
are found in numerous hypothalamic nuclei that are implicated in the regulation of 
feeding behaviour and glucose homeostasis. Thus, before commencing rAAV studies, it 
was important to identify which glucose sensing region of the hypothalamus was most 
likely to be involved in the regulation of food intake. 
To do this, rats were fasted for 24 or 48 hours and subsequently GK activity assay was 
performed on punch biopsy taken from the ARC, VMN and PVN. Fasting, for either 24 
or 48 hours, resulted in a significant increase in GK activity in the ARC with no effect 
observed in either the PVN or the VMN. For this reason, the ARC was chosen as the 
primary target for rAAV induced up-regulation of GK.  
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5.1.1 Summary of rAAV results 
 
Injection of rAAV-GKS into the ARC resulted in a significant increase in food intake 
and bodyweight gain compared to rAAV-eGFP injected controls. The increase in 
bodyweight was subsequently found to result from a specific increase in adipose tissue 
with no difference in lean mass between the groups. 
In the second cohort I included an additional GKS group that were pair fed to the 
control group in order to assess the role of food intake in the observed differences in 
bodyweight gain. In this study, there was no difference in bodyweight gain between the 
GKS animals that were pair fed to the control and the control group. This would suggest 
that the difference in bodyweight gain between the GKS group and controls in the 
previous study could be attributed to the increased food intake of the GKS group. 
However, during this study, the food intake of the ad libitum fed GKS group was not 
significantly greater than controls, despite their increased bodyweight gain. Thus, 
increasing GK mRNA in the ARC appears to result in complex metabolic changes 
which require further investigation. 
 In the next study, GKS animals and their controls were fed a high calorie “western 
style” diet. In this study, as was the case with previous cohorts, the GKS group gained 
significantly more weight than the controls and food intake was significantly increased. 
This study was important because the constitution of the standard chow does not closely 
match that of westernised humans; being high in starch and low in fat (see appendix II).  
Next, I investigated the effect of increased ARC GK mRNA on intake of sugars by 
offering animals a 10% w/v glucose solution for 24 hours. GKS animals consumed a 
greater volume of the glucose containing solution throughout much of the recorded 24 
hour period. Interestingly, there was no difference in the intake of a fructose containing 
solution at any time point. Fructose is not directly sensed via the GK pathway in 
glucose-sensing neurones, this result suggests that treatment had a specific effect on 
glucose metabolism.  
In experiments in which rats were offered a glucose solution in addition to standard 
chow the GKS group displayed an increased preference to glucose over standard chow 
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compared to controls. At glucose concentrations below 40% the increased intake of 
glucose in the GKS group resulted in a normalisation of food intake, and total energy 
intake was not different between the groups. This effect was also observed in a 
longitudinal study lasting 31days, in which total energy intake (from standard chow and 
glucose) and weight gain were not different between the groups. This was the first 
longitudinal study in which the GKS group did not gain significantly more weight than 
controls.   
In addition to its effects on food intake, increasing GK mRNA in the ARC produced 
profound effects on glucose homeostasis. GKS animals were considerably more glucose 
tolerant than controls despite their increased adiposity. The improved glucose tolerance 
of GKS animals was associated with increased glucose-stimulated insulin release. 
Next I performed an insulin tolerance test to assess the effect of increased ARC GK 
mRNA on insulin sensitivity. There was no difference between the groups during the 
early time points of the insulin tolerance test, this suggests that treatment does not affect 
peripheral insulin sensitivity. However, the fact that plasma glucose was different at 
later time points could suggest dampening of the hormonal counter regulatory response 
to hypoglycaemia (discussed below).   
 
5.1.2 Mechanism of action  
 
Increasing GK in the ARC is hypothesised to increase the sensitivity of glucose-sensing 
neurones to a given quantity of glucose. In this model, neurones would essentially 
“perceive” local glucose concentrations to be higher than they actually are due to 
increased glycolysis. The results of the glucose and insulin tolerance tests are consistent 
with this hypothesis. 
 During the glucose tolerance test plasma glucose did not increase to the same degree in 
the GKS group compared to controls. The lower plasma glucose in the GKS group was 
the result of increased glucose-stimulated insulin release. Insulin release is regulated 
both autonomously at the level of the pancreatic β-cell and neurally. It has been 
suggested that glucose sensing in the CNS may predominate over pancreatic glucose 
sensing in the regulation of insulin secretion. Indeed, ICV glucose infusion has been 
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shown to increase plasma insulin independent of changes in plasma glucose (Schultz-
Klarr et al, 1994).  
The enhanced insulin release of the GKS animals in this study is interesting for two 
reasons. Firstly, this data suggests that ARC glucose sensing may be important in the 
regulation of insulin secretion. Secondly, it supports the hypothesis that increasing GK 
causes neurones to „perceive‟ local glucose concentrations to be higher than they 
actually are. In this case, leading to a hypersensitivity of the system and exaggerated 
insulin secretion following glucose administration. This is also likely to occur following 
food intake. 
During the insulin tolerance test, plasma glucose was lower in the GKS group compared 
to control at the later time points. One explanation for this finding may be a dampening 
of the hormonal counter regulatory response to hypoglycaemia (CRR). 
The CRR involves a reduction in plasma insulin combined with increased plasma 
glucagon, noradrenaline and adrenaline, as well as increased sympathetic and 
parasympathetic outflow from the CNS (Cryer, 1993).  The CRR increases plasma 
glucose in the absence of food by increasing glycolysis and gluconeogenesis in the liver 
while simultaneously decreasing peripheral glucose utilization.     
In type I diabetes, the CRR is dampened by repeated hypoglycaemia, such that a lower 
blood glucose threshold must be met before it is initiated (Cryer, 1997).This in turn 
leads to an increase in both the frequency and severity of hypoglycaemic events 
experienced. It has been estimated that 2-10% of deaths in type I diabetic patients are 
the result of severe hypoglycaemia related to hypoglycaemia unawareness and a 
dampening of the CRR (Cryer, 2009;Skrivarhaug et al, 2006). 
In a recent paper, Levin et al tested the hypothesis that alterations in VMH GK 
expression affect the CRR to hypoglycaemia.  Bilateral injection of Compound A (a GK 
activator) blunted the CRR to insulin-induced hypoglycaemia causing reductions in 
glucagon, noradrenaline and adrenaline compared to controls (Levin et al, 2008). 
Conversely, both acute and chronic down regulation of GK, via alloxan and short 
hairpin RNA, results in an increase in adrenaline response to hypoglycaemia (Sanders et 
al, 2004). Thus, increasing GK activity in the VMH appears to blunt the CRR while 
decreasing GK activity may heighten it.  
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In this work, I increased GK mRNA in the ARC using rAAV-GKS. During the ITT, 
there was no difference between the groups before 60 minutes. However, at 60 and 120 
minutes plasma glucose was significantly lower in the GKS group compared to controls. 
Increasing GK mRNA in the VMH has been shown to decrease the release of counter 
regulatory hormones in response to insulin-induced hypoglycaemia. The fact that the 
GKS animals had lower plasma glucose at later time points is consistent with this 
finding. This is also consistent with the hypothesis that GK mRNA over-expression in 
the ARC alters the sensitivity of glucose sensing neurones. In this case, because 
neurones would „perceive‟ local glucose levels to be higher than they were, plasma 
glucose would have to fall to a lower level before the CRR was initiated. 
What is not immediately clear is why increasing GK mRNA in the ARC would increase 
food intake and bodyweight gain. Glucose has been shown to have an inhibitory effect 
on food intake when administered to the VMH. It could therefore be hypothesised that 
increasing GK in the ARC, which is believed to increase glucose metabolism, would 
also inhibit food intake rather than increasing it. One potential explanation for this 
finding is that the effect of treatment on food intake could be secondary to its effects on 
glucose homeostasis. 
As discussed previously, hypoglycaemia can increase food intake. Interestingly, 
repeated insulin-induced hypoglycaemia decreases the hormonal CRR but increases the 
drive to feed (Sanders et al, 2006). This suggests that these two aspects of the 
glucostatic mechanism might be differently regulated. It is also possible that in the face 
of a decreased hormonal CRR the drive to feed could be increased in order to maintain 
plasma glucose.  
 If the CRR of the GKS group is decreased (as suggested by the results of the ITT) it is 
possible that they may need to consume a greater quantity of food in order to maintain 
their plasma glucose levels.  
It is also possible, that following food intake, the enhanced glucose-stimulated insulin 
release of the GKS group might lead to more rapid storage of incoming glucose (as is 
suggested by the GTT results). It has been shown that most spontaneous meals are 
preceded by a small dip in blood sugar (Dunn-Meynell et al, 2009). If blood sugar falls 
more quickly in the GKS animals after every meal, it is feasible that the frequency of 
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these small dips in blood sugar would be increased, especially if the CRR is defective. 
This in turn might increase meal frequency.  
The phenotype of the GKS group is similar to that of rats in which the VMH has been 
lesioned in that  both display hyperphagia associated with hyperinsulinemia (Hustvedt 
& Lovo, 1972). Furthermore, in both models, hyperinsulinemia occurs as a result of 
manipulation of the VMH, albeit by entirely different methods. Lesioning the VMH 
results in hyperinsulinemia within 20 minutes (Berthoud & Jeanrenaud, 1979). This 
shows that hyperinsulinemia precedes hyperphagia in this model. Interestingly, celiac 
vagotomy of VMH lesioned rats results in normalisation of plasma insulin levels and 
food intake (Inoue et al, 1991). This suggests that hyperinsulinemia may underlie the 
changes observed in food intake and that hyperinsulinemia per se may be sufficient to 
increase food intake; a concept further supported by the fact that intensive insulin 
therapy and Glibenclamide treatment in diabetic patients are associated with weight 
gain (UK Prospective Diabetes Study (UKPDS) Group, 1998).  
Mild hyperinsulinemia might also explain why the GKS group consumed more glucose 
than the controls. Anecdotally, hypoglycaemia is associated with an increased drive to 
consume sugary foods (Hunt et al, 1990;Smith & Sauder, 1969). In humans, high 
plasma insulin has been shown to increase food intake and also to increase the 
palatability of sweet tasting foods (Rodin et al, 1985). A study investigating glucose 
intake in rats showed that rats normally preferentially consume a 10% glucose solution 
over a 35% glucose solution. However, following an insulin injection, the preference 
shifted and rats consumed a greater quantity of the 35% glucose solution (Jacobs, 1958). 
Taken together, this suggests that certain deviations in plasma glucose and insulin are 
able to influence food preference in a manner that helps to restore normoglycaemia. The 
high insulin levels of the GKS group might therefore explain why they showed a 
preference for glucose over standard chow compared to controls.  
It is also possible that increasing GK mRNA in the ARC could directly increase the 
drive to consume foods containing glucose. A number of cell types with mammalian 
biology are dependent on glucose including erythrocytes. Despite this, storage of 
glucose is extremely limited. It might therefore be advantageous for mammals to be able 
to detect food sources that are high in glucose, especially during fast. In support of this 
notion, it has recently been shown that chronic food restriction increases sweet taste 
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receptor mRNA on rat taste buds. In addition, fasting has been shown to enhance the 
preference for a high concentration saccharin solution which suggests nutritional state 
can influence preference for sweet tasting foods (Chen et al, 2010). In early experiments 
in this work, fasting was shown to increase GK activity in the ARC of wild type animals 
suggesting that GK expression is influenced by nutritional state. When GK mRNA was 
artificially increased in the ARC using rAAV animals showed a clear preference for 
glucose containing solutions compared to the controls. It is perhaps possible that GK in 
the ARC might also be involved in modulating preference to sweet food in response to 
nutritional status.   
 
5.1.3 The significance of this work 
 
This work is of significance for a number of reasons. Firstly, this is the first study to 
chronically increase hypothalamic GK mRNA. Secondly, the effects of this treatment 
have revealed interesting and in some cases unexpected results which have broader 
significance.   
At present, a number of pharmaceutical companies are investigating the application of 
small molecule GK activators in the treatment of type II diabetes mellitus. GK 
activators have been shown to act on β-pancreatic cells to increase glucose-stimulated 
insulin release and on the liver to increase glucose uptake  (Grimsby et al, 2003).  In a 
recent review, it was hypothesised that GK activators might represent a “magic bullet” 
in the treatment of diabetes because, in addition to their effects on glucose homeostasis, 
they might also reduce food intake if they are able to cross the blood brain barrier (Al-
Hasani et al, 2003).      
The results of this work support and extend the notion that increased GK activity would 
have beneficial effects on glucose stimulated insulin release. Indeed, while much focus 
has been placed on the effect of GK activation in the pancreas this work has shown that 
increasing GK mRNA in the ARC alone is sufficient to increase glucose stimulated 
insulin release and glucose tolerance. If GK activators do cross the blood brain barrier it 
is likely that they would increase glucose-stimulated insulin release both locally at the 
pancreas and via their effects in the hypothalamus.     
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The suggestion that GK activators would decrease food intake is not supported by this 
work. In fact, the opposite was observed; increased ARC GK mRNA resulted in 
hyperphagia and obesity. Obesity and increased adiposity underlie the great majority of 
type II diabetes cases (Bloomgarden, 2000). If GK activators increase food intake and 
weight gain in a similar fashion to rAAV-GKS this could negatively influence their 
efficacy as a treatment for type II diabetes. That said, increased weight gain is a 
common side effect in type II diabetic patients treated with intensive insulin therapy or 
sulfonylureas such as Glibenclamide (UK Prospective Diabetes Study (UKPDS) Group, 
1998). These treatments are sufficiently efficacious despite their effect on weight gain 
and it is possible that this would also be true of GK activators. 
The results of this thesis also partially support Jean Mayer‟s 1954 “Glucostatic 
hypothesis.” Mayer correctly predicted the existence of glucose-sensing neurones in the 
VMH. However, his prediction that glucose-sensing neurones would be involved in the 
regulation of feeding behaviour has remained unsubstantiated despite significant 
research effort. This work is the first to show that chronic alteration of hypothalamic 
GK mRNA influences food intake and adiposity. Since up-regulation of GK is 
hypothesised to increase the sensitivity of glucose sensing neurones this work supports 
Mayer‟s prediction that these cells are involved in the regulation of food intake. 
However, it is presently unclear whether this is a direct effect on feeding behaviour or a 
consequence of the treatments effect on glucose homeostasis.  
 
5.1.4 Future work  
 
At the outset of this work, I sought to investigate the physiological function of glucose-
sensing neurones in the hypothalamus by manipulating GK expression. The results of 
this thesis suggest that regulation of energy balance and glucose homeostasis are among 
the primary physiological roles of glucose-sensing neurones in the ARC. However, 
further investigation is required to resolve a number of issues.  
Having chosen the ARC as a target for this study, the primary objective was to increase 
GK activity by stereotaxic injection of rAAV-GKS. Despite the observed phenotypic 
differences between the groups, I was unable to show that rAAV-GKS injection had 
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increased GK activity in the ARC of the treatment group compared to controls. 
Increased GK mRNA expression in the hypothalamus was established using QPCR and 
was confirmed by in situ hybridization. Furthermore, I showed that transfection of HEK 
293T cells with GKS-pTR-CGW (the plasmid from which the rAAV-GKS was 
produced) resulted in increased GK activity. Taken together, these data support the 
notion that injection of rAAV-GKS into the ARC increases GK activity therein. 
However, this has not been confirmed experimentally. 
In order to fully validate the results of these studies it will be necessary to increase the 
accuracy of the punch biopsy technique used. During the early studies on the effect of 
fasting on GK activity, punch biopsies were taken from coronal brain sections and 
positive results were achieved. During the studies investigating the effect of iARC 
rAAV-GKS injection, punch biopsies were taken from sagittal sections and this failed to 
show a change in GK activity. Future GK assays should be performed on punches taken 
from coronal sections. Considering the magnitude of the increase in GK mRNA 
expression it is possible that this would be sufficient to confirm increased GK activity. 
If this were not sufficient, it would be necessary to investigate methods to improve the 
GK assay such as the addition of a GK activator to the assay as described by  Zelent et 
al (Zelent et al, 2006).     
Altering GK expression has been shown (by other investigators) to influence the 
electrophysiological properties of glucose-sensing neurones.  However, in the present 
study I have been unable to investigate the effect of rAAV-GKS on the 
electrophysiological properties of glucose-sensing neurones. To investigate the 
electrophysiological properties of neurones it would be necessary to collaborate with a 
group that has expertise in performing this technique. rAAV does not infect 100% of 
neurones at the injection site. To improve the results of electrophysiological analysis, it 
would be advantageous to introduce to a method to detect neurones that had been 
infected. One option would be to alter the GKS-pTR-CGW cassette to include the eGFP 
gene. This would allow the identification of rAAV infected neurones using florescent 
microscopy.       
One of the major findings of this work was that increasing GK mRNA in the ARC 
results in increased feeding and subsequently increased adiposity. I have hypothesised 
that the effect on feeding behaviour could be secondary to the effect of treatment on 
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glucose homeostasis. However, this hypothesis does not exclude the possibility that the 
treatment might also be affecting gene expression and peptide release at the level of the 
hypothalamus.  
QPCR analysis of hypothalami taken from animals in cohort two revealed no difference 
in the expression of any feeding related genes assayed. The brains used in this 
experiment were harvested from rats in the early light phase and rats had not been fasted 
overnight so food intake in the hours prior to harvest was almost certainly variable. 
Hypothalamic gene expression and the activity of glucose-sensing neurones are 
dynamic and dependent on feeding state. It is therefore possible that any changes 
brought about by over expression of GK mRNA may also be dependent on the 
nutritional status of the animal. In order to investigate this possibility, I would repeat the 
QPCR in two further groups. Brains from the first group would be harvested following 
an overnight fast and brains from the second group after consumption of a controlled 
quantity of glucose; to assess the effect of treatment during hyperglycemia and 
hypoglycaemia. 
 It would also be interesting to investigate the effect of increased ARC GK mRNA on 
the release of hypothalamic neuropeptides such as α-MSH and NPY using ex-vivo 
hypothalamic explants. This method has been used successfully by Parton et al who 
showed that glucose-sensing of POMC neurones is lost following high fat feeding 
(Parton et al, 2007). In this study, α-MSH release from explants was shown to increase 
as glucose concentrations in the assay media were increased; an effect lost in the brains 
of obese mice. Since increased GK is hypothesised to increase the sensitivity of 
neurones to a given quantity of glucose, it is possible that it might also affect the release 
of α-MSH and NPY from explants incubated in a glucose-containing media. This might 
help to explain the effect of treatment on food intake.  
Another issue that is unresolved is whether increasing GK in the ARC has effects on 
energy balance beyond its effects on food intake. In most studies, GKS animals 
consumed significantly more chow than control and gained significantly more weight. 
In cohort two, the GKS group gained significantly more weight than the controls but 
their food intake was not significantly higher. It is possible that this finding is purely 
anomalous. Equally, this finding could suggest that treatment has decreased energy 
expenditure. NPY expressing neurones of the hypothalamus have been shown to be 
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sensitive to glucose. In addition, NPY has a well-accepted role in the regulation of 
energy balance in rodents via it effects on brown adipose tissue (Egawa et al, 1991). If 
rAAV-GKS influences NPY release, it is also possible that it would affect brown 
adipose tissue metabolism and energy balance. For these reasons, it would be 
advantageous to observe a future cohort in the comprehensive laboratory animal 
monitoring system (CLAMS). CLAMS allows for accurate and detailed observation of 
numerous parameters including food intake, physical activity, carbon dioxide 
production and oxygen consumption.  
Increasing GK mRNA in the ARC had profound and repeatable effects on glucose 
homeostasis. The increased glucose tolerance of the GKS group was shown to be due to 
an increase in glucose-stimulated insulin release. However, the physiological 
mechanism by which this occurs was not investigated.  
As discussed above, lesioning of the VMH results in obesity and hyperinsulinemia, 
mainly due to disinhibition of pancreatic insulin secretion  (Hustvedt & Lovo, 
1972;Inoue et al, 1991). This model shares the main phenotypic characteristics of the 
rAAV-GKS group in this study; being both hyperphagic and hyperinsulinemic. 
Selective vagotomy of the efferent celiac (pancreatic) branch of the vagus decreases 
plasma insulin and food intake in VMH lesioned rats (Inoue et al, 1991). 
 To extrapolate the involvement of the celiac vagus branch in the mild hyperinsulinemia 
of GKS animals, glucose tolerance test could be performed in GKS animals that had 
been subjected to celiac vagotomy. This procedure might also influence the food intake 
and adiposity of the GKS group (as it does in VMH lesioned rats) and could provide 
further clues as to the source of their observed hyperphagia.    
Finally, it will be important to investigate the effect of down-regulation of GK mRNA 
in the ARC using anti-sense rAAV. In the present study, GK mRNA expression was 
increased 14-fold following rAAV-GKS injection into the ARC. While this may not 
necessarily equate to a 14-fold increase in enzymatic activity, it is possible that 
treatment may have increased GK activity to supraphysiological levels. It is therefore 
possible that the effects observed in this work are pharmacological rather than 
physiological. Decreasing GK expression using anti-sense rAAV would add weight to 
this study because down-regulation of gene expression tends to be more suggestive of a 
physiological role.  
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1. Appendix I – Solutions 
 
aCSF (K+ = 5.9mM)  
NaHCO3 20mM 
NaCl  126mM 
Na2HPO4 0.9mM 
KCL  5.9mM 
CaCl2  1mM 
MgSO4 0.09mM 
Glucose  5mM 
Trasylol 10ml/L 
Ascorbic Acid 176mg/L 
Distilled H2O 540ml/L 
 
3M Alcoholic KOH solution:   
 Add 39g KOH pastels to 200 ml 65% ethanol 
 
5M ammonium acetate 
Dissolve 385g CH3.COONH4 in 600ml autoclaved distilled water, then make 
up to 1l. 
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2M Calcium chloride: 
10.8g CaCl2.6H2O was dissolved in 20ml GDW and sterilise by filtration 
through 0.22µm filter and store in 1ml aliquots at -20˚C 
 
 
Caesium chloride-saturated propan-2-ol: 
Mix 100g CsCl2, 100ml GDW and 100ml propan-2-ol and leave to settle. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA): 
In 800ml autoclaved water dissolve 186.1g C10H14H2O8Na2.2H2O and adjust to 
pH 8.0 with 1M NaOH. Make up to 1L with water 
 
Gel loading buffer: 
Mix 3.125ml 80% glycerol, 50μl 0.5M EDTA, and 10mg orange G in 6.075ml 
of autoclaved distilled water. 
 
Glucokinase extraction buffer: 
Dissolve 0.508g MgCl2, 0.913g Sodium ethylenediamine tetraacetate, 
5.591g KCl and 0.35ml 2-mercaptoethanol in 500ml GDW. Use 1M 
KOH to alter the pH of the solution to 7.3. 
Gly- Gly: 
  Dissolve 6.6g Gly –gly in 500ml. Use 5M KOH to alter pH to 8. 
GTE  
Mix 2.5ml 1M Tris-HCl, pH 8.0, 2ml 0.5M C10H14H2O8Na2.2H2O and 5ml 18% 
glucose and top up to 100ml. Sterilise by passing through a 0.2μm filter. 
 
HEPES-buffered saline (HBS) 
 280mM NaCl, 10mM KCl, 1.5mM Na2HPO4, 12mM dextrose, 50mM HEPES 
(Sigma) pH7.07.  Sterilise by filtration through 0.22µm filter and store in 5ml 
aliquots at -20˚C 
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Hybridisation buffer  
Dissolve 0.5g dried milk powder in 48ml GDW and 0.5ml 500mM EDTA. Add 
25ml 1M Na phosphate, 25 ml 20 % SDS, 2.5mM ATA. 
LB culture media 
Dissolve 5g sodium chloride, 10g tryptone and 5g yeast extract to 1l of 
distilled water. Adjust to pH 7.5 with 10M sodium hydroxide and sterilise by 
autoclaving. 
 
Lysis buffer 
Add 8.765g NaCl, 6.055g Tris, make up to 1l with GDW and adjust to pH8.5. 
 
1M magnesium chloride 
Dissolve 203.3g MgCl2 in 1L GDW. 
3M potassium acetate  
Dissolve 294.4g CH3COOK in 500ml water, add 115ml glacial acetic acid and 
water up to 1L. 
 
2M sodium acetate 
pH 5.2: Dissolve 164.1g CH3COONa in 800ml a/c water, adjust to pH 5.2 with 
glacial acetic acid and make up to 1L with water 
 
5M sodium chloride  
 Dissolve 292.2 g NaCl in 1L GDW. 
 
20% sodium dodecyl sulphate (SDS)  
Add 200g SDS to 800ml a/c water, heat to 60˚C while stirring. Allow to cool 
and make up to 1L with water. 
 
0.2% sodium hydroxide 1% SDS 
Add 3ml 10M NaOH to 140ml GDW, mix and add 7.5ml 20% SDS. 
 
20xSSC   
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Dissolve 1.753g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 
700ml GDW,  adjust to pH 7.7 with 10M NaOH and make up to 1L with GDW. 
 
 
50 x TAE 
Dissolve 242g Trizma base in 843ml water and mix in 57ml glacial acetic acid 
and 100ml 0.5M C10H14H2O8Na2.2H2O. 
 
 
0.1 x TE 
 1mM Tris-HCl, pH 0.8 and 0.1mM EDTA, pH 0.8 
 
2M Tris-HCl, pH 8.0: 
dissolve 121.1g Trizma base in 450ml GDW and adjust to pH 8.0 with 
HCl.  Make up to 500ml. 
Versene  
 2.7mM KCl, 0.14M NaCl 1.5mM KH2PO4, 8mM Na2HPO4.2H2O, 3mM EDTA, 
0.1% phenol red. 
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2. Appendix II - Figures 
 
Figure 0.1 Schematic of a coronal section of the rat brain 
Reproduced from “The Rat Brain in Stereotaxic Co-ordinates” (Paxinos & Watson C, 2007).  
The level is 3.36mm posterior to bregma, which corresponds approximately to the co-ordinates 
used to target the ARC in this work (-3.4 from bregma). The ARC is highlighted in red.  
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Table 0.1 Nutritional information for RM1 normal chow diet 
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Table 0.2 Nutritional information for high energy diet (Research Diets Inc, USA) 
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3. Appendix III- Randomisation method and 
calculations  
Randomisation 
In all experiments, rats were randomised into groups of equal mean bodyweight as 
described below.  
Animals were weighed on the day before surgery. Bodyweights were entered into a 
Microsoft Excel spread sheet and sorted from the highest to lowest. The column to the 
right of bodyweight data was labelled “Group”. In the group column the number “1” or 
“2” was inserted next to each bodyweight in the following order from lowest to highest 
“1,2,2,1,1,2,2,1,1,2”. Next, the data was sorted by group and the mean for both groups 
calculated. If there was less than a 2g difference between the mean of both groups, no 
further action was taken. If this was not the case, animals were randomly moved 
between groups until the means were within 2g. 
  
Glucose assay  
Plasma glucose concentration was determined using reagents and methods from Randox 
Laboratories Ltd (see 3.3.9.5). Following incubation, the A500 of the samples was 
measured in a spectrophotometer. The A500 of samples was compared to a standard 
curve to give the glucose concentration in the reaction. Prior to the assay samples were 
diluted by a factor of 1 in 5 in normal saline. To calculate plasma glucose concentration 
the concentration of glucose in the assay reaction was multiplied by five.  
 
Example: 
Cohort: Two 
Group: rAAV-GKS  
Rat I.D: 5  
A500: 0.4627 
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Assay reaction glucose concentration from standard curve: 0.952mmol/l 
Plasma glucose= assay reaction glucose concentration x dilution factor 
Plasma glucose:  0.952mmol/l x 5 = 4.76mmol/l 
 
Glucokinase activity assay  
The glucokinase activity assay was performed as described in 2.3.5.2. Following 
incubation, the A340 of the samples was measured in a spectrophotometer. The A340 of 
samples was compared to a standard curve for glucokinase activity (units of enzymatic 
activity). To correct for variation in the size of samples collected the results of the GK 
activity assays were corrected to sample protein concentration.  
 
Example:   
Cohort: One 
Group: rAAV-eGFP  
Rat ID: 29 
Nucleus: ARC 
A340: 0.347 
 
Sample GK activity from standard curve: 0.028units  
Sample protein concentration: 0.352mg/ml  
GK activity units/mg protein = sample GK activity/sample protein concentration 
GK activity: 0.028units/0.352mg/ml = 0.079units/mg protein  
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4. Appendix IV – List of suppliers 
Advanced Biotechnology Centre, Imperial College, London, UK 
Animalcare Limited, Dunnington, York, UK 
Applied Biosystems, Warrington, UK  
ATCC, Middlesex, UK  
Bayer UK Ltd, Bury St Edmunds, UK 
Beckman Coulter (U.K.), Buckinghamshire, UK 
Bright Instrument Company, Huntingdon, Cambridgeshire, UK 
Boehringer Ingelheim, Berkshire, UK   
Charles River, Bicester, UK 
Clintech, Dublin, Ireland  
David Kofp Instruments, Tujunga, CA, USA 
Du Pont, Bristol, UK  
Eli Lilly & Co.Ltd, Basingstoke, UK  
Eppendorf, Hamburg, Germany 
Fine Science Tools, Linton, UK  
Fisher Scientific UK, Loughborough, Leicestershire, UK 
GE Healthcare, Buckinghamshire, UK 
Genomics Core Laboratory, Imperial College London, UK  
Graphpad Prism, Graphpad Sorfware, San Diego, CA, USA 
Helena biosciences, Sunderland, UK 
Invitrogen Life Technologies, Paisley, UK 
Kodak, Hemel Hempstead, Hertfordshire, UK 
LEO Pharma, Buckinghamshire, UK  
L.E West, Barking, UK 
Life Sciences Technology, Eggenstein, Germany 
Linco Research, Missouri, USA  
Microvette, Sarstedt, Numbrecht, Germany  
Millipore, Watford, Hertfordshire, UK  
Millpledge Veterinary, Nottinghamshire, UK  
New England Biolabs (UK) Ltd, Hitchin, Hertfordshire, UK 
Novagen, Nottingham, UK 
Oswell DNA Services, Southampton, UK 
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Parke-Davis, Pontypool, UK   
Plastics-One, Roanoke, Virginia, USA 
Pierce, Rockford, IL, USA  
Promega, Madison, WI, USA 
Randox Laboratories Ltd, County Antrim, UK 
Research Diets Inc, New Brunswick, NJ, USA 
Shandon Southern Products Ltd, Runcorn, UK 
Sigma Ltd, Poole, Dorset, UK 
Special Diet Services, Witham, Essex, UK 
ThermoFisher Leicestershire, UK 
Tyco Healthcare, Hampshire, UK 
Vet Tech Solutions Ltd, Cheshire, UK  
VWR International Ltd, Poole, UK 
Wallac, Waltham, MA, USA 
WPA, Cambridgeshire, UK 
 
 
 
